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It is now recognised that coagulation factor concentrates may cause immunological
abnormalities in haemophilia patients, irrespective of HIV status. It has been
proposed that these disturbances of the immune system are caused by either the
massive protein load, specific impurities or by viruses in coagulation factor
concentrates. There has been a recent claim that the major contaminant in factor
VIII concentrates is transforming growth factor (3 (TGF-J3) and its presence may
partially explain the reported immunomodulatory effects in HIV negative
haemophiliacs.
This study investigated the effects that coagulation factor concentrates of varying
purity have on in vitro assays of immune function. The nature of the contaminants
causing these effects was also investigated.
The results demonstrate that all conventional and ion-exchange chromatographically
purified coagulation factor concentrates inhibit lymphocyte proliferation in vitro.
These concentrates also contain measurable amounts of active TGF-(3. In contrast,
immunoaffinity purified and recombinant coagulation factor concentrates do not
inhibit lymphocyte proliferation and contain very tittle active TGF-p. The levels of
TGF-J3 detected in coagulation factor concentrates correlated with the degree of
inhibition of lymphocyte proliferation. However, the amount of TGF-(3 present in
the concentrates could account for only a small portion of the inhibitory activity. In
addition, neutralising antibody specific to TGF-(3 only partially reversed the
inhibitory effects that concentrates had on lymphocyte proliferation. In conclusion,
while TGF-J3 is present in concentrates, the amount detectable (and its relative
potency) suggest it is only a minor immunosuppressive contaminant in coagulation
factor concentrates.
Part of the inhibitory activity of some higher purity products was removed by
dialysis, suggesting that low molecular weight components, such as citrate were
responsible for a proportion of the inhibitory activity of these products. No portion
of the inhibitory activity of conventionally fractionated products was dialysable.
Gel filtration experiments on an ion-exchange purified factor VIII concentrate
suggest the presence of several inhibitory components which appear variably in
different batches of this concentrate. Six peaks of lymphocyte proliferation
inhibitory activity were detected, one with a molecular weight of >970 kDa, three
peaks of inhibitory activity with molecular weights of approximately 550 kDa, 220
kDa, 120 kDa, a peak with a molecular weight <68 kDa and one with a molecular
weight of approximately 6.5 kDa. The inhibitory fractions with molecular weight
<68 kDa contained active TGF-(3 and the fractions with a molecular weight of
approximately 6.5 kDa were confirmed to be low molecular weight components
used in the formulation of this product. The four high molecular weight
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Factor VIII and factor IX play important roles in the blood coagulation cascade,
Figure 1. The clinical importance of factor VIII and factor IX, in the maintenance
of haemostasis is evident from the occurrence of haemophilia A and haemophilia B
in individuals with reduced function or amount of these proteins.
1. The History of Haemophilia and its Treatment
Haemophilia is an ancient disease, first described as a severe haemorrhagic tendency
found in males of certain families, by the Talmudic Rabbi Judah in 500 AD (Rosner,
1969). Although the existence of haemophilia was recognised as early as this the
first widely read report in modem medical literature of a haemophilia-like condition
was that by an American physician John Otto in 1803. Otto described the syndrome
of a bleeding tendency occurring only in males, and transmitted by apparently
normal females (Otto, 1803).
The first successful treatment of haemophilia was achieved in 1840 by Lane, who
demonstrated that transfusion of fresh, whole blood could be used to control a
haemophilia associated bleeding episode (Lane, 1840). In 1911 Addis published a
paper in which he showed that the prolonged clotting time of haemophiliac blood
could be corrected by normal plasma in vitro, concluding that a plasma factor is
absent from haemophiliac blood (Addis, 1911). This lead to the treatment of
haemophiliac bleeding episodes with citrated plasma by Feisly in 1923 (Feisly,
1923). The nature of this plasma deficiency was later to be ascribed to
antihaemophiliac globulin by both Brinkhouse and Quick in 1947 (Brinkhouse,
1947; Quick, 1947) and subsequently assigned the Roman numeral VIII (Wright,
1962).
The idea that haemophilia might be due to more than one type of defect first arose
from the findings of Pavlovsky (1947). Pavlovsky reported that the blood from two
haemophiliac patients was mutually corrective both in vitro and in vivo. This
observation that there were multiple types of haemophilia was subsequendy
confirmed by Schulman & Smith (1952), Aggeler et al (1952) and Biggs et al
(1952). These researchers independently described cases which exactly resembled
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haemophilia, both clinically and genetically, but which were due to a deficiency not
of factor VIII, but of a new previously unrecognised clotting factor. Aggeler et al
called this new clotting factor 'plasma thromboplastin component' (PTC), and the
disease 'PTC deficiency', while Biggs et al named the absent factor 'Christmas
factor', and the disease 'Christmas disease' after their first patient. This absent
factor was later assigned the Roman numeral IX.
Deficiency in factor VIII was subsequently called haemophilia A, and the absence of
factor IX haemophilia B.
Interwoven with the history of haemophilia A and haemophilia B, is the autosomal
clotting disorder von Willebrand's disease, which was first described in 1926, by
von Willebrand. The disorder is caused by a deficiency of von Willebrand factor
(vWF), a large glycoprotein found in platelets, plasma and endothelial cells. vWF is
involved in the interaction of platelets with the vessel walls, therefore a defect or
deficiency in the protein leads to a failure in primary haemostasis. Another function
of vWF is to bind factor VIII, protecting it from proteolysis, and hence inactivation.
Due to this interaction, a reduction in the level of circulating vWF leads to a
reduction in factor VIII levels.
The therapy of haemophilia using whole blood or plasma transfusion was hampered
by the minute concentrations of these coagulation factors, their short half life and
hence the large volume of whole blood or plasma required. The normal plasma
concentration of factor VIII has been estimated to be between 100 and 200 ng/ml
(Fulcher & Zimmerman, 1982), and the concentration of factor IX approximately
5 |ig/ml. Early attempts to isolate factor VIII from normal human plasma for the
treatment of haemophilia A were only partially successful (Pohle & Taylor, 1937;
Lozner et al\ 1939: Lozner & Taylor, 1939). The year 1946 saw the first specific
product for the treatment of haemophilia, factor VIII rich Cohn fraction 1 (Cohn et
al, 1946). This classical method involved cold-ethanol precipitation of proteins
from human plasma, yielding a product that contained approximately 5-fold purified
factor VIII. Further precipitation of this cryoprecipitate by glycine (Wagner et al,
1964; Johnson et al, 1964) or polyethylene glycol (Johnson et al, 1966) and the
application of these techniques to extraction from large plasma pools, saw the
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advent of more potent, clinically useful factor VIII preparations. The material
produced by these methods was remarkably stable and soluble, allowing it to be
sterile filtered to 0.22 pm, frozen and lyophilised.
The first factor IX concentrates produced for the treatment of haemophilia B, were
manufactured by calcium phosphate absorption of EDTA anticoagulated plasma
(Pool & Shannon, 1965). However, EDTA plasma is unsuitable for the recovery of
factor VIII. The introduction of citrate based anticoagulants in plasma collection,
prompted the development of alternative procedures for the preparation of factor IX
concentrates. Ion-exchange adsorption was used to purify factor IX from the
supernatant which remains following cryoprecipitation. The anion exchanger
diethylaminoethyl (DEAE) bound to Sephadex was used for this purpose. This
method results in the several hundred fold purification of factor IX as well as other
vitamin K dependent factors (factor II, factor X, protein C and protein S) (Casillias
et al, 1969; Hoag et al, 1969; Middelton et al, 1973).
Even though some of these coagulation factor concentrates are enriched several
hundred fold over plasma, less than one percent of the protein contained in these
concentrates is actually coagulation factor. Consequently, haemophiliacs treated
with these products are exposed to a large load of foreign proteins. In addition, the
raw material for every lot of coagulation factor concentrate is a pool of plasma
collected from up to 20,000 donors. This has exposed patients receiving these
products to the risk of blood-borne viruses, such as the human immunodeficiency
virus (HIV) and hepatitis B and C. These complications of therapy have made it
necessary to develop highly purified, more efficacious and safer coagulation factor
concentrates.
Over the past few years, advances in protein fractionation techniques such as ion-
exchange chromatography, affinity chromatography and immunoaffinity
chromatography have enabled manufacturers to produce highly purified plasma
derived concentrates (Burnouf et al, 1991; Weinsein, 1989; Feldman et al, 1989;
Hrinda et al, 1991). In addition, advances in recombinant DNA technology and the
cloning of the factor VIII and factor IX genes (Gitschier et al, 1984. Toole et al,
1984; Choo et al, 1982; Kurachi & Davie, 1982) have facilitated the production of
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recombinant coagulation factor concentrates (Boedeker, 1992; Gomperts et al,
1992). The production of highly purified and recombinant concentrates has
revolutionised the treatment of haemophilia and vastly improved the efficacy and
safety of these coagulation factor concentrates.
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2. Haemophilia
2.1 Genetics of Haemophilia
Haemophilia is one of the most common inherited bleeding disorders in humans.
Haemophilia A and haemophilia B are both X-linked recessive diseases, occurring
almost exclusively in males. The frequency of haemophilia is approximately 1 in
5,000 male births (1 in 10,000 in the general population) (Rizza & Spooner, 1983).
Factor VIII deficiency accounts for 85% of these cases, factor IX deficiency for a
further 14%, the remaining cases being rare congenital disorders such as factor XI,
X, VII and V deficiency. Because the defective factor VIII and factor IX genes are
located on the X chromosome, haemophiliac males possess no normal gene and
therefore manifest the clinical disorder. Females with haemophilia A or B are rare
(Barrow & Graham, 1974). Cases include females homozygous for the defective
gene (the offspring of a union of a haemophiliac male and a carrier female), and
carrier females whose paternal X chromosome demonstrates functional
abnormalities at the factor VIII locus, resulting in hemizygosity. These
abnormalities of the X chromosome can occur by two mechanisims. The first is
extreme lyonisation resulting in the preferential inactivation of the healthy paternal
X chromosome (Nisen et al, 1986; Ingerslev et al, 1989; Nisen & Waber, 1989;
Kling et al, 1991). The second mechanism is a genetic abnormality for haemophilia
in a female with only one X chromosome, such as mosaicism for Turner's
syndrome, genotype XX/XO (Gilchrist et al, 1965; Neuschatz & Necheles, 1973).
2.2 Laboratory Diagnosis of Haemophilia A and Haemophilia B
As previously mentioned, factor VIII and vWF are present in plasma as a complex,
and factor VIII levels are dependent on vWF levels. Therefore, the laboratory
investigation of patients suspected of having haemophilia A requires a distinction
between vWF deficiency and factor VIII deficiency. Investigation of potential
haemophilia A patients involves a factor VIII coagulant activity assay, a vWF
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antigen assay and ristocetin cofactor activity assay. The vWF antigen assay
measures the quantity of vWF in plasma. The ristocetin cofactor activity assay is a
functional assay for vWF, which measures vWF supported agglutination of human
platelets by ristocetin.
Patients with haemophilia A will have reduced factor VIII coagulant activity, but
normal vWF levels and function, whereas patients with vWD (von Willebrand
disease) will have reduced factor VIII coagulant activity, as well as reduced vWF
levels or function.
Investigation of potential haemophilia B patients requires a factor IX coagulant
activity assay. Haemophilia B patients will have reduced factor IX levels.
However, other causes of reduced factor IX must be excluded, such as liver disease.
Carriers of haemophilia A and B may have reduced levels of factor VIII and factor
IX respectively, and may bleed excessively following trauma or surgery. In many
carriers however the coagulation factor levels will fall within the normal range.
2.3 Clinical Severity of Haemophilia
The severity of the clinical features which manifest in haemophilia patients usually
correlates well with the levels of factor VIII or factor IX activity in patient plasma.
The condition in patients whose factor VIII or IX levels are less than 1% of normal
(<0.02 U/ml) is classified as "severe". Patients whose factor VIII or IX levels are
greater than 5% of normal but less than 40% (0.05-40 U/ml) are usually considered
"mild" haemophiliacs. Patients whose factor VIII or IX levels fall between these
two ranges are classified as "moderate" (Brettler & Levine, 1994; Roberts &
Lozier, 1991). Approximately 50% of diagnosed cases suffer from severe
haemophilia, moderate and mild cases accounting for around 25% each.
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2.4 Clinical Features of Haemophilia
Both haemophilia A and B are characterised by repeated episodes of spontaneous
bleeding or prolonged bleeding as a result of trauma. In severely affected patients
spontaneous, haematomas and haemarthroses are typical. Mildly affected patients
rarely suffer from haemarthroses, and only bleed excessively as a result of definite
trauma. The clinical features demonstrated by moderately severe haemophiliacs he
somewhere between these two.
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3. Factor VIII
3.1 Function of Factor VIII
The physiological response to blood vessel injury is the sequential activation of
plasma proteases in the blood coagulation pathway. Activation of these plasma
proteases leads to the localised generation of thrombin, and ultimately the
conversion of soluble fibrinogen to insoluble fibrin and the formation of a fibrin clot.
Historically the coagulation factor cascade has been considered to be composed of
two parts, the extrinsic system which is initiated by the activation of factor VII by
tissue factor, and the intrinsic system, which is initiated by the activation of factor
XII by collagen, negatively charged surfaces and kallikrein. Tissue factor, expressed
by cells at the site of haemostasis, is thought to be the most important initiator of
the coagulation cascade.
Factor VIII is a critical participant in the blood coagulation pathway, Figure 1.
Factor VIII is itself devoid of enzymatic activity, but acts as a cofactor to accelerate
the activation of factorX by activated factor IX (factor IXa) (Fujikawa et al, 1974).
Factor VIII is proteolytically activated by thrombin to yield activated factor VIII
(factor Villa). It is this activated form of factor VIII, which in the presence of
platelets and calcium, dramatically enhances the Vmax of factor X activation by
factor IXa (Griffith et al, 1982; Neuenschwander & Jesty, 1988). This means that
the reaction occurs slowly in the presence of platelets and calcium only and is
greatly accelerated by factor Villa through a direct effect on the interaction of the
enzyme factor IXa and the substrate, factor X.
3.2 Structure of Factor VIII
Factor VIII is one of the largest, least stable coagulation factors, and has a complex
polypeptide composition. Understanding of the structure of factor VIII has arisen
from two recent advances. The first was the further purification of factor VIII free
of vWF, from factor VIII concentrates and human plasma by immunoaffinity
25
chromatography (Fulcher & Zimmerman, 1982; Fay et al, 1982; Rotblat et al,
1985; Ganz et al, 1988). Partial sequence data derived from this highly purified
human factor VIII (Vehar et al, 1984) enabled the second advance to be made, the
cloning of the human factor VIII gene, from which the primary structure of factor
VHI was elucidated (Gitschier et al, 1984; Toole et al, 1984; Wood et al, 1984).
(i) PurifiedFactor VIII
Factor VIE purified from factor VIII concentrates consists of multiple polypeptides
of approximately 80-210 kDa (Fulcher & Zimmerman, 1982; Rotblat et al, 1985).
The largest molecular mass species found in plasma, being the single chain 330 kDa
species (Rotblat et al, 1985). The purified form of factor VIII is a two-chain, metal-
ion-stabilised complex which consists of a variable heavy chain of 90-210 kDa and a
light chain of 80 kDa, Figure 2 (Fulcher et al, 1985; Andersson et al, 1986; Eaton
et al, 1986; Fay et al, 1986). The metal ion in the factor VIII complex is presumed
to be calcium (Fass et al, 1982; Andresson et al, 1986; Eaton et al, 1987). The
nature and the site of the cation-interaction with factor VIII is unknown, but could
involve either calcium induced conformational change favouring the binding of the
light and heavy chains or direct metal ion-bridging of the subunits.
(ii) RecombinantFactor VIII
The deduced amino acid sequence of factor VIII, obtained from the cloned cDNA
sequence, predicts a mature polypepetide of 2,332 amino acid residues with a
calculated molecular weight 264,763 Daltons (Vehar et al, 1984). Sequence
analysis also indicates 25 potential asparagine-linked glycosylation sites
(Tuddenham et al, 1979). The addition of carbohydrate would account for the
largest circulating form of approximately 330 kDa (Rotblat et al, 1985). The amino
acid sequence also shows that factor VIII is a heterodimer of an 80 kDa light chain
in association with a 90-210 kDa heavy chain, and that these chains are both derived
from a larger precursor peptide.
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Further analysis of the amino acid sequence revealed that the structure of factor
VDI can be divided into three sets of domains; the triplicate A domains, a B domain
and two C domains (Vehar et al, 1984). These occur in the order Al: A2: B: A3:
CI: C2, Figure 2. The A domains show structural homology to ceruloplasmin, the
copper binding plasma protein, suggesting that the A domains of factor VIII may be
involved in metal ion binding (Church et al, 1984: Vehar et al, 1984). The two C
domains which both occur in the C-terminus of the factor VIII light chain exhibit
homology to the discoidin lectins (Vehar et al, 1984). Discoidins are capable of
binding negatively charged phospholipids, implying that the light chain is perhaps
involved in binding factor VIH to the cell surface. The B domain is encoded entirely
by exon 14 of the factor VIII gene (Wood et al, 1984) and contains 18 of the 25
potential asparagine-linked glycosylation sites. The B domain displays no homology
to other proteins. The amino acid sequence of factor V, another cofactor involved
in the blood coagulation cascade, shows a high degree of homology to factor VIII.
Indeed cofactors V and VIII exhibit 40% homology within the A and C domains,
their B domains sharing no homology. The functional significance of the B domain
is unknown. A recombinant factor VIII product has recently been developed in
which the B domain is deleted and replaced by a short connecting sequence of the
first 5 and the last 9 amino acids of the B domain. This factor VIII molecule has
been reported to have full biological activity (Berntorp et al, 1995; Berntorp et al,
1995a; Fijnvandraat et al, 1995; Smeds et al, 1995). Clinical trials with the
product are ongoing.
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3.3 Interaction of Factor Vm with vWF
The interaction of factor VIII with the multimeric glycoprotein vWF is the best
characterised of its interactions with other components of the haemostatic system.
Following vascular injury, a series of events takes place which begins with platelet
adhesion and aggregation, a process in which vWF participates by "gluing" platelets
to exposed subendothelium (Weiss et al, 1978; Baumgartner et al, 1980). Another
function of vWF is to act as a carrier protein for factor VIII stabilising it upon
secretion (Kaufman et al, 1988). Based on these functions it is thought that vWF
may bring factor VIII to the site of the vascular damage. vWF has also been
reported to protect factor VIII from activation by factor Xa (Hamer et al, 1987) and
inactivation by activated protein C (Koedam et al, 1988). vWF does not however
protect factor VIE from thrombin proteolysis (Hamer et al, 1987).
Circulating levels of factor VIII are dependent upon complex formation with vWF.
This is most evident in severe von Willlebrand's disease in which patients with
complete deletion of the vWF gene have greatly reduced factor VIII levels (Ngo et
al, 1988). Each vWF monomer of 250 kDa contains one factor VIII binding site
(Lollar & Parker, 1987). Whether each binding site in a vWF multimer is capable of
binding a factor VIII molecule is unclear, however, complexes in the molecular
weight range of 1-10 x 103 kDa are formed. Monoclonal antibody binding studies
have localised vWF binding to factor VIII to a region of highly acidic amino acids,
residues 1673 to 1684 within the amino terminus of the factor VIII light chain


























FIGURE 1: The Blood Coagulation Cascade.
Tissue factor, which is the initiator of the extrinsic pathway is thought to be the
most important initiator of the blood coagulation cascade. The mechanism of
initiation of the intrinsic pathway is represented by the light grey arrows.
Activated coagulation factors are marked with a small case a.
Abbreviations: PLT = platelets; TF = tissue factor.
(Diagram adapted from Foster & Zimmerman, 1989)
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3.4 Activation of Factor VIII
A number of blood coagulation serine proteases modulate the activity of factor VIII
activity by specific proteolysis. The activation of factor VIII procoagulant activity
by thrombin was first reported by Rapaport in 1963. Following this initial
discovery, Hoyer & Trabold (1981) demonstrated that the activation of factor VIII
was associated with a reduction in molecular weight as determined by gel filtration
studies. Proteolysis of both the heavy and the tight chain is necessary for activation,
Figure 2. Thrombin cleavage of the heavy chain at arginine residue 740 generates a
90 kDa polypeptide which is subsequently cleaved at arginine residue 372 to
generate two fragment of 50 and 43 kDa (Eaton et al, 1986). Thrombin also
cleaves the 80 kDa tight chain at arginine residue 1689 generating a 73 kDa
polypeptide (Eaton et al, 1986). Each thrombin cleavage site is bordered by acidic
amino acids, which may be thrombin binding sites. Mutation of arginine residues
372 and 1689 results in factor VIII molecules resistant to cleavage by thrombin and
loss of cofactor function. Mutation at site 740 also yields a factor VIII molecule
resistant to thrombin cleavage but has no effect on cofactor function (Pitman &
Kaufman, 1988). This suggests that activation requires cleavage at sites 372 and
1689 but not at 740. It is thought that cleavage at site 1689 by thrombin is essential
for the release of factor VIII from vWF, as this would result in the loss of the vWF
binding site, residues 1673 to 1684. The importance of cleavage at residues 372
and 1689 for activation of factor VIII is demonstrated by haemophilia A patients
who have mutations at either residue. In contrast to most haemophilia A patients,
these patients have normal levels of factor VIII, as assessed immunologically, but no
detectable factor VIII activity (Gitschier et al, 1988; O'Brien & Tuddenham,
1989).
Factor Xa also activates factor VIII in the presence of phospholipid (Davie et al,
1975). However, since only thrombin activates factor VIII in tissue factor activated
plasma and because small amounts of thrombin are generated continuously in vivo
(Bauer & Rosenberg, 1987) it is thought that thrombin is the sole activator of factor
VIII in vivo.
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3.5 Activated Factor VIII
Attempts to study activated factor VIII (factor Villa) have been hampered by its
short half life. A study on thrombin activated porcine factor VIII suggested that the
active form was a heterotrimer comprising 50 kDa, 43 kDa and 73 kDa fragments
(Lollar & Parker, 1989; Lollar & Parker, 1991), this has been supported by Fay et al
(1991). The present evidence indicates that activated factor VIII is a heterotrimer,
which comprises heavy chain residues 1-372 (Al domain) and 373-740 (A2 domain)
plus light chain residues 1690-2332 (A3-C1-C2 domains) in a metal ion dependent
complex, Figure 2.
3.6 Inactivation of Factor VIE
The molecular events which lead to factor VIII inactivation in vivo are unclear.
Activated protein C (APC) has been shown to inactivate factor VIII by proteolysis.
Activated protein C cleaves the 50 kDa factor VIII heavy chain at arginine residue
336 to generate a 45 kDa peptide, Figure 2 (Fulcher et al, 1984; Eaton et al, 1986;
Walker et al, 1987). Mutagenesis of arginine residue 336 results in a factor VIII
molecule with an increased specific activity. However, on thrombin activation, the
336 mutant did lose activity, suggesting that other cleavage sites are likely to be
important for inactivation (Pitman & Kaufman, 1988)
Factor Xa has also been shown to inactivate factor VIII by proteolysis at position
1721-1722. More recently, it has been shown that incubation of factor VIII with
physiological concentrations of highly purified activated factor IX resulted in the
inactivation of factor VIII (O'Brien et al, 1992). This inactivation correlated with
the cleavage of factor VIII at arginine 336 on the heavy chain, and at residues 1719-
1720 on the tight chain. The heavy chain cleavage at 336 was identical to that
accomplished by APC, and the tight chain cleavage similar to that by factor Xa. It is
now believed that both APC and factor IXa inactivate factor VIII in vivo, this may
explain why most individuals with protein C deficiency do not suffer from
thrombosis (Miletich et al, 1987).
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45 kDa 43 kDa 73 kDa
FIGURE 2: Domain Structure and Proteolytic Cleavage Sites of Factor VIII.
Factor VIII is cleaved by a protease(s) within the B domain to generate a 210 kDa
heavy chain and an 80 kDa light chain, either during biosynthesis, secretion or during
circulation. Activation of factor VIII coincides with proteolysis of the light and heavy
chains by thrombin. The shaded areas correspond to regions of acidic amino acids.
Abbreviations: Arg = arginine, APC = activated protein C.
Adapted from Pitman & Kaufman, 1988.
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4. Factor VIII Gene Structure
The gene that codes for factor VIII is located at the distal end of the long arm of the
X chromosome at band Xq28. The factor VIII gene is one of the largest genes
known, comprising nearly 186 kbp, which represents approximately 0.1% of the X
chromosome (Gitschier et al, 1984; Toole et al, 1984). The DNA encoding factor
VIII is divided into 26 separate exons, the complete gene consisting of
approximately 9 kb of exon and 177 kb of intron. The gene encodes a 9 kb
messenger RNA, which translates into a precursor protein of 2332 amino acids
residues plus a 19 amino acid signal sequence (Gitschier et al, 1984; Toole et al,
1984; Truett et al, 1986).
4.1 Factor VIII Gene Mutations
An international database of mutations in the factor VIII gene has been compiled,
and is updated annually and published in Nucleic Acids Research. At the last update
the haemophilia A database had 543 patient entries and 296 unique molecular events
were recorded. These included 43 short deletions or insertions, 78 large deletions,
138 different amino acid substitutions and 24 nonsense mutations (Tuddenham et al,
1994). Approximately 25% of single base pair substitutions within the factor VIII
gene involve cytosine to thymine transitions. This nucleotide substitution is now
recognised to be the most frequent DNA change in the human genome, arising from
spontaneous deamination of methylated cytosine residues. All of the above
mutations recorded in the database account for only approximately 50% of the
haemophilia A patient entries, no mutations being detected in the remaining 50%
(Higuchi et al, 1991). The only defect observed in these patients was a lack of
mRNA species that spanned intron 22 of the factor VIE gene (Naylor et al, 1992).
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It is now known that this remaining 50% of haemophilia A cases result from major
inversions at the tip of the long arm of the X chromosome. The inversions involve
three highly homologous DNA sequences of approximately 9.5 kb. One copy is
found within intron 22 of the factor VIII gene, the remaining two copies 500 kb
proximal to the factor VIII gene. Intrachromosomal recombination can occur
between the copy within intron 22 and either of the two proximal copies. This
results in a separation and inversion of exons 1 to 22 of the factor VIII gene to a
position 500 kb proximal of the remaining introns 23-26, and hence complete
inactivation of the gene (Lakich et al, 1993; Naylor et al, 1993).
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5. Factor IX
5.1 Function of Factor IX
The plasma protease factor IX plays a critical role in the blood coagulation pathway,
Figure 1. The proenzyme factor IX is converted to its active form factor IXa, in the
presence of calcium ions, by activated factor XI (intrinsic pathway) or by tissue
factor complexed to activated factor VII (extrinsic pathway), Figure 1. Factor
IXa's function is to activate factor X. Although information on this reaction is
incomplete, factor IXa appears to bind to the activated cofactor Villa and, in the
presence of calcium ions and platelets, to form a complex known as tenase. This
tenase complex converts the proenzyme factor X to its enzyme form factor Xa. As
previously discussed, factor Villa acts as a cofactor, increasing the Vmax of the
activation of factor X by factor IXa (Griffith et al, 1982; Neuenschwander & Jesty,
1988).
5.2 Structure of Factor IX
Human factor IX circulates as a single polypeptide chain of 415 amino acids. It has
a molecular weight of 55 kDa, of which approximately 20% is carbohydrate. Upon
activation the single chain is cleaved forming a 45 kDa protein which consists of a
heavy and a light chain, Figure 3. Two potential asparagine linked sites are found at
residues 157 and 167, and an oligosaccharide residue is attached at serine 53.
The structure of factor IX can be divided into four distinct domains. The Gla
domain extends from residues 1 to 46 and contains 12 y-carboxyglutamic acid
residues. A major function of this domain is calcium dependent phospholipid
binding. In addition, residues 3 to 11 of this domain are also essential for binding
factor IX to endothelial cells (Cheung et al, 1992).
Factor IX contains two epidermal growth factor (EGF) like domains, EGF-1 and
EGF-2 (Stenflo, 1991). The EGF-1 domain comprises residues 47 to 84. The
function of this domain is unclear. However, it does contain one high affinity
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calcium binding site, which has been suggested to be involved in the conformational
changes necessary for interaction with factor VIII and factor X. The EGF-2 domain
comprises residues 85 to 124. The function of this domain is also unknown;
however, it has been suggested that it is necessary for factor IXa incorporation into
the tenase complex.
Residues 145 to 180 are known as the activation peptide, as this section is cleaved
from the zymogen during factor IX activation. Although this section contains most
of the carbohydrate, no specific function has been attributed to it.
The domain extending from residues 181 to 145, is known as the catalytic domain.
This region contains an active site which is typical of all serine proteases, histidine
221, aspartate 269 and serine 365. Following cleavage of the activation peptide, the
heavy chain amino terminal valine 181 forms an ion pair with asparagine 364. This
ion pair formation positions the active site serine 365 for interaction with factor IX
substrate, factor X (Hamaguchi et al, 1993).
5.3 Activation of Factor IX
Factor IX is the zymogen of a serine protease and has no enzyme activity in the
single chain form. Factor IX is activated by the cleavage of two peptide bonds
arginine 145 - alanine 146 (the a cleavage) and arginine 180 - valine 181 (the (3
cleavage). This results in the release of a short activation peptide, molecular weight
10 kDa, and the generation of activated factor IX, Figure 3. Although the
activation peptide is cleaved from the zymogen during activation, it appears to
remain non-covalently associated with the molecule. Activated factor IX has a
molecular weight of 45 kDa and consists of a heavy and a light chain, connected by
a disulphide bond.
In vitro, both factor XIa (Davie, 1987) or factor Vila complexed to tissue factor
(Osterund & Rapaport, 1977), in the presence of calcium are capable of cleaving
bonds 145 to 146 and 180 to 181. It is not known how factor IX is activated in
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vivo. Activation of factor IX has no requirement for a cofactor, unlike the
activation of all other steps in the coagulation factor cascade involving the
activation of a vitamin K-dependent protein (factor VII, factor X), Figure 1.
Furthermore, the activation rates are relatively slow in comparison with other
activation steps in the coagulation pathway. This inefficiency in factor IX activation
is thought to be physiologically important in providing a control step in coagulation.
5.4 Inactivation of Factor IX
In vitro, factor IX is inactivated slowly by anti-thrombinm (Rosenberg et al, 1975).
The potential role of plasma protease inhibitors other than anti-thrombin III in the
clearing of factor IXa from the circulation is unknown.
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FIGURE 3: Activation of factor IX. Factor IXa or factor Vila-tissue factor,
cleaves the Arg 145-Ala146 bond to generate factor IXa, with the activation peptide
remaining linked to the heavy chain. The Arg180-Val181 bond is then cleaved to
generate the active form factor IXa. Abbreviations: Ala = alanine, Arg =
arginine, Ser = serine, Tyr = tyrosine, Val = valine.
(Adapted from High & Roberts, 1995)
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6. Factor IX Gene Structure
The factor IX gene is located on the X-chromosome at band Xq27, about 40
megabases proximal to the factor VIII gene. The factor IX gene is approximately
33.5 kbp long, and comprises of 8 exons (Choo et al, 1982; Kurachi & Davie,
1982). The gene encodes a 1.4 kb messenger RNA, which translates into a
precursor protein of 461 amino acid residues.
6.1 Factor IX Gene Mutations
As with factor VIII gene mutations resulting in haemophilia A, a database of factor
IX gene mutations resulting in haemophilia B has been compiled. The last update of
the haemophilia B database contained information on 1142 patients and reported the
detection of 476 unique mutations. The mutations included 97 short deletions or
insertions, 291 different amino acid substitutions and 106 mutations resulting in
STOP codons. Within the factor IX gene approximately 32% of mutations resulting
in termination codons or amino acid substitutions are a result of C to T transitions
(Giannelli et al, 1994). This database does not include information reported in the
literature on a number of patients who have complete or partial gene deletions or
complex gene rearrangements.
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7. Coagulation Factor Concentrates Available for the Treatment of
Haemophilia
A range of products are available for the treatment of haemophilia, including various
factor VIII and factor IX concentrates derived from human plasma and biosynthetic
factor VIII products.
7.1 Feedstock Preparation
Human plasma for fractionation is collected from donors either as a whole blood
donation, from which the cellular components are removed, or by plasmapheresis,
where the cellular components are removed and returned to the patient. Plasma is
collected in a solution of anticoagulant to prevent the donation from clotting.
Following donation, the separated plasma is stored frozen for later processing.
Since, virtually all factor VIII purification methods begin with the extraction of
factor VIII from cryoprecipitate, freeze-thawing operations are of importance.
Several stages of freeze-thaw process can be identified: freezing to -27°C and
storage, the first stage of thawing of the plasma to -10°C and the second stage of
thawing to a liquid state at 0-2°C. The plasma is then ready for entry into the
fractionation process. Factor VIII is contained in the cryoprecipitate which forms
when frozen plasma is thawed, and factor IX in the supernatant; therefore
cryoprecipitate is used as a feed stock for factor VIII production and the




Precipitation was the protein separation technology initially used for fractionation of
factor VIII, and ethanol selected as the precipitation reagent because of its volatile
behaviour which enables it to be removed by drying technology (Edsall, 1947).
Precipitation is a process whereby proteins are separated according to their
solubility differences. The solubility of a protein is affected by a large number of
parameters, some of these are specific to each protein and cannot be altered, e.g.
molecular size, amino acid sequence and composition. The solubility of a protein is
also altered by its enviroment This may be changed easily, e.g. pH, temperature
and ionic strength. Modifications of these variable parameters can be used to cause
a selected protein or group of proteins to leave solution, hence precipitation.
Concentrates produced by this method are known as intermediate purity factor VIII
concentrates as they contain less than 10 IU of factor Vlll/mg of protein and
contain many other contaminating proteins such as fibrinogen and fibronectin. This
type of concentrate is being used less than formerly in the UK, as higher purity
concentrates, produced by chromatography and recombinant DNA techniques are
now readily available. Examples of this type of concentrate which are still licensed
for infusion are Profilate OSD (Alpha Therapeutic Corporation) and Haemate P
(Behringwerke).
7.3 Affinity Chromatography
Affinity chromatography is based on the adsorption principal. Adsorption is a
technique whereby selected proteins or groups of proteins can be separated by
selective binding from solution to a solid phase material. Solid phase reagents can
be categorised according to the forces responsible for adsorption, for example
charge interaction (ion-exchange), chemical interaction (affinity) and interaction
with specific antibodies (immunoaffinity).
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(i) Ion-exchange Chromatography
The principle of ion-exchange chromatography is that charged molecules adsorb to
ion-exchangers reversibly, so that molecules can be bound and eluted by changing
their ionic enviroment. Ion-exchangers can be used to separate molecules according
to charge. Their chromatographic behaviour of proteins on an ion-exchange column
is also sensitive to charge distribution and density and the molecular weight of the
molecule. Separation on ion-exchangers is usually in two-stages; first the substance
to be separated is bound to the exchanger using conditions that give stable and tight
binding. The column is then eluted with buffers which compete with the bound
material for the binding sites.
A method for the preparation of factor IX concentrates is ion-exchange using the
anion exchanger DEAE. Factor IX concentrates produced by this method contain
approximately 10-20 IU of factor IX/mg of protein. Examples of factor IX
concentrates produced by this method are Defix (Scottish National Blood
Transfusion Service, S.N.B.T.S.), and 9A (Bio Products Laboratory, B.P.L.).
However, concentrates produced by this method also contain other vitamin K
dependent procoagulant proteins such as factors II, VII and X. In addition trace
amounts of other proteins such as factor XII, a2-macroglobulin and ceruloplasmin
have been detected in these concentrates (Pejaudier ex al, 1987). Factor IX
concentrates produced by this method are considered to be of intermediate purity as
they contain many other proteins and have a low specific activity. Further
purification following ion-exchange chromatography is necessary to remove these
proteins. Immunoaffinity chromatography or a second anion exchange
adsorption/desorption step, followed by affinity chromatography using dextran
sulphate, has been used for this purpose. Factor IX preparations which are double
purified by these methods are considered to be "high purity" products. An example
of a concentrate produced by this method is AlphaNine SD (Alpha Therapeutic
Corporation). Figure 4 outlines a typical plasma fractionation process used by
S.N.B.T.S in the production of their high purity factor IX concentrate, High Purity
IX.
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The anion exchanger DEAE has also been used in the further purification of factor
VIII from precipitate (Burnouf et al, 1991). By changing the pH or the ionic
strength of the buffers used to elute the column, specific proteins can be purified;
also, by careful selection of the solid phase matrix to which the DEAE is bound,
further purification on the basis of molecular weight can be achieved. Factor VIII
concentrates produced by ion-exchange have a specific activity of >100IU of factor
Vlll/mg of protein and are considered to be high purity concentrates. Factor VIII
concentrates of this type are now widely prescribed in place of those manufactured
by conventional precipitation. Examples of this type of factor VIII concentrate are
High Potency Factor VIII (HPVIII) now known as Liberate (S.N.B.T.S.) and
Immunate (Immuno).
A typical plasma fractionation operation producing ion-exchange purified factor
VIII is shown in Figure 4. The process outlined here is based on the plasma
fractionation processes used by S.N.B.T.S. to produce the factor VIII concentrate
HPVIII.
For the manufacture of factor VIII concentrate, the cryoprecipitate formed during
the freeze-thawing processes is resuspended and the proteins separated by cold-
ethanol precipitation. Cold ethanol precipitation is the dominant protein separation
technique used in plasma fractionation (Kistler & Nitschmann, 1962; Hoist et al,
1978). Several precipitation steps are necessary to ensure the removal of fibrinogen
and fibronectin (Newman et al, 1971; Thorell & Blomback, 1984; Ng et al, 1986),
which are poorly soluble adherent proteins which may hamper subsequent
chromatographic and filtration operations. Following the precipitation of protein,
residual proteins of the prothrombin complex are removed by adsorption to
aluminum hydroxide (Newman et al, 1971). The separation of proteins by
precipitation is complete when the solid and liquid phases have been separated.
Centrifugation is used for this purpose. At this point, most manufacturers include a
viral inactivation step such as solvent detergent treatment, pasteurisation or heat
treatment. Subsequent to viral inactivation, chemicals used in solvent-detergent
treatment or stabilisers used in pasteurisation must be removed by further
purification. This may be achieved chromatographically, using either ion-exchange
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or immunoaffmity adsorption or size exclusion chromatography. Since factor VIII
is only a trace protein in plasma, highly purified preparations will contain only small
amounts of protein. It is therefore necessary that the product be carefully
formulated to minimise adsorption of factor VIII to the container surface and to
make it compatible with the final stages of manufacture such as freeze drying and
sterile filtration. This may be achieved by adding amino acids or human albumin to
the product, increasing ionic strength, preventing adsorption to the container and
providing a bulking agent for freeze drying (Mcintosh & Foster, 1990).
(ii) ChemicalAffinity Chromatography
Chemical affinity chromatography is based on the same adsorption principle as ion-
exchange but, instead of utilising charge effects, affinity of the protein to certain
chemicals is exploited.
Factor VIII can be further purified by passing precipitate through columns
containing heparin coupled to cross-linked agarose. vWF has an affinity to heparin,
and since vWF is bound to factor VIII, it is separated form other contaminating
proteins. An example of a factor VIII product purified by this technique, which is
licensed, is Alphanate (Alpha Therapeutic Corporation). Factor VIII produced by
this method has a specific activity of 1000 IU of factor Vlll/mg of protein.
However it is unstable and requires the addition of human albumin as a stabiliser.
Factor IX purified by DEAE ion-exchange may also be further purified by chemical
affinity to metal chelates bound to solid matrix columns, Bio Products Laboratory



















































FIGURE 4: Typical plasma fractionation operation.
The fractionation procedures outlined here are based on processes at the Protein
Fractionation Centre, Scottish National Blood Transfusion Service, Edinburgh.
(Adapted from Foster, 1994)
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(Hi) Immunoaffinity Chromatography
Factor VIII can be further purified from precipitate by using monoclonal antibodies
directed against vWF (Monoclate P, Armour Pharmaceutical Company) or factor
Vni (Hemofil M, Baxter Laboratories). When monoclonal antibody to vWF is used
to purify factor VIII, the column is eluted with a calcium solution. Since calcium is
a known stabiliser of factor VIII, it is gently dissociated from the vWF bound to the
column. Following purification by the monoclonal antibody affinity column, the
factor VHI containing elute is subjected to ion-exchange chromatography to remove
any unwanted material, including murine antibody. Factor VIII purified by
immunoaffinity is unstable, as it is purified without vWF, therefore human serum
albumin is added as a stabiliser. Factor VIII concentrates purified by this method
have a specific activity of approximately 3000 IU of factor Vlll/mg of protein prior
to the addition of albumin.
Factor IX can also be further purified from DEAE adsorption prepared concentrates
by using a monoclonal antibody to factor IX. Only one concentrate is at present
produced by this method, Mononine (Armour Pharmaceutical Company).
7.4 Recombinant DNA Techniques
Development of recombinant factor VIII began in 1984 when the factor VIII gene
was characterised and cloned (Gitscher et al, 1984; Toole et al, 1984). Chinese
hamster ovary (CHO) cells were chosen as the cells to produce recombinant factor
VIII. The factor VIII cDNA was introduced into an expression vector and
transfected into CHO cells. However, factor VIII biosynthesis by CHO cells is
limited due to instability of the mRNA, inefficient secretion and the instability of the
protein in the media. Attempts to improve efficiency of production have focused
primarily on the development of cDNA constructs which lack most of the B domain.
As previously mentioned, the B domain is not required for normal procoagulant
function (Toole et al, 1986). Indeed, increased yields of factor VIII have been
observed from CHO cells transfected with B domain-less cDNA. A recombinant
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product without the B domain is at present undergoing clinical trials (r-VIII SQ,
Pharmacia).
Factor VIII is purified from medium harvested from CHO cell cultures initially by
immunoaffinity chromatography. The factor VIII eluted from the column is then
further purified by ion-exchange which removes any residual contaminating
components. Following this, the recombinant factor VIII has albumin added as a
stabiliser. The specific activity of these products is more than 3000 IU of factor
Vin/mg of protein before the addition of albumin.
Although the factor IX gene was cloned and sequenced in 1982 (Kurachi & Davie,
1982; Choo et al, 1982) a recombinant factor IX concentrate for clinical use has yet
to be licensed. Many problems have hindered the production of recombinant factor
IX. These problems relate to the many post-translational modifications which are
required to produce active functional factor IX. Most expression systems are
unable to perform the modifications, which include glycosylation, cleavage of the
propeptide and carboxylation. Therefore, large amounts of non-functional protein
are produced along with small amounts of functional protein. In addition, there are
fewer patients with haemophilia B than haemophilia A and, therefore, not the same
financial incentive to produce factor IX concentrates as there is to produce factor
VIII concentrates.
7.5 Sterile Filtration and Freeze Drying
Concentrates prepared for infusion into patients must be sterile at the point of use.
This is achieved by filtration of the finally formulated solutions through a series of
filters, down to a final 0.2 |im membrane filter. Processing beyond this point, such
as dispensing and freeze drying must all be carried out under sterile conditions.
Preparations for use in patients must have a defined shelf life and must retain their
biological activity for this length of time. Freeze drying of products fulfills these
criteria. Freeze drying involves the separation of water from non-volatile
constituents by sublimation from a frozen state (Nicholson, 1977). For this process
the product is cooled to a temperature below which no significant liquid-solid
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phase transition exists. The majority of the water is then sublimated from heating
the frozen product under reduced pressure. When sublimation is complete further
heat and pressure is applied to remove residual moisture. A final moisture content
of approximately 2% is usually achieved.
As discussed above, there are many different types of coagulation factor concentrate
available for the treatment of haemophilia. At present these concentrates are
labelled as "intermediate purity", "high purity" and "very high purity" based on the
specific activity, which is the amount of coagulation factor activity present per mg
of protein (IU/mg). Specific activity of a product is determined at the point of
manufacture when the coagulation factor is at its purest. However, there is much
controversy surrounding this method of labelling.
Immunoaffinity purified products contain almost exclusively factor VIII and only
trace amounts of fibrinogen and fibronectin. This type of product, following
chromatography, has a specific activity of approximately 3000 IU/mg. However,
these products are unstable as factor VIII is purified without its natural stabiliser
vWF. In order to aid stablisation and administration, purified human serum albumin
is added following elution from the immunoaffinity column. Factor IX products
produced by immunoaffinity do not require the addition of albumin as a stabiliser.
As with immunoaffinity purified products coagulation factors produced by
recombinant methods are unstable and therefore have albumin added as a stabiliser.
These products, before the addition of stabiliser, have a specific activity of
approximately 3000 IU/mg of protein. One particular recombinant factor VIII
product which has no B domain is an exception, in that it is very stable, eliminating
the need to add protein stabilisers.
Ion-exchange purified products contain factor VIII complexed to its stabiliser vWF
and trace amounts of fibrinogen and fibronectin. On elution from chromatography
columns, products are formulated direcdy and have a specific activity of >100
IU/mg. Other remaining proteins, including vWF in factor VIE concentrates, are
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considered to be "contaminants" and the specific activity is reduced accordingly.
The vWF content of ion-exchange purified factor VIII concentrates can vary
greatly, from almost physiological concentrations to none at all (Fricke & Wong,
1989).
Controversy exists around the addition of stabilisers to some concentrates. As
albumin is considered as a stabiliser, the specific activity quoted by some
manufacturers is not altered after its addition. Following the addition of albumin the
final specific activity is reduced from approximately 3000 IU/mg of protein to less
than 10 IU/mg of protein. In addition, albumin used to stabilise these products is
prepared from pooled human plasma and contains approximately 95% albumin, the
remaining 5% being other proteins. The effect that these contaminating proteins
should have on calculating specific activity remains under intensive debate. For the
purpose of this study, coagulation factor concentrates are classified according to
their method of manufacture:




- recombinant DNA technology manufactured
An exception to the above classification is factor IX concentrates prepared by
DEAE ion-exchange but not further purified to remove other vitamin K dependent
procoagulant proteins. These concentrates are considered to be of intermediate
purity and are categorised accordingly. Factor IX concentrates further purified by
ion-exchange are categorised so, as are those further purified by affinity.
49
8. Other Products Available for the Treatment ofHaemophilia
As previously mentioned, patients with mild to moderate haemophilia A (factor VIII
levels 2-40% of normal) only bleed excessively as a result of trauma or surgical
procedures. Unlike patients with severe haemophilia who require coagulation factor
replacement therapy, treatment with l-Deamino-8-D-arganine vasopressin
(DDAVP) is usually sufficient treatment for most bleeding episodes.
DDAVP is a synthetic analogue of vasopressin, which has been shown to prevent
bleeding in patients with mild to moderate haemophilia A or von Willebrand Disease
(Mannucci et al, 1977). Treatment with DDAVP is of no value to haemophilia B
patients. The mechanism by which DDAVP increases factor VIII and vWF is
unclear, but it is thought to stimulate the release of factor VIII from storage sites
(Mannucci et al, 1981).
Treatment of mild to moderate haemophilia A by this method has reduced the need
for blood products, thereby reducing the risk of transfusion acquired diseases such
as, HTV and hepatitis B and C. DDAVP is administered to the patient either by
intravenous or subcutaneous injection or intranasally, by the use of a simple
atomiser.
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9. Infectious Complications of Coagulation Factor Replacement
Therapy
Coagulation factor concentrates have been associated with the transmission of
viruses. Concentrates have been shown to have transmitted; hepatitis A virus
(Mannucci, 1992), hepatitis B virus (Mannucci et al, 1988), hepatitis C virus
(Watson et al, 1992), hepatitis D virus (Kingdon, 1970), B19 parvovirus (Azzi et al,
1992) and human immunodeficiency virus (HIV) (CDC, 1987a; CDC, 1987b). For
this reason, measures to prevent viral transmission by coagulation factor
concentrates have been introduced.
9.1 Virucidal Treatment of Coagulation Factor Concentrates
In order to minimise the risk of viral transmission by plasma derived coagulation
factor concentrates, blood donors at low-risk of viral infection are selected and
screening of blood donations has been implemented. At present in the UK all
donations are screened for hepatitis B, hepatitis C and HIV-1 and -2. However,
these methods alone are not sufficient to abolish viral transmission and a few virally
infectious donations escape detection. Residual viruses that may have escaped
detection at donor screening may be destroyed during concentrate manufacture by
specific inactivation steps, such as pasteurisation, dry heat and solvent detergent
treatment.
(i) Dry Heating
Terminal dry heating of lyophilised concentrates by manufacturers first began in the
early 1980's. Concentrates were exposed to temperatures between 60°C and 68°C
for up to 72 hours. Clinical evaluation of patients receiving these concentrates
provided clear evidence that some concentrates "virally inactivated" at these
temperatures still transmitted the hepatitis viruses (Colombo et al, 1985; Allain et
al, 1986; Preston et al, 1985; Lush et al, 1988; Blacnchette et al, 1991, Pistello et
al, 1991) and HIV (White et al, 1986; van den Berg et al, 1986; Mariani et al,
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1987; Weisser, 1988; Dietrich et al, 1990; Remis et al, 1990; Williams et al,
1990). Dry heating at a higher temperature of 80°C for 72 hours is currently being
used to virally inactivate the concentrates 8Y (factor VIII concentrate), 9A (factor
IX concentrate) manufactured by BioProducts Laboratory (BPL) and Defix (factor
IX concentrate) manufactured by S.N.B.T.S. Products heated in this manner show
good coagulation factor recovery after the heating step (Foster & Mcintosh, 1992).
The advantage of heat treatment is that it can be carried out on the freeze dried
product in its final container. Clinical studies on the viral safety of these
concentrates have shown no transmission of the hepatitis viruses or HIV (Study
Group of the UK Haemophiliac Centre Directors, 1988; Skidmore et al, 1990;
Evans et al, 1991; Bennett et al, 1993). However, viral escape of the non-
enveloped B19 Parvovirus has been reported (Williams et al, 1990a).
(it) Pasteurisation
This virucidal method is currently used in the production of both intermediate purity
concentrates, such as Haemate P (factor VIII concentrate) manufactured by
Behringwerke) and concentrates purified by immunoaffinity, such as Monoclate P
manufactured by Armour Pharmaceutical Company. This treatment involves the
heating of the concentrate to 60°C in aqueous solution for a period of 10 hours.
The loss of coagulation factor activity is one disadvantage of this method. There
are no simple stabilising formulations for heating solutions of products which
contain labile biological activities like factor VIII. Factor VIII activity can only be
stabilised against pasteurisation by the addition of high concentrations of
carbohydrate and glycine. However, such formulations cannot be used for final
products and extra processing is required to remove the stabilisers after viral
inactivation.
Studies on HIV transmission have shown that pasteurised concentrates have an
excellent safety record; indeed a large retrospective study on 155 patients treated
solely with pasteurised concentrate since 1979, reported that no HIV
seroconversions had occurred in over 9 years (Schimpf et al, 1989). Furthermore,
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when the immunoaffinity purified factor VIII concentrate Monoclate P was spiked
with HIV, virus inactivation studies showed that pasteurisation reduced HIV by
10.5 logio in comparison to an unheated control solution (Hrinda et al, 1990).
Patients treated with the pasteurised intermediate purity factor VIII concentrate
Haemate P also showed no clinical or serological signs of infection with hepatitis,
although some patients developed serological signs of infection with the heat
resistant, non-enveloped B19 parvovirus (Azzi et al, 1992).
86 previously untransfused children who were treated solely with Haemate P were
followed for up to 10 years. These patients were found to be consistently
serologically negative for hepatitis C and showed no signs of infection with the virus
(Kreuz et al, 1992).
Only nine cases independent of these studies have reported viral infection with
hepatitis B or C (Brackmann et al, 1988; Schulman et al, 1992; Gerritzen et al,
1992; Shopnick et al, 1995). Therefore, even though the record of hepatitis safety
of pasteurised concentrates reported by studies is excellent, there appears to be
some risk of hepatitis infection even after pasteurisation.
(iii) Vapour Heating
This procedure was developed by Immuno and involves heating dried powder at
60°C for 10 hours in the presence of steam, under a pressure of 1190 mbar in a
closed container.
Initial trials of 28 previously untransfused patients receiving concentrate virally
inactivated by this method, reported that 4 out of the 28 patients had developed
clinical or serological evidence for hepatitis B infection (Mannucci et al, 1988), 1
patient also developed hepatitis C (Mannucci et al, 1990). A subsequent study of
50 patients treated with vapour heated concentrate recorded no case of hepatitis or
HIV infection (Mannucci et al, 1992a; Shapiro & the International Factor Safety
Study Group, 1992). Whether these favourable results are due to an improvement
in this viral inactivation method is unknown.
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(iv) Solvent/Detergent
This method of viral inactivation involves the addition of an organic solvent tri (n-
butyl) phosphate (TNBP) and a detergent (sodium cholate, Tween 80 or Triton X-
100) at a bulk intermediate step in the manufacturing process. This method has
been evaluated extensively in blood product applications and shows good product
yield. Extensive processing steps after treatment ensure only trace amounts of these
chemicals remain in the final concentrate. These chemicals lyse viruses with lipid
envelopes, thereby inactivating large amounts of hepatitis B, hepatitis C, hepatitis D
and HIV. This procedure has the advantages of being relatively simple and
maintains high yields of biologically active factor VIII. Solvent/detergent treatment
is now the most widely used of the viral inactivation procedures.
Several clinical studies have shown that no cases of hepatitis B, hepatitis C or HIV
infection have occurred in a large number of previously untreated patients, treated
exclusively with solvent/detergent inactivated product (Horowitz et al, 1988;
Gazengel et al, 1988; Noel et al, 1989; Gonzaga & Boneker, 1990; Mariani et al,
1993; Addiego et al, 1992; Dipaolantonio et al, 1992). However, this viral
inactivation procedure is ineffective on non-enveloped viruses, such as hepatitis A
and B19 parvovirus. Infection with B19 parvovirus has occurred in a number of
haemophiliacs infused with solvent/detergent treated concentrate (Azzi et al, 1992).
In addition, B19 parvovirus DNA has been detected in solvent/detergent treated
concentrates (Lefrere et al, 1994). An outbreak of infection with another non-
enveloped virus, hepatitis A, has been recorded in 85 haemophiliacs from four
countries, all treated with solvent/detergent factor VIII concentrate manufactured
by Octapharma (Mannucci, 1992; Gerritzen et al, 1992a; Temperley et al, 1992;
Peerlinck & Vermylen, 1993).
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(v) Combined Virus Inactivation Techniques
In order to obtain absolute viral inactivation of both enveloped and non-enveloped
viruses, manufacturers are beginning to use combined inactivation procedures.
Chemical procedures such as solvent/detergent and physical methods such as
heating or ultrafiltration are usually combined. Examples of products which
undergo dual viral inactivation procedures are given below.
The factor IX concentrate Mononine manufactured by Armour, is virally inactivated
using the chemical sodium thiocyanate and the inactive virus removed by
ultrafiltration. Clinical trials assessing the viral safety of this concentrate are
currently in progress. The ion-exchange purified concentrates from Immuno,
Immunate STIM plus (factor VIII concentrate) and Immunine STIM plus (factor IX
concentrate) are virally inactivated using two separate procedures, one chemical and
one physical. The first is a Polyglycate treatment, which specifically inactivates
retroviruses. These concentrates then receive terminal virus inactivation by vapour
heating. Factor VIII concentrates which are both solvent/detergent treated then
terminally heat treated are currently being developed by manufacturers including
Alpha Therapeutic Corporation, Novo Nordisk, Octapharma and Aima.
(vi) Viral Safety ofRecombinant Products
Coagulation factors produced by recombinant methods should carry no risk of
transmitting blood borne viruses. However, there is a risk of infection from the
human albumin used to stabilise these products and the bovine albumin used in the
cell culture medium. There is also a theoretical risk that viruses associated with
mammalian cell cultures may be pathogenic in humans. In order to minimise the risk
of viral transmission from bovine or human albumin, manufacturers virally inactivate
these preparations before use in the manufacturing process. Manufacturers claim
that there is no risk of the hamster cells used in the manufacture of recombinant
products carrying viruses harmful to humans. However, as an additional precaution,
some manufacturers have introduced viral inactivation methods into the production
process. Clinical studies on the viral safety of recombinant products are currently in
progress.
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10. Immunological Abnormalities in Haemophiliacs Receiving
Coagulation Factor Replacement Therapy
The occurrence of HIV infection and AIDS in haemophiliacs (Ludlam, 1994),
resulting from the use of contaminated coagulation factor concentrates, has led to
an intensive study of the immune system of both HIV negative and HIV positive
haemophiliacs. It is now recognised that clotting factor concentrates may cause
immunological abnormalities, in haemophilia patients, distinct from those related to
HIV infection. It has been proposed that these disturbances of the immune system
are caused by the massive protein load (Ludlam et al, 1983), specific impurities
(Wadhwa et al, 1994) or viruses (Evans et al, 1995; Pasi et al, 1995) in coagulation
factor concentrates. These immune abnormalities which are observed in vivo and in
vitro are summarised in Table 1 and Table 2 respectively.
10.1 Immune Abnormalities Observed in vivo in Haemophiliacs in the
Absence ofHIV Infection
As early as 1983 investigators demonstrated that haemophilia A patients have a
reduced ratio of CD4+ lymphocytes to CD8+ lymphocytes (Ludlam et al, 1983;
Menitove et al, 1983). This is partly due to a reduction in CD4+ lymphocytes (Carr
et al, 1984; Moffat et al, 1985; Antonaci et al, 1987; Cuthbert et al, 1992).
However, this ratio is also lowered due to an absolute increase in the numbers of
CD8+ lymphocytes (Gamba et al, 1987; Freedman et al, 1987). Interestingly,
haemophilia B patients treated with factor IX concentrates had T lymphocyte
subsets comparable to that of normal controls (Carr et al, 1984; Cuthbert et al,
1992). No correlation was found between clotting factor consumption and T
lymphocyte subset alterations (Carr et al, 1984).
CD4+ lymphocytes of haemophiliacs receiving replacement therapy are affected not
only quantitatively but also qualitatively. Cell mediated immunity, as assessed by
the intradermal injection of recall antigens or dinitrochlorobenzene (DNCB), has
revealed that HIV negative and HIV positive haemophiliacs are, to a large extent,
unable to develop delayed hypersensitivity responses, which are an in vivo indicator
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of CD4+ T cell function (Brettler et al, 1986; Madhok et al, 1986; Cuthbert et al,
1992). Cell mediated immunity was found to be depressed to a greater extent in
haemophilia A patients than in haemophilia B patients. A positive correlation
between impairment of cell mediated immunity and annual factor VIII consumption
has been demonstrated (Brettler et al, 1986; Madhok et al, 1986; Cuthbert et al,
1992). However, no such correlation was observed in the recipients of factor IX
concentrates (Cuthbert et al, 1992).
It has been reported that haemophiliacs have an increased incidence of tuberculosis
(Beddall et al, 1985) and recurrent hepatitis B (Williams et al, 1988). More
recently, an HIV negative individual treated with factor VIII concentrate presented
with oesophageal candidiasis, a condition suggestive of immune dysfunction
(Watson et al, 1992a). This evidence suggests that the previously mentioned
abnormalities of the immune system may be of clinical importance.
10.2 Abnormalities Observed in vitro in Cells of the Immune System Derived
from Haemophiliacs Receiving Coagulation Factor Replacement Therapy
(i) T Lymphocytes
Peripheral blood mononuclear cells (PBMC) from haemophilia A patients show a
reduction in response to activation with the T cell mitogens phytohaemagglutinin
(PHA) and concanavalin A (Con A), in comparison to control cultures (Froebel et
al, 1983; Lederman et al, 1983; Moffat et al, 1985; Mahir et al, 1988).
T lymphocytes from haemophiliacs have also been shown to have a reduced capacity
to produce interleukin 2 (IL-2) following PHA stimulation in vitro (Madhok et al,
1990; Madhok et al, 1991). This impaired production occurs irrespective of HIV
antibody status, mean annual dose of factor VIII concentrate and liver disease
severity.
Similarly, the production of interferon y (IFN-y) by T lymphocytes from HIV
negative haemophiliacs is reduced (Ruffault et al, 1988).
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More recently, Evans and colleagues (1995) studied the responses of lymphocytes
derived from haemophiliacs to T cell mitogens. Three groups of haemophiliac boys
and one control group were studied. Group 1 comprised 18 haemophiliac boys who
were HIV negative and HCV negative. Group 2 comprised 12 HCV positive
patients and Group 3 comprised 18 patients who were both HIV and HCV positive.
Haemophiliacs negative for both HIV and HCV showed no significant reduction in
lymphocyte proliferation in response to mitogens, when compared to the control
group. Lymphocytes from boys of both groups 2 and 3 showed impaired response
to mitogens compared to group 1 and the control group. No correlation between
the factor VIII concentrate received and proliferative response was observed. The
authors suggested that infection with viruses, such as HCV, may account for this
impaired lymphocyte response and other similar lymphocyte function abnormalities.
(ii) B Lymphocytes
In normal individuals the pool of circulating B lymphocytes contains cells at
different stages of activation; resting, partially activated, and fully activated cells
which spontaneously secrete immunoglobulin. Studies on B lymphocytes from both
HIV positive and HIV negative haemophiliacs have shown an increase in numbers of
partially and fully activated B lymphocytes and consequently
hypergammaglobulinaemia (Brevia et al, 1985). These findings were initially
attributed to allogenic stimulation by foreign proteins which contaminate
coagulation factor concentrates. Recently a study of B lymphocyte dysfunction in
haemophiliacs demonstrated that the majority ofHIV negative patients have in vitro
immunoglobulin production similar to controls. Only in HIV negative patients with
severe fiver disease is increased spontaneous immunoglobulin production observed
(Madhok et al, 1991). These results suggest that fiver disease and not replacement
therapy is the cause of B cell abnormalities in HTV negative haemophiliacs.
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(iii) Monocytes
Monocytes from haemophiliacs receiving high amounts of coagulation factor
concentrate have significantly lower expression of human leukocyte antigen-DR
(HLA-DR), leukocyte function associated antigen-1 (LFA-1) and CR3 antigen (Roy
et al, 1988). In addition, haemophiliac monocytes demonstrate reduced adhesion
and an impairment in their response to chemotactic stimuli. No correlation between
these observations and patient HIV status was found. However, a correlation
between all of these changes and the annual dose of factor VIII concentrate was
observed.
Furthermore, a deficiency in monocyte-T cell interaction after in vitro exposure to a
bacterial antigen was observed in patients receiving factor VIII concentrates
(Mannhalter et al, 1986). This functional defect in the early phase of the immune
response, which has previously been described in patients with primary
immunodeficiency (Eibl et al, 1982; Eibl et al, 1982a), may contribute to
haemophiliacs' increased risk of opportunistic infections.
On the other hand, a recent study by Pasi et al (1995) suggested that impairment of
monocyte function in haemophiliacs is due to viral infection rather than replacement
therapy. Monocyte antigen presentation and cytokine production was studied in the
same groups as Evans et al, 1995 (see previous section on T lymphocytes). The
group which were both HIV and HCV negative showed no significant reduction in
antigen presentation nor in IL-1 and IL-6 secretion, in comparison to the control
group. Monocytes derived from the HCV positive, HIV negative, group
demonstrated a significant reduction in antigen presentation, but no reduction in IL-
1 or IL-6 secretion. Monocytes from HIV and HCV positive group showed both a
reduction in antigen presentation and in cytokine secretion. The authors suggest
that the reduction of IL-1 and IL-6 production is due to HIV infection and conclude




Polymorphonuclear leukocytes form both HIV negative and HIV positive
haemophiliacs have been shown to have impaired chemotactic, phagocytic and
killing abilities. This is thought to be due to a significant decrease in the release of
leukocyte inhibitory factor (LIF) and leukocyte derived chemotactic factor (LDCF)
(Antonaci et al, 1987).
(v) Natural Killer Cells
Natural killer (NK) cells from haemophiliacs who received large infusions of
intermediate purity clotting factor concentrate were assessed for reactivity to EFN-
a, -(3, -y (Matheson et al, 1986). In repeated experiments it was demonstrated that
haemophiliac NK cells had an impaired response to IFN-f3 and IFN-y, but a normal
response to IFN-a. Down-modulation of IFN receptors may cause this impaired
response. It has been suggested that the down-modulation of these receptors is
caused by chronic antigen stimulation as a result of the treatment of haemophilia
with intermediate purity coagulation factor concentrates, which contain many
foreign proteins. There was no correlation of these findings with HIV status
(Matheson et al, 1986).
10.3 Effects of Coagulation Factor Concentrates on in vitro Immunological
Assays
(i) Lymphocyte Proliferation
In vitro studies have demonstrated that intermediate purity factor VIII and factor IX
concentrates can inhibit the proliferation of lymphocytes in a dose dependent
manner, in response to the mitogens PHA and Con A. Reductions in PHA- and Con
A-induced transformation occur when certain concentrates are incubated with
normal human PBMC preparations (Froebel et al, 1983; McDonald et al, 1985;
Lederman et al, 1986). Limited data are available regarding the effects of products
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prepared by chromatography, immunoaffinity or recombinant techniques. However,
what information there is suggests as purity increases the inhibitory effect decreases
(Schreiber etal, 1987; Hay&McEvoy, 1989; Vermot-Desroches et al, 1992).
Intermediate purity concentrates have also been shown to impair lymphocyte
proliferation in response to recall antigens (McDonald et al, 1985; Lederman et al,
1986) and to the monoclonal antibody OKT3 (Wang et al, 1985).
Inhibition of lymphocyte proliferation by coagulation factor concentrates in the
absence ofmitogens, recall antigens or OKT3 has not been observed.
Mixed lymphocyte reactions have been performed in the presence of coagulation
factor concentrates. These assays involve stimulating PBMC with allogeneic
lymphocytes in the presence of coagulation factor concentrates. The results from
different research groups employing this assay system are conflicting. Batchelor et
al (1992) reported that intermediate purity factor VIII and factor IX concentrates
enhanced the proliferation of lymphocytes in response to allogenic cells. Enhanced
proliferation was not observed with monoclonal antibody purified preparations.
However, an ion-exchange purified concentrate enhanced proliferation in this assay
system, though to a lesser extent. Those preparations which enhanced proliferation
did not do so in the absence of the allogenic stimulator cells, suggesting the
presence of co-mitogenic factor(s) in some concentrates. Enhancement of
proliferation is, paradoxically, compatible with inhibition of specific immune
function, including delayed-type skin reactions (Ascher & Sheppard, 1990). If these
coagulation factor preparations were to enhance lymphocyte activation in vivo in
response to naturally occurring immune stimuli or those present in concentrates,
there may be a decreased response to other antigens.
In contrast, three other groups reported that factor VIII concentrates inhibited
allogenic mixed lymphocyte reactions (Lederman et al, 1986; Schreiber et al, 1987;
Hay & McEvoy, 1989). However, the results from these groups cannot be
compared to those of Batchelor et al, as the concentrates studied were different and
no technical details of culture conditions used were provided by Lederman et al
(1986), Schreiber et al (1987) or Hay & McEvoy (1989).
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(ii) Interleukin 2 Production
IL-2 is a potent T-cell growth factor, whose secretion is thought to be important in
the development ofmany immunological functions. In vitro studies have shown that
coagulation factor concentrates can inhibit IL-2 secretion by mitogen stimulated
human lymphocytes or Jurkat tumor cells (human lymphoblastoid T cell line)
(Lederman et al, 1986; Thorpe et al, 1989; Madhok et al, 1990; Wadhwa et al,
1992; Wadhwa et al, 1994). Thorpe et al investigated the effects of a range of
factor VIII and factor IX concentrates on IL-2 secretion. The results demonstrated
that intermediate purity factor VIII concentrates inhibited IL-2 secretion, whereas
monoclonal antibody purified factor VIII concentrates did not. Factor IX
concentrates purified by DEAE cellulose chromatography also inhibited IL-2
secretion. These findings were supported and expanded by Wadhwa et al (1992 &
1994) whose results demonstrated that some, but not all, intermediate purity factor
VIII concentrates and those purified by ion-exchange chromatography displayed
similar inhibitory characteristics, whereas monoclonal antibody purified and
recombinant factor VIII concentrates did not cause any inhibition of IL-2 secretion.
Attempts have been made to correct the inhibitory effect of some factor VIII
concentrates on lymphocyte mitogen responses by adding exogenous IL-2 (Hay et
al, 1990). Although the addition of 250 IU/ml of IL-2 was observed to increase
lymphocyte mitogenic responses at all concentrations of factor VIII, it did not
completely reverse the inhibitory effect. This suggests the inhibition of mitogen-
stimulated lymphocyte transformation is not due to the suppression of IL-2
secretion alone.
This is supported by Wadhwa et al (1992) who observed that the addition of large
amounts of recombinant IL-2 to PHA-stimulated lymphocytes could not entirely
reverse the inhibition of IL-2 receptor expression by factor VIII concentrates. This
led them to conclude that the inhibition of lymphocyte inhibitory mitogenic
responses by factor VIII concentrates is due to more than one mechanism.
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T lymphocytes produce IL-2 in response to antigen stimulation and IL-1 secreted by
antigen presenting cells (Smith, 1988). Since, IL-2 production by Jurkat cells
proceeds independently of IL-1, it is unlikely that the inhibition caused by factor
VIII and factor IX concentrates is mediated through interference with the response
to, or production of, EL-1 (Lederman et al, 1986).
(iii) Activation Marker Expression
Incubation of PHA-stimulated lymphocytes with intermediate purity factor VIII
concentrates causes a reduction in the expression of some cell surface activation
markers. The expression of early activation markers CD25 (IL-2 receptor) and
CD71 (transferrin receptor) and the late activation marker HLA-DR, on both CD4+
and CD8+ lymphocytes, is reduced on incubation with intermediate purity
concentrates (Hay et al, 1990; Wadhwa et al, 1992). CD25 expression is the most
profoundly affected, a 95% reduction being observed in the presence of a particular
factor VIII concentrate (Hay et al, 1990). Less marked changes were observed in
CD71 and HLA-DR expression.
The effects of an ion-exchange purified factor VIII concentrate on the expression of
activation markers was also studied by Vermot-Desroches et al (1992). After
exposure of PBMC to the ion-exchange product, a reduction in the induction of
CD25, CD71 and HLA-DR expression was observed. In addition, there was
reduced up-regulation of the late antigens CD38 (marker for activated T cells) and
CD 11a/CD18 (LFA-la and LFA-1(3 respectively). Incubation of PBMC with this
factor VIII concentrate did not influence the expression of the very early antigen
CD54 (inter-cellular adhesion molecule; ICAM-1). The authors suggest that this
product inhibits lymphocyte proliferation by interacting at a precise early step in the
T cell activation process.
It has been proposed that inhibition of IL-2 secretion is a result of the down
regulation of CD25 (IL-2 receptor) by component(s) in some factor VIII
concentrates, as addition of exogenous EL-2 failed to correct the inhibitory effects of
the concentrates on lymphocyte function (Hay et al, 1990).
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On the other hand, Wadhwa et al (1992) suggested that it is the suppression of IL-2
secretion that causes the down regulation of CD25 expression. Since addition of
exogenous IL-2 does partially reverse concentrate inhibition of PHA-induced up
regulation of CD25. The authors suggest that factor VIII concentrates which inhibit
CD25 expression do so by partially inhibiting IL-2 secretion, which results in
impaired up-regulation of CD25.
(iv) Monocyte Function
The monocyte system is critical for the elimination of microbes (David, 1987). The
incubation of monocytes from healthy individuals with certain factor VIII
concentrates has been shown to affect the phagocytic function of monocytes, by
reducing the expression of IgG Fc receptors in the membrane (Eibl et al, 1987;
Mannhalter et al, 1988). This down-modulation results in an impairment of
bacterial killing and a decrease in the generation of free oxygen radicals. The
reduction in expression of IgG Fc receptors is comparable to that achieved after
pre-treatment ofmonocytes with heat-aggregated IgG, a known down-modulator of
Fc receptors (Mannhalter et al, 1987). This immune modulating activity is thought
to be attributable to a very high molecular weight compound (molecular weight
>1,270 kDa), containing IgG, IgM and traces of factor VIII.
Since the transmission of viral infections by clotting factor concentrates has
complicated the treatment of haemophilia, heat treated concentrates are widely
used. Concern was expressed that this type of virucidal treatment might cause the
formation of aggregates and increase adverse effects (Bird et al, 1985). However,
the degree of impaired monocyte function is unrelated to the mode of virus
inactivation (Mannhalter et al, 1988; Pasi & Hill, 1990). Pasi & Hill (1990)
nevertheless demonstrated that product purity does influence the degree of
monocyte Fc dependent phagocyte function and that, as product purity increases,
the observed inhibitory action of the concentrate fell.
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The impairment of monocyte phagocytic function by some factor VIII concentrates
may lead to a defect in antigen handling (Mannhalter et al, 1986). This, together
with the other in vitro observations, may account for the previously mentioned
susceptibility of haemophiliacs to viral infection.
(v) Natural Killer Cells
The effect of an intermediate purity factor VIII concentrate on natural killer cell
activity was investigated by Lederman et al (1986). Natural killer activity against
tumour antigens was assessed by a standard chromium release assay. The
concentrate was found to have minimal effect on natural killer activity, even at high
concentrations.
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11. Immunomodulatory Components in Coagulation Factor
Concentrates Affecting Lymphocyte Mitogenic Responses
11.1 Dialysable, Low MolecularWeight Inhibitory Component
It has been suggested that a dialysable, low molecular weight component of
coagulation factor concentrates is either partially or fully responsible for the
observed inhibition of lymphocyte proliferation in vitro.
McDonald et al (1985) reported that inhibition of proliferation of PBMC by
intermediate purity coagulation factors was entirely due to a dialysable component.
Proliferation of lectin or recall antigen stimulated PBMC was inhibited by a factor
VBI concentrate and a factor IX concentrate. Dialysis of these concentrates led to a
complete loss of inhibitory activity. In addition, when the buffers used in the
preparation of these coagulation factors were tested for their ability to inhibit
PBMC proliferation, the degree of inhibition was similar to that obtained with the
concentrates. A common component of these buffers was citrate. Indeed sodium
citrate alone was an effective inhibitor in their assay systems. A subsequent report
by Wang et al (1986) supported the above findings by demonstrating that the
inhibitory effect an intermediate purity factor VIII concentrate had on lymphocyte
proliferation was completely abrogated by dialysis.
Another group investigating the effects of an ion-exchange purified factor VIII
concentrate on PHA-stimulated PBMC proliferation demonstrated that a significant
portion of the inhibitory activity was due to the presence of a dialysable, low
molecular weight component (Vermot-Desroches et al, 1992). Vermot-Desroches
et al also reported that the inhibitory influence that this product had on markers of
lymphocyte activation was modified following dialysis. The expression of early
activation markers CD25 and CD71, and the late activation markers CD 11a/CD18,
CD38 and HLA-DR was inhibited by this factor VIII concentrate. After dialysis, no
significant inhibition of PHA-induced expression of these markers was observed.
The effects that dialysis has on concentrates which affect the in vitro secretion of
IL-2 by lymphocytes was investigated by Wadhwa et al (1992). A range of factor
VIII products of varying purity and process of manufacture were dialysed and their
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effects on IL-2 secretion studied. The results demonstrated that only 5-20% of the
inhibitory activity of intermediate purity products could be removed by dialysis. In
contrast, 40-60% of the inhibitory activity of ion-exchange purified products was
removed by dialysis. The authors suggest the greater dialysable inhibitory
component in ion-exchange products is due to stabilisers such as citrate being added
to these products to prevent degradation during viral inactivation.
11.2 Fractionation of Immunomodulatory Factor VIII Concentrates
Gel filtration of a conventional intermediate purity factor VIII concentrate which
inhibited PHA-stimulated lymphocyte proliferation, revealed two peaks of inhibitory
activity (Lederman et al, 1986). One of molecular weight 200 kDa, which co-
migrated with factor VIII coagulant activity and antigen, another of molecular
weight 60 kDa found in fractions devoid of factor VIII coagulant activity or antigen.
The authors also reported that fractions of intermediate molecular weight enhanced
lymphocyte proliferation. These fractions did not enhance lymphocyte proliferation
in the absence of PHA. The authors suggest that the 200 kDa species is either
factor VIII itself or that a substance bound or co-migrating with factor VIII inhibits
lymphocyte proliferation. The smaller protein was also unidentified.
Results of size exclusion chromatography on factor VIII concentrates which
inhibited IL-2 secretion by lymphocytes revealed similar results (Wadhwa et al,
1992). The results showed that most of the inhibitory activity was located in a
protein fraction with a molecular weight of approximately 200 kDa. A much
smaller peak of inhibitory activity was also observed at a molecular weight of
approximately 60 kDa. In some concentrates, a strongly inhibitory component
eluted at the total column volume, the expected elution point for buffer salts.
The 200 kDa fraction contained large amounts of fibrinogen and fibronectin.
However, the authors suggest that these are unlikely to be responsible for the
inhibitory action, since the purified proteins when tested had no effect on IL-2
secretion. Fractions from non-inhibitory factor VIII concentrates showed no
inhibitory effects.
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Thorpe et al (1989) analysed the protein composition of factor VIII concentrates of
varying purity and manufacture by gel permeation chromatography, using fast
protein liquid chromatography (FPLC). Despite differences in inhibition of IL-2
secretion by the various concentrates, the size exclusion chromatography profile
was similar in both inhibitory and non-inhibitory concentrates. Comparison with
purified proteins showed a fibrinogen peak and an albumin peak. Factor VIII itself
was recovered in the void volume. A peak with a molecular weight <10 kDa was
recovered and assumed to be low molecular weight stabilisers.
11.3 Transforming Growth Factor Beta
It has recently been demonstrated that transforming growth factor beta (TGF-J3) is
major contaminant of some factor VIII concentrates (Wadhwa et al, 1994). Levels
of TGF-P detected in factor VIII concentrates by bioassay were found to correlate
strongly with their ability to inhibit IL-2 secretion by a PHA-stimulated T cell line.
Furthermore, the authors stated that the addition of a specific TGF-(3 antibody
reversed the inhibitory effect of some concentrates on IL-2 secretion.
The authors suggest that some of the in vitro effects that coagulation factor
concentrates have on cells of the immune system, resemble the actions of TGF-(3.
Indeed, the proliferation and IL-2 secretion of mitogen stimulated lymphocytes is
inhibited by both purified TGF-(3 (Fox et al, 1992; Ahuja et al, 1993) and some
coagulation factor concentrates (Froebel et al, 1983; McDonald et al, 1985;
Lederman et al, 1986; Vermot-Desroches et al, 1992; Thorpe et al, 1989;
Madhok et al, 1990; Wadhwa et al, 1992). In addition, TGF-(3 has been
demonstrated to impair monocyte function (Tsunawaki et al, 1988), as have some
factor VIII concentrates (Eibl et al, 1987; Mannhalter et al, 1987; Pasi & Hill,
1990).
TGF-|3 comprises a family of multifunctional polypeptides that regulate the cellular
growth and differentiation of a wide variety of cells (Sporn et al, 1987; Massague,
1990). The TGF-p family in man consists of TGF-pl, TGF-J32 and TGF-(33. TGF-
P is released from cells, and circulates in plasma as a latent complex which does not
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bind to receptors (Pricher et al, 1986; Wakefield et al, 1988; Massague, 1990).
Several configurations of latent TGF-P have been identified, including the large
latent complex and the TGF-P-a2-macroglobulin (a2M) form (O'Connor-McCourt
&Wakefield, 1987; Wakefield et al, 1988; Huang et al, 1988).
Wadhwa et al, suggest that the presence of TGF-(3 in factor VIII concentrates, in
both active and latent forms is unsurprising, since all the concentrates studied were
plasma derived. They suggest that feedstock plasma may contain residual platelets,
which are the predominant producers of TGF-p, and that the handling and storage
of plasma prior to cryoprecipitation could cause the lysis of platelets and the release
of latent TGF-p; subsequent purification procedures and viral inactivation steps
yielding the active cytokine.
In summary, from the evidence in the literature it would appear that the main
candidates responsible for the in vitro immune modulation by some coagulation
concentrates, are TGF-P and a dialysable low molecular weight component.
Whether the presence of these contaminants in coagulation factor concentrates




The majority of the evidence in the literature suggests that the greater the purity of
the product, the less immune modulation it is likely to cause in vitro. It has been
postulated that high purity factor VIII concentrates, which contain less allogenic
proteins than intermediate purity concentrates, might induce less deterioration of the
immune system of HIV positive haemophiliacs and reduce the immune modulation
in HIV negative haemophilacs.
(i) Studies in HIV Positive Haemophiliacs
In order to evaluate the above hypothesis, Brettler et al (1989) studied the decline in
CD4+ counts in HIV positive haemophiliacs receiving concentrates of varying
purity. CD4+ cell decline have previously been demonstrated to have a predictive
value for the onset of AIDS (Eyster et al, 1987; Philips et al, 1991). Seven HIV
positive haemophiliacs receiving a monoclonally purified product were followed for
a period of 2 years. These patients' CD4+ counts remained stable over the period of
study. Patients receiving intermediate purity factor VIII were chosen as
retrospective controls. The CD4+ counts of the control group also remained stable.
The response to skin test antigens was the only difference observed between the two
groups. The group treated with monoclonally purified concentrate showed a
decrease in skin anergy. In contrast, the group treated with intermediate purity
concentrate showed an increase in skin anergy. The authors suggested immune
function in HIV positive patients may be stabilised by more highly purified
concentrates.
This study prompted a number of similar investigations into the CD4+ counts and
cellular immunity of both HIV positive and HIV negative haemophiliacs receiving
replacement therapy. Several reports support the hypothesis put forward by Brettler
et al that monoclonally purified concentrates stabilise the immune system of HIV
positive haemophiliacs.
de Biasi et al (1991) studied 20 HIV positive haemophiliacs. Half were treated with
intermediate purity Kryobulin TIM3, the remainder treated with immunoaffinity
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purified Hemofil M. Following a two year study period, the authors reported a
significant steady decline in CD4+ counts in the group treated with intermediate
purity concentrate. The CD4+ counts of the group receiving monoclonally purified
concentrate showed no significant change. Furthermore, in the group being treated
with monoclonally purified concentrate, four out of six patients, who on entry to the
study were anergic acquired reactivity to skin testing. Other similar studies,
comparing immuoaffinity purified concentrates to intermediate purity concentrates,
supported the findings of de Biasi et al (Seremitis et al, 1990; Goldsmith et al,
1991; Seremitis et al, 1993; Goedert et al, 1994). Two of these studies however
demonstrated that, despite a stabilisation in CD4+ counts on treatment with a
monclonal antibody purified concentrate, there was no difference in the development
of AIDS or death, between these patients and those of the control group (Seremitis
et al, 1993; Goedert et al, 1994).
Three studies do not support the view that product purity may influence immune
parameters (Mannucci et al 1992b; Hilgartner et al, 1993; Varon et al, 1994).
Mannucci et al (1992) monitored the CD4+ counts and cell mediated immunity in
HIV positive haemophiliacs. One half of the study group were treated with
intermediate purity Kryobulin, the remainder being treated with an ion-exchange
purified product Beriate P. Over the two year follow up period, both groups
demonstrated similar rates of decline in CD4+ counts. The was also no difference in
cell mediated immunity between the two groups. A study by Hilgartner et al (1993)
compared the CD4+ counts in two groups of patients, one group on monoclonally
purified factor VIII concentrate, the other on intermediate purity factor VIII
concentrate. No significant difference was found between the two groups. A study
by Varon et al (1994), comparing the effects of a monoclonal antibody purified
concentrate to an ion-exchange purified concentrate on CD4+ counts in HIV
positive individuals, found no significant benefit on treatment with the monoclonal
product.
71
(ii) Studies in HIV Negative Haemophiliacs
There are fewer reports of comparative studies in HIV negative patients. The
available data suggest a continuing decline in CD4+ counts in previously untreated
patients, whether they are being treated with intermediate purity (Teitel et al, 1989;
Cuthbert et al, 1990; Fukatake et al, 1991) or monoclonally purified products
(Fukatake et al, 1991), albeit at a slower rate than in HTV infected haemophiliacs.
In contrast to the above, a three year study on previously untreated HIV negative
haemophiliac boys (Evans et al, 1991) demonstrated that treatment with an
intermediate purity factor VIII concentrate 8Y has no effect on CD4+ counts.
In summary, to date studies assessing the effect of factor VIII products of different
purity on the rate of CD4+ decline in haemophiliac patients, has resulted only in one
small study demonstrating a significant difference between groups of patients on
different purity concentrates.
There is no doubt that immunological abnormalities are present in haemophilia
patients. It is, however, under debate whether these abnormalities are due to
coagulation factor replacement therapy. Since many of these studies failed to take
into account the impact viral infections, other than HIV, have on the immune system
(Makris et al, 1991; Higgins & Goodall, 1991). It has been postulated that
infections with agents other than HIV are responsible for the observed immune
modulation. This view is supported by the findings of Evans et al (1991). Evans
and colleagues' study on previously unexposed patients, treated solely with
intermediate purity factor VIII concentrate for five years, found no immune
abnormalities. These patients also showed no signs of infection with HIV, hepatitis
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General Materials and Methods
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1. Coagulation Factor Concentrates
A sample of commercial and non-commercial coagulation factor concentrates was
selected for the purpose of this study. These samples were of varying purity and
processes of manufacture. Tables 3(a) and 3(b) (pages 79 and 80) provide a
summary of manufacturing information on these products and a list of their specific
activities. The clotting factor activities of all the batches of the products examined
are listed in appendix 1 (i), (ii) and (iii). All coagulation factor concentrates were
reconstituted according to manufacturers' instructions, and either tested immediately
or aliquoted and frozen at -70°C until required.
1.1 Defibrination of Z8 and 8Y
Two of the intermediate factor VIII concentrates (S.N.B.T.S. Z8, and B.P.L 8Y)
used in this study were found to be prone to clotting during incubation in assays, for
this reason these concentrates were defibrinated prior to use. Concentrates were
reconstituted according to manufacturers' instructions and defibrinated using sterile
orange sticks following the addition of 2000 U bovine thrombin (Pentex, UK). The
sterile orange sticks were used to gently stir the factor VIII solution until all fibrin
clots were removed. No other concentrates used in this study required defibrination
as all remained clot free throughout the culture period.
2. Cell Culture
2.1 Culture Medium
All cells were cultured in RPMI 1640 medium supplemented with; 100 units/ml
penicillin, 100 |ig/ml streptomycin and 0.03% L-glutamine. Varying percentages of
heat-inactivated foetal calf serum (FCS) were added, depending on cell type. The
same batch of FCS was used throughout each series of experiments, unless stated
otherwise. All products were supplied by Sigma-Aldrich Company Ltd, UK. All
reagents were sterile and sterile handling procedures were applied throughout.
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2.2 Culture Conditions
All cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO2.
2.3 Cryopreservation of Cells
Cryopreservation stocks of cell lines were stored in 10% dimethylsulpoxide in FCS,
in liquid nitrogen and could be recovered from this source without difficulty for use
in bioassay within a few days.
2.4 Screening for Mycoplasma
All cell lines were screened regularly for mycoplasma contamination using the Gen-
Probe Mycoplasma Tissue Culture Rapid Detection System Kit (Gen-Probe
Incorporated, San Diego, CA, USA) according to manufacturers instructions.
This kit employs the principle of nucleic acid hybridisation to detect mycoplasma in
tissue culture. Using in-solution hybridisation and ribosomal RNA detection,
positive samples were detected in three hours. The test kit contained a 3H-labelled
DNA probe homologous to Mycoplasma and Acholeplasma ribosomal RNA. Using
this probe all species that commonly infect tissue cultures can be detected.
3. Harvesting Cells and Direct Beta Counting
Cell cultures in 96-well plates were harvested using the Packard Micromate 196 Cell
Harvester, onto filtermats (Skatron Instruments Ltd. UK). The filters were dried in
an oven before the radioactivity incorporated into cellular DNA was estimated by
direct beta counting using a Packard Matrix 96 Direct Beta Counter. The data were
then processed using the computer spreadsheet software Quattro Pro.
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4. Manipulation of Data
All data from lymphocyte proliferation assays and cytokine bioassays was obtained
expressed as cpm from the Direct Beta Counter. The inhibitory percentage of cell
proliferation, IL-2 secretion or IL-6 secretion was determined by the following
formula:
% inhibition ofproliferation = 100 X
IL-2 or IL-6 secretion.
1-
cpm of test - cpm of background
cpm of control - cpm ofbackground
For calculation of percentage inhibition for lymphocyte proliferation assays, cpm of
background refers to cells cultured in media alone, and cpm of control to cells
stimulated with PHA in the absence of coagulation factor concentrate.
For calculation of percentage inhibition for TGF-pl bioassays, cpm of background
was eliminated from this formula and cpm of control referred to Mv-l-Lu cells
cultured in media in the absence of coagulation factor concentrates.
5. Statistical Analysis
Student's t-test was used to compare statistically the sample means from two
different populations (e.g. viability of PHA-stimulated lymphocytes incubated with
coagulation factor concentrates to the viability of the same population of
lymphocytes incubated without coagulation factor concentrate).
The strength of association between two quantitative variables was measured by a
sample statistic, the correlation coefficient. The correlation coefficient between two
independent variables (e.g. percentage inhibition of lymphocyte proliferation by a
concentrate and the amount of TGF-p in that concentrate) was calculated using
Spearman's rank correlation coefficient.
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It is now recognised that patients receiving coagulation factor replacement therapy
may have abnormalities of the immune system, irrespective of HIV status. These
abnormalities have been observed both in vivo and ex vivo. It has been proposed
that these disturbances are caused either by the massive protein load, specific
impurities or the effect of viruses in coagulation factor concentrates.
Efforts to identify contaminants responsible have involved testing coagulation factor
concentrates, and manipulations of these concentrates in various in vitro assay
systems which assess immunomodulating activity. One such assay commonly used
for this purpose is the PHA-stimulated lymphocyte proliferation assay (Froebel et al,
1983; McDonald et al, 1985; Lederman et al, 1986; Hay & McEvoy, 1989;
Vermot-Desroches et al, 1992). PHA is a T cell stimulator which causes non-
dividing lymphocytes to proliferate and differentiate, so that they display some of
the same functional characteristics as antigen activated lymphocytes (Sharon, N.
1983). For this reason, mitogenic stimulation of lymphocytes with PHA is
commonly used to detect immune modulating activity. At the outset of this study
limited data were available on the effects of factor VIII, factor IX and von
Willebrand factor concentrates prepared by ion-exchange, affinity, immunoaffinity
and recombinant techniques in this assay. Hence, a wide range of commercial and
non-commercial coagulation factor concentrates of varying purity were selected to
be assayed for their immune modulating activity by PHA-stimulated lymphocyte
proliferation assay.
Even though many researchers have used lymphocyte proliferation assays to assess
the immunomodulatory activity of concentrates, the reported concentration of PHA
used for stimulation of proliferation and the length of incubation before harvest
varies greatly. Experimental conditions can often affect the outcome of experiments
as exemplified by the data obtained from mixed lymphocyte reactions. One group
reporting enhanced lymphocyte proliferation three others reporting inhibition of
proliferation (Lederman et al, 1986; Schrieber et al, 1987; Hay & McEvoy, 1989;
Batchelor et al, 1992). Since, PHA concentration and incubation time are both
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important factors whose variability can alter the results significantly, great care was
taken to optimise the assay before testing the concentrates.
Another widely used method of assessing the immune modulation of coagulation
factor concentrates, is the study of the effects coagulation factor concentrates have
on IL-2 secretion by PHA-stimulated T cells (Lederman et al, 1986; Thorpe et al,
1989; Wadhwa et al, 1992; Wadhwa et al, 1994). At the outset of this study the
data available on the effects of factor VIII concentrates of varying purity on IL-2
secretion was much more complete than that from lymphocyte proliferation studies.
The results demonstrated that some, but not all, intermediate purity factor VIII
concentrates and those purified by ion-exchange chromatography inhibited IL-2
secretion, whereas monoclonal antibody purified and recombinant products did not.
However, no study had directly compared the effects of a sample of coagulation
factor concentrates on both PHA-stimulated lymphocyte proliferation and IL-2
secretion. Therefore, in order to present a full set of data on the immune
modulating effects of coagulation factor concentrates chosen for this study, it was
necessary to test for their effects on IL-2 secretion by PHA-stimulated T cells as
well as for their effects on proliferation.
All publications relating to the effects of factor VIII concentrates on IL-2 secretion
use almost identical experimental conditions. For this reason, I have used the same
set of experimental conditions as published thereby allowing comparison between
IL-2 secretion data on my sample of concentrates and that reported in the literature.
Having established which coagulation factor concentrates from my chosen sample
have the ability to inhibit lymphocyte function, a brief study of the mechanism of
inhibition was considered appropriate. Direct cytotoxicity of intermediate purity
and ion-exchange purified concentrates on PHA-stimulated lymphocytes had been
examined previously (McDonald et al, 1985; Lederman et al, 1986; Wang et al,
1986; Vermot-Desroches et al, 1992), and concentrates of both levels of purity
found not to mediate their effects on lymphocyte proliferation by cytotoxicity.
However, the effects of other inhibitory coagulation factor concentrates, or those
purified by affinity techniques had not been examined. Therefore, in order to
establish whether these concentrates inhibited lymphocyte proliferation by
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cytotoxicity, the viability of PHA-stimulated lymphocytes incubated in the presence
and absence of coagulation factor concentrate was estimated by nigrosin dye
exclusion experiments.
The cytokine IL-6 is also expressed by lymphocytes and its production up-regulated
by numerous signals including mitogenic stimulation and the cytokine IL-2 (Hirano,
1994). IL-6 has several important immunological functions, including effects on T
cell activation, growth, differentiation and IL-2 secretion (Lotz et al, 1988; Tosato
& Pike, 1988; Uttenhove et al, 1988). Since, IL-6 secretion by lymphocytes is up-
regulated by IL-2, a fall in IL-6 production by lymphocytes incubated with an
inhibitory concentrate would be expected. For this reason the effects that the
sample of coagulation factor concentrates have on the secretion of IL-6 by
lymphocytes was also examined.
The information obtained from the above experiments has provided a detailed study
on the immune modulating effects of coagulation factor concentrates of varying
purity. In addition, these experiments have allowed the comparison of the effects
that coagulation factor concentrates have on two commonly used assay systems,
lymphocyte proliferation and lymphocyte IL-2 secretion. Finally, further insight into




1.1. Separation of Peripheral Blood Mononuclear Cells fromWhole Blood
Peripheral blood mononuclear cells (PBMC) were separated from fresh heparinised
venous blood or citrated buffy coats (Scottish Blood Transfusion Service
{S.N.B.T.S.}, Edinburgh, UK) collected from donations of healthy human blood.
Heparinised blood samples were diluted 1:2 and citrated buffy coats diluted 1:4 with
RPMI 1640. PBMC were isolated by centrifugation over Lymphoprep (Density
1.077 g/ml. Nycomed Ltd, UK) at 800g for 15 minutes. The cells at the interface
were removed and washed twice in RPMI 1640 medium containing 10% FCS. The
mononuclear cells were subjected to slow-speed centrifuge runs at 150g for 10
minutes to separate from contaminating platelets, then used immediately.
1.2 Origin and Maintenance of Cell Lines
(i) CTLL Cells
The IL-2 dependent murine T cell line, CTLL was obtained from the European
Collection of Animal Cell Cultures (ECACC No: 87031904. Porton Down,
Salisbury, UK) for use in IL-2 bioassays. Cells were maintained at a density of 3-
9xl04 cell/ml, in 25 cm2 culture flasks in RPMI 1640 medium supplemented with
10% FCS, 20% human PBMC conditioned medium and 20 IU/ml recombinant




The IL-6 dependent murine hybridoma B cell line, B9, were obtained from D.
Hutchins (MRC, Edinburgh) for use in IL-6 bioassays. Cells were maintained in 25
cm2 culture flasks on RPMI 1640 medium containing 10% FCS plus a 1/100
dilution of human PBMC conditioned medium. Cultures were maintained on a three
day feeding schedule.
1.3. Preparation of Human PBMC Conditioned Medium
Conditioned medium required for maintenance of the cell lines CTLL and B9 was
prepared by isolating PBMC from several human buffy coats and culturing them at a
concentration of 5xl06 cells/ml in RPMI 1640 medium supplemented with 5% FCS
and 90 pg/ml PHA (Reagent grade. Murex Diagnostics Ltd, UK) (Grimm &
Rosenberg, 1982). Cultures were incubated for 40 hours before supernatants were
harvested by centrifugation at 150g for 15 minutes, then at 1500g for 15 minutes.
The resulting conditioned medium from the different buffy coats was combined,
sterile filtered and frozen at -70°C until required.
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2. Lymphocyte Proliferation Assays
2.1 Optimisation of Lymphocyte Proliferation Assay
Proliferative responses of PBMC to various concentrations of PHA were measured
by culturing PBMC in 96-well flat bottomed microtitre plates (Falcon Microtest III.
A & J Beveridge Ltd. UK) with increasing concentrations of PHA. For this
purpose, serial doubling dilutions of PHA in culture medium (0.7-720 pg/ml) were
prepared in triplicate, in 100 pi volumes. To each PHA dilution, coagulation factor
concentrate was added at a final concentration of 2 IU/ml. A PBMC suspension
containing lxlO6 cells/ml in RPMI 1640 medium supplemented with 10% FCS was
prepared and 100 pi added to each well. Control cultures of PBMC alone and
PBMC with dilutions of PHA, in the absence of coagulation concentrate, were
included. Cultures were incubated for 96 hours before harvesting, as described
elsewhere (page 77). Proliferation of cells in response to PHA was measured by
pulsing cultures with lpCi/well of [methyl-3H]thymidine (Amersham Life Science,
UK) 18 hours before cell harvesting.
Having established the optimal PHA concentration for examining the effects of
coagulation factor concentrates on lymphocyte proliferation the optimal length of
culture was determined. For this purpose, six identical plates containing 100 pi
PBMC suspension, as detailed above, were stimulated with the optimal
concentration of PHA (1 pg/ml) and incubated with 100 pi of increasing
concentrations of a factor VIII concentrate (0.5-2 IU/ml) prepared in culture
medium. Plates were harvested on consecutive days as described elsewhere (page
77). Proliferation of cells in response to PHA was measured by pulsing cultures
with lpCi/well of [methyl-3H]thymidine (Amersham Life Science, UK) 18 hours
before cell harvesting.
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2.2 Optimised PHA Stimulated Lymphocyte Proliferation Assay
Proliferative responses to 1 (ig/ml PHA were measured by culturing PBMC in 96-
well flat-bottomed microtitre plates. For this purpose, a cell suspension of lxlO6
cells/ml in RPMI 1640 medium supplemented with 10% FCS was prepared.
Triplicate wells containing 100 |il of cell suspension and 100 |il of serial doubling
dilutions of coagulation factor concentrates (0.004-2 IU/ml) were prepared in
culture medium. The levels of coagulation factor concentrates used for assay
purposes reflect levels readily achievable in vivo during replacement therapy
(Batchelor et al, 1992).
Control cultures of PBMC in culture medium alone, PBMC and PHA alone, and
PBMC plus coagulation factor concentrate in the absence of PHA, were included in
each assay. Cultures were incubated for 96 hours before harvesting. Proliferation
of cells in response to PHA was measured by pulsing cultures with lpCi/well of
[methyl-3H] thymidine 18 hours before cell harvesting.
In order to overcome the variability of donor responses to mitogen, each batch of
coagulation factor concentrate was tested three times on PBMC suspensions
prepared from three individuals.
In some assays heparin (Leo Laboratories Ltd, UK) was included in the culture
medium at a final concentration of 1 IU/ml. Exogenous IL-2 (recombinant. Sigma-
Aldrich Company Ltd.) was also added to some PHA-stimulated lymphocyte
proliferation assays at a final concentration of 10 IU/ml or 100 IU/ml.
2.3 Cell Viability
The effects of coagulation factor concentrates on the viability of PHA-stimulated
lymphocytes was investigated by nigrosin dye exclusion. Triplicate wells containing
1 ml of a cell suspension of lxlO6 cells/ml in RPMI 1640 media supplemented with
10% FCS were prepared and incubated with or without 1 IU/ml of coagulation
factor concentrates. PHA was included at a final concentration of 1 (ig/ml.
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Viability was estimated at 24 hour intervals by counting 200 cells four times and
calculating the mean percentage nigrosin positive cells. Cell viabilty of cells in the
presence or absence of coagulation factor concentrates was compared using a paired
r-test.
3. Cytokine Bioassays
3.1 Stimulation of Interleukin 2 Secretion
For stimulation of IL-2 secretion, PBMC were washed in RPMI 1640 medium and
then resuspended at 2xl06 cells /ml in RPMI 1640 medium containing 10% FCS and
90 |ig/ml PHA (Thorpe et al, 1989). To investigate the effects of clotting factor
concentrates on IL-2 secretion, 1 ml aliquots of cell suspension were incubated with
or without 1 IU/ml of clotting factor concentrate in 12-well flat bottomed microtitre
plates (Costar Ltd.). Control cultures of PBMC in culture medium alone, PBMC
and PHA alone, and PBMC plus coagulation factor concentrate in the absence of
PHA were included in each assay. Supematants were harvested by centrifugation
after 48 hours and stored at -20°C until assayed for IL-2.
3.2 Interleukin 2 Bioassay
IL-2 was measured using a bioassay based on the mouse T cell line, CTLL's
dependence on EL-2 (Gillis et al, 1987; Wadhwa et al, 1991). CILL cultures were
fed, as previously described, 48 hours prior to inclusion in the IL-2 bioassay. For
assay CILL cells were washed twice in PBS and resuspended at a concentration of
1x10s cells/ml in RPMI 1640 medium supplemented with 10% FCS. Triplicate
wells, in 96-well flat-bottomed plates were set up containing 50 |il cell suspension
and either 50 (i.1 of test supernatant or 50 (il of a titration of a standard recombinant
IL-2 (Sigma-Aldrich Ltd.). Control cultures of CTLL cells in the presence of 1
IU/ml of coagulation factor were included in each assay. Cultures were incubated
for 18 hours, then pulsed for 4 hours with 0.5 (iCi/ well [methyl-3H]thymidine prior
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to harvesting. A standard curve of counts per minute (cpm) versus concentration of
IL-2 was plotted and activity of unknown samples determined by comparing test
results with the standard curve.
3.3 Stimulation of Interleukin 6 Secretion
For stimulation of EL-6 secretion, PBMC were washed in RPMI 1640 medium and
then resuspended at lxlO6 cells/ml in RPMI 1640 medium containing 10% FCS and
90 (ig/ml PHA. To investigate the effects of clotting factor concentrates on IL-6
secretion, 1 ml aliquots of cell suspension were incubated with or without 1 IU/ml
of clotting factor concentrate in 12-well flat bottomed microtitre plates. Control
cultures of PBMC in culture medium alone, PBMC and PHA alone, and PBMC plus
coagulation factor concentrate in the absence of PHA were included in each assay.
Supernatants were harvested by centrifugation after 24 hours and stored at -20°C
until assayed for IL-6.
3.4 Interleukin 6 Bioassay
IL-6 bioactivity was measured using a [methyl-3H]thymidine incorporation assay
based on the growth response of the IL-6 dependent cell line B9 (Hutchins et al,
1990). B9 cells were fed as previously described 48 hours prior to inclusion in the
IL-6 bioassay. Cells were washed in RPMI 1640 medium to remove residual
growth factor and resusupended at a concentration of 4xl04 cells/ml in RPMI 1640
medium supplemented with 10% FCS. Triplicate wells, in 96-well flat-bottomed
plates were set up containing 100 |il aliquots of cell suspension and either 100 (0.1 of
test supernatant containing IL-6 or 100 |il of a titration of a standard recombinant
IL-6 (Sigma-Aldrich Ltd.). Control cultures of B9 cells in the presence of 1 IU/ml
of coagulation factor concentrates were included in each assay. Cultures were
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incubated for three days and pulsed for the final five hours of culture with lpCi of
[methyl-3H]thymidine prior to harvesting. A standard curve of cpm versus
concentration of IL-6 was plotted and activity of unknown samples determined by
comparing test results with the standard curve.
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RESULTS
1. Effects of Coagulation Factor Concentrates on Lymphocyte
Proliferation Following Stimulation with PHA.
1.1 Optimisation of Lymphocyte Proliferation Assay
Many researchers have studied the effects of coagulation factor concentrates on
PHA stimulated lymphocyte proliferation. However, the PHA concentration used
to stimulate the cells has varied greatly. To determine the optimal concentration of
PHA for stimulation of proliferation, lymphocytes were incubated with increasing
concentrations of PHA (0.7-720 fig/ml). A semilog graph was constructed of
concentration of PHA (logarithmic) versus cpm (linear), Figure 5. Optimal
proliferation was observed with 22.5 and 45 pg/ml PHA. The effects of 2 IU/ml of
two factor VIII concentrates were tested at each concentration of PHA, enabling a
concentration of PHA to be determined at which coagulation factor concentrates
caused the greatest inhibition. The intermediate purity concentrate 8Y was found to
inhibit proliferation, the immunoaffinity purified concentrate Monoclate P did not.
Inhibition of proliferation by the intermediate purity concentrate was observed to be
at its greatest at 0.7 to 5.6 (ig/ml of PHA. A final concentration of 1 |ig/ml of PHA
was selected for use in lymphocyte proliferation assays, since it lay within the
optimal range and had been used previously by some researchers (McDonald et al,
1985; Vermot-Desroches et al, 1992).
As with the PHA concentration used to stimulate the cells, the reported time of
harvesting of proliferation assays also varies. To determine the optimal time to
harvest the lymphocyte proliferation assays, identical plates containing lymphocytes
stimulated with 1 (ig/ml PHA, and increasing concentrations of factor VIII




FIGURE 5: Dose response of lymphocytes to the T cell mitogen
PHA, and the effect 2 IU/ml of two factor VIII concentrates have
on lymphocyte proliferation stimulated by different
concentrations of PHA.
o PHA alone
♦ Monoclate-P (immunoaffinity purified)




FIGURE 6: Inhibition of proliferation of PHA-stimulated
lymphocytes by a factor VIII concentrate. The peak response
of lymphocytes to 1 fig/ml PHA occured on day 5.
Proliferation was routinely assayed for on day 4 and found
to be adequate.
<5 PBMC + PHA alone
— -a— PBMC + PHA + 0.5 IU/ml factor VIII concentrate
-n PBMC + PHA + 1 IU/ml factor VIII concentrate
-• PBMC + PHA + 2 IU/ml factor VIII concentrate
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The peak response of lymphocytes to 1 |ig/ml PHA occurred on day 5. However,
proliferation was routinely assayed on day 4 and found to be adequate.
This preliminary experiment demonstrates that inhibition of lymphocyte proliferation
by this factor VIII concentrate occurs in a dose-dependent manner.
1.2 PHA-Stimulated Lymphocyte Proliferation Assay
Following optimisation of culture conditions, the sample of commercial and non¬
commercial coagulation factor concentrates (concentrates of factors VIII, IX and
von Willebrand factor) were examined for their ability to inhibit PHA-stimulated
lymphocyte proliferation. Concentrates were tested in triplicate over a range of
concentrations (0.004-2 IU/ml), which are readily achievable during replacement
therapy.
Results obtained from lymphocyte proliferation assays were expressed in cpm. The
average cpm of each dilution triplicate was calculated and converted to percentage
inhibition of proliferation using the formula on page 73. Since, each batch of
concentrate was tested in three separate lymphocyte proliferation assays, with
lymphocytes from three different donors, an average percentage inhibition was
calculated for each dilution point. Once the results for each batch were compiled,
semilogarithmic graphs were plotted, displaying log concentration of coagulation
factor concentrate (IU/ml) versus percentage inhibition of lymphocyte proliferation,
Figures 7-24.
More than one batch of concentrate was tested, where possible. In these cases the
average percentage inhibition at each coagulation factor dilution point for the
batches was calculated and plotted against the log concentration of coagulation
factor concentrate (IU/ml). The standard deviation between batches is represented
on the graphs as error bars.
All coagulation factor concentrates which inhibited PHA-stimulated lymphocyte




FIGURE 7: Inhibition of proliferation of PHA-stimulated




FIGURE 8: Inhibition of proliferation of PHA-stimulated





FIGURE 9: Inhibition of proliferation of PHA-stimulated




FIGURE 10: Inhibition of proliferation of PHA-stimulated





FIGURE 11: Inhibition of proliferation of PHA-stimulated




FIGURE 12: Inhibition of proliferation of PHA-stimulated





FIGURE 13: Inhibition of proliferation of PHA-stimulated




FIGURE 14: Inhibition of proliferation of PHA-stimulated
lymphocytes by six batches of the ion-exchange purified factor VIII




FIGURE 15: Inhibition of proliferation of PHA-stimulated
lymphocytes by five batches of the ion-exchange purified factor VIII




FIGURE 16: Inhibition of proliferation of PHA-stimulated




von Willebrand Factor (IU/ml)
FIGURE 17: Inhibition of proliferation of PHA-stimulated
lymphocytes by one batch of the ion-exchange purified von
Willebrand factor concentrate Concentre De FacteurWillebrand.
Lymphocyte Proliferation Assay
factor VIII (IU/ml)
FIGURE 18: Inhibition of proliferation of PHA-stimulated





FIGURE 19: Inhibition of proliferation of PHA-stimulated




FIGURE 20: Slight inhibition of proliferation PHA-stimulated














FIGURE 21: Slight inhibition of proliferation of PHA-stimulated



















FIGURE 22: Absence of inhibition of proliferation of
PHA-stimulated lymphocytes by one batch of the immunoaffinity













FIGURE 23: Absence of inhibtion of proliferation of
PHA-stimulated lymphocytes by one batch of the immunoaffintiy
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FIGURE 24: Absence of inhibition of PHA-stimualted
lymphocyte proliferation by two recombinant factor VIII products
Kogenate and Recombinate.
° Kogenate * Recombinate
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The percentage inhibition of proliferation of PHA-stimulated lymphocytes achieved
by 1 IU/ml of each batch of concentrate is summarised in Tables 4(a), (b) and (c).
All intermediate purity coagulation factor concentrates caused almost total inhibition
of lymphocyte proliferation, Table 4(a), Figures 7-13. One exception was a batch of
the factor VIII concentrate 8Y, manufactured by BPL. This particular batch
inhibited PBMC proliferation by only 49% when present at this concentration.
All ion-exchange purified coagulation factor concentrates, when present at a
concentration of 1 IU/ml, inhibited PBMC proliferation to some extent, Table 4(b),
Figures 14-17. However, one product in this category, AlphaNine SD, possessed
significantly less inhibitory activity than other products of the same group, Figure
16.
All affinity purified products also inhibited proliferation of PHA-stimulated
lymphocytes to some extent, Table 4(c), Figures 18-20. However, the factor IX
concentrate 9MC, purified by metal chelate affinity was less inhibitory than the other
affinity purified products Alphanate and Alpha VIII, both factor VIII concentrates
purified by heparin affinity.
The immunoaffinity purified and recombinant coagulation factor concentrates, when
present at 1 IU/ml, in general had no effect on lymphocyte proliferation, Table 4(c),
Figures 21-24. The only exception being the factor VIII concentrate 8SM, which
caused 19% inhibition of proliferation.
Concentrates, in general, exhibited little batch to batch variation. For instance, six
batches of Immunate gave inhibitory activities ranging from 57% to 70% (mean
66.4%). However, the factor VIII concentrate HPVIII manufactured by S.N.B.T.S.







Intermediate Z8 1-369 82
Z8 1-378 84
Profilate SD AR2003A 99
Profilate SD AR2004A 94
Profilate SD AR2008A 97
Profilate OSD AR4205A 77
8Y FHC0484 85
8Y FHC 0494 49
8Y FHC4133 97




TABLE 4(a):- Summary of lymphocyte proliferation assay results for
intermediate purity products.
Percentage inhibition of lymphocyte proliferation represents values obtained at 1
IU/ml of coagulation factor concentrate. Products marked with * are factor IX
concentrates. All others are factor VIII concentrates.
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Purification Product Batch % Inhibition of
Number Lymphocyte
Proliferation











AlphaNine SD* CA21401A 12
AlphaNine SD* CA2403AB 26
Concentr6 De 87920070 67
Facteur
WiEebrand#
Range 12 - 70
TABLE 4(b):- Summary of lymphocyte proliferation assay results for ion-
exchange products.
Percentage inhibition of lymphocyte proliferation represents values obtained at 1
IU/ml of coagulation factor concentrate. Products marked with * are factor IX
concentrates, that marked with # is a von Willebrand factor concentrate. All







Affinity Alpha Vffl AP2005A 79
Alpha VIE AP2006A 76
Alpha VIII AP2008A 83
Alphanate AS4701A 97
9MC* PMC 2203 17
Immunoaffinity 8 SM FHD4143 19
Monoclate P J53706 5
Mononine* J82612 0
Recombinant Kogenate ADAH1 0
Recombinate 95F22A250 0
TABLE 4(c):- Summary of lymphocyte proliferation assay results for
affinity, immunoaffinity purified and recombinant products.
Percentage inhibition of lymphocyte proliferation represents values obtained at 1
IU/ml of coagulation factor concentrate. Products marked with * are factor IX
concentrates. All others are factor VIII concentrates.
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Correspondence with Alpha Therapeutic Corporation, the manufacturers of
coagulation factor concentrates, including the factor VIII concentrates Profilate SD
and Alphanate, prompted the addition of 1 IU/ml heparin to the tissue culture
medium. Alpha Therapeutic research and development laboratories observed a clot
forming while carrying out lymphocyte proliferation assays with their intermediate
purity factor VIII concentrate Profilate SD. Their laboratories reported that the
addition of 1 IU/ml heparin eliminated this problem and suggested that clot
formation interfered with lymphocyte proliferation, producing an artifactual result.
The results demonstrate that PHA-stimulated proliferation of lymphocytes is
inhibited by both intermediate purity Profilate SD and affinity purified Alphanate
and the addition of heparin does not abrogate inhibition, Figure 25. The only two
concentrates which formed clots during incubation were the intermediate purity
factor VIII concentrates Z8 and 8Y. This problem was resolved by defibrination of
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FIGURE 25: Absence of any effect of 1 IU/ml heparin on the
inhibition of proliferation of PHA-stimulated lymphocytes by two
factor VIII concentrates, intermediate purity Profilate SD (batch
AR2003A) and affinity purified Alphanate (AS4701A).
o Profilate SD




2. Effects of Coagulation Factor Concentrates on IL-2 Secretion by
PHA-Stimulated Lymphocytes
The sample of coagulation factor concentrates previously tested in lymphocyte
proliferation assays were also tested for their effects on IL-2 secretion by PHA-
stimulated lymphocytes, using the method of Thorpe et al (1989). Lymphocytes
were optimally stimulated with 90 (ig/ml PHA in the presence and absence of 1
IU/ml coagulation factor concentrate. Supernatants from these cultures were
assayed in triplicate for IL-2 using a bioassay, which is based on the cell line
CTLL's dependence on IL-2.
Results were obtained expressed as cpm. The average cpm of each triplicate was
calculated and converted to percentage inhibition of IL-2 secretion using the
formula on page 73. Where possible, more than one batch of each concentrate was
tested.
The results demonstrate that lymphocytes stimulated with PHA produced lower
levels of IL-2 in the presence of some coagulation factor concentrates. The
percentage inhibition of IL-2 secretion caused by 1 IU/ml of each concentrate is
summarised in Table 5. All intermediate purity coagulation factor concentrates
inhibited IL-2 secretion when present at a final concentration of 1 IU/ml. The most
inhibitory concentrates of this class were the factor IX concentrates Defix and 9A.
Ion-exchange purified coagulation factor concentrates in general did not cause great
inhibition of IL-2 secretion, range 0 to 24% inhibition of IL-2 secretion, Table 5.
As with the lymphocyte proliferation assay results, the effects on IL-2 secretion by
the two affinity purified products differed considerably, Alphanate causing greater
inhibition than 9MC.
The immunoaffinity purified factor VIII concentrates tested in this system caused no
inhibition of IL-2 secretion. Recombinant products were not tested in this system.
The percentage inhibition of lymphocyte proliferation for each concentrate was
found to correlate with the percentage inhibition of IL-2 secretion. Using the







Intermediate Profilate SD AR2003A 31
Profilate SD AR2008A 26
Profilate OSD AR4205A 56













AlphaNine SD* CA21401A 11
AlphaNine SD* CA2403AB 20
Range 0-24
Affinity Alphanate AS4701A 25
9 MC* PMC 2203 7
Immunoaffinity 8 SM FHD 4143 0
Monoclate P J53706 0
TABLE 5: Interleukin 2 bioassay results.
Percentage inhibition of interleukin 2 secretion, represents values obtained at 1
IU/ml of clotting factor concentrate. Products marked with * are factor IX
concentrates. All others are factor VIII concentrates.
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DISCUSSION
1. Effects of Coagulation Factor Concentrates on PHA-Stimulated
Lymphocyte Proliferation
As previously stated lymphocyte proliferation in response to the mitogen PHA has
been used as an assay to measure the effects that intermediate purity coagulation
factor concentrates have on immune function. However, limited data was available
regarding the effects of concentrates prepared by chromatography, immunoaffinity
or recombinant techniques. Therefore it was seen to be necessary to test all the
current purities of product available in this system.
Since, the experimental conditions for PHA-stimulated lymphocyte proliferation
assays used by other researchers tend to vary, preliminary experiments to determine
optimal assay conditions were carried out. Optimisation experiments clearly
demonstrate that experimental conditions such as PHA concentration can
significantly affect the outcome, Figure 5. With increasing PHA concentration a
reduction in inhibition of proliferation by the coagulation factor is observed. This
suggests that the degree to which coagulation factor concentrates inhibit
lymphocyte proliferation is somewhat determined by PHA concentration.
Nonetheless, the concentrates continue to inhibit PHA-stimulated lymphocyte
proliferation to some extent until the PHA concentration becomes toxic, implying
that the inhibitory effect of concentrates is not totally dependent on PHA
concentration. These observation suggest that data obtained using different
expreimental conditions cannot be relaibly compared.
Following optimisation of the assay, the coagulation factor concentrates selected for
study were tested over a range of concentrations which are readily achievable during
replacement therapy. In agreement with previous studies (Frobel et al, 1983;
McDonald et al, 1985; Lederman et al, 1986), intermediate purity factor VIII and
factor IX concentrates were found to inhibit PHA-stimulated lymphocyte
proliferation in a dose dependent manner, Figures 7-12. In addition, I have
demonstrated that some ion-exchange chromatography and affinity purified
concentrates also cause inhibition of lymphocyte proliferation; whereas, those
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purified by immunoaffinity and recombinant techniques do not, Figures 13-24. All
factor VIII, factor IX and von Willebrand factor concentrates of intermediate purity
and some of those purified by ion-exchange chromatography inhibited lymphocyte
proliferation. Concentrates had no observed effect on non-stimulated lymphocytes.
A general trend was observed whereby, as the product purity increased the
inhibition of proliferation decreased, Tables 4(a)-4(c) Thus, in vitro the purer the
product the less immune modulating activity it possess. A few exceptions to this
generalisation were noted. For example one batch of the intermediate purity factor
VIII concentrate 8Y, possesses notably less activity than the other two batches
tested. Differences in inhibitory activities between products belonging to the same
purification group are perhaps not surprising, since variations in manufacturing
techniques will inevitably lead to differences in the abundance or molecular weight
of contaminants, this being reflected in the values of percentage inhibition of
lymphocyte proliferation.
2. Mechanism of Inhibition of PHA-Stimulated Lymphocyte Proliferation by
Coagulation Factor Concentrates
Having established that some coagulation factor concentrates have the ability to
inhibit lymphocyte mitogenic responses, the mechanism of inhibition was
investigated. Cytotoxicty of intermediate and ion-exchange purity factor VIII
concentrates on PHA-stimulated lymphocytes had been examined by other
researchers and concentrates of both levels of purity found not to mediate their
inhibitory effects on lymphocyte proliferation by direct cytotoxicity. However, the
effects of other coagulation factor concentrates, or of those purified by affinity
techniques had not been examined.
In agreement with previous studies, the inhibition of proliferation caused by
intermediate and ion-exchange factor VIII concentrates was found not to be caused
by direct cytotoxicity, as the viability of PHA-stimulated lymphocytes incubated
with the concentrate was the same as in the control culture (data not shown). Other
inhibitory coagulation factor concentrates, factor IX and von Willebrand factor
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concentrates did not affect cell viability, neither did the inhibitory affinity purified
concentrate Alphanate (data not shown).
It has been suggested that the addition of 1 U/ml heparin to lymphocyte
proliferation assays when testing coagulation factor concentrates eliminated all
inhibitory effects (personal communication from Alpha Therapeutic Corporation).
It had been noted, on testing the intermediate purity concentrate, Profilate SD, in
similar PHA-stimulated lymphocyte proliferation assays, that a clot formed, which
interfered with lymphocyte proliferation, producing an artifactual result. In my
experience, no clotting was observed with any coagulation factor concentrate, of
any purity, in any assay, and furthermore the addition of heparin to lymphocyte
proliferation assays did not reverse the inhibitory effect of Profilate SD nor that of
their affinity purified factor concentrate Alphanate. From these results it can be
concluded that the inhibition of lymphocyte proliferation caused by coagulation
factor concentrates is not mediated either by the coagulation factors themselves nor
by cytotoxic effects. This is supported by Lederman et al (1986) who found that
inhibition of PHA-stimulated lymphocyte proliferation was not mediated by the
coagulant effects of preparations. Lederman et al reported that concentrations of
heparin and plasmin sufficient to completely inhibit factor VIII activity did not
abrogate the inhibitory effects of intermediate purity factor VIII concentrates.
3. Effects of Coagulation Factor Concentrates on IL-2 Secretion by PHA-
Stimulated Lymphocytes
The same range of concentrates tested in PHA-stimulated lymphocyte proliferation
assays was also tested for effects on IL-2 secretion by PHA-stimulated lymphocytes.
Only concentrates of intermediate purity were observed to cause significant
inhibition of IL-2 secretion by lymphocytes. Those purified by ion-exchange,
affinity or immunoaffinity techniques did not cause significant inhibition of IL-2
secretion, Table 5. Unfortunately, recombinant products were not available at the
time for testing in this system.
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On comparison of these results to published data (Wadhwa et al, 1992), it can be
seen that where identical concentrates are used (although on different batch
numbers) the results are in close agreement. However, the overview of results from
the Wadhwa et al paper would to suggest that there is no obvious relationship
between product purity and inhibition of IL-2 secretion. In contrast, I have
observed a general trend whereby, as the specificity of the manufacturing technique
increased, (and hence product purity increased) the mean inhibition of IL-2 secretion
by PHA-stimulated lymphocytes for each product group decreased. These
conflicting conclusions may be due to different concentrates being used to represent
each purity group. However, my conclusion is supported by the trend also shown
by lymphocyte proliferation assay data, where again the purer the product the less
inhibitory effects it displays.
The percentage inhibition of lymphocyte proliferation and percentage inhibition of
IL-2 secretion by each coagulation factor concentrate was found to correlate, using
the Spearman rank test. This infers that results obtained by either of my assay
systems are directly comparable and are measuring a similar inhibitory phenomenon.
There are exceptions where the inhibition of proliferation and IL-2 secretion do not
correlate. For example, six batches of the ion-exchange purified factor VIII
concentrate Immunate were found to cause profound inhibition of lymphocyte
proliferation but had no effect on IL-2 secretion. This suggests that in these cases,
the assays are perhaps measuring slightly different proportions of the same
contaminants or different biological activities resulting from different inhibitory
contaminants. These discrepancies may also be due to the fact that when observing
lymphocyte proliferation one is taking into consideration all mechanisms affecting
cellular proliferation, whereas with IL-2 secretion only one pathway of inhibition is
considered.
From this series of experiments, which have assessed the immune modulating
capabilities of coagulation factor concentrates of varying purity, it can be concluded
that the purer the product the less effect it will have on lymphocyte function in vitro.
Whether this is the case for lymphocyte function in vivo, is the subject of intensive
debate.
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As this thesis was aimed at investigating the nature of immunomodulatory
contaminants in coagulation factor concentrates, an assay system had to be chosen
in which to test manipulations of these concentrates for such activities. The two
assay systems described thus far both have drawbacks. However, in comparison to
the assay which measured inhibition of IL-2 secretion, the lymphocyte proliferation
assay is less labour intensive. It does not require the use of cell lines which have
their own drawbacks such as infection with mycoplasma and loss of response to the
cytokine of interest. In addition, lymphocyte proliferation appears to be more
sensitive to the inhibitory effects of concentrates. This is perhaps because as
previously suggested, with lymphocyte IL-2 secretion only one mechanism of
inhibition is being observed. Whereas, with lymphocyte proliferation all mechanisms
leading to reduced lymphocyte transformation are being measured. Taking the
above into consideration, the PHA-stimulated lymphocyte proliferation assay was
chosen for use in the further study of immunomodulatory activity in factor VIII
concentrates.
4. Effects of Coagulation Factor Concentrates on IL-6 Secretion by PHA-
Stimulated Lymphocyte Proliferation
As previously discussed, the cytokine IL-6 is also secreted by lymphocytes and its
production up-regulated by both mitogenic stimulation and by IL-2. Therefore, it
would follow that if IL-2 secretion is inhibited by some coagulation factor
concentrate, IL-6 secretion will alo be reduced.
I have examined the effects of factor VIII, IX and von Willebrand factor
concentrates of varying purity on IL-6 secretion by PHA-stimulated lymphocytes
and measured the bioactivity of IL-6 using a [methyl-3H]thymidine incorporation
assay based on the growth response of the IL-6 dependent murine B cell line B9.
The results obtained demonstrated that concentrates did not affect IL-6 production
as was expected (data not shown). Nevertheless, these results agree with Wadhwa
et al (unpublished data, Wadhwa et al, 1994) who also demonstrated that factor
Vni concentrates did not effect IL-6 secretion.
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CHAPTER 4
Is TGF-p Involved in Factor VIII Induced
Suppression of Immune Function?
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INTRODUCTION
In September 1994 a report was published by Wadhwa et al which identified TGF-P
as a major contaminant in some factor VIII concentrates, and claimed that it is a
major contributory factor to the inhibitory effect on cytokine secretion shown by
some concentrates. Wadhwa et al (1992) had previously reported that some, but
not all, intermediate purity factor VIII concentrates and those purified by ion-
exchange chromatography inhibit IL-2 secretion from PHA-stimulated T
lymphocytes. Using a specific bioassay, TGF-P levels were estimated in the various
factor VIII concentrates. These levels were found to strongly correlate with the
degree of inhibition of IL-2 secretion from T lymphocytes exhibited by each
product. No detectable TGF-P was found in non-inhibitory concentrates.
Furthermore, when an antibody specific to TGF-pi was included in IL-2 bioassays
along with the factor VIII concentrates, the inhibitory effects of some concentrates
was partially reversed. From the results obtained in TGF-P neutralising
experiments, the authors concluded that TGF-p is a major contributory factor to the
inhibitory activity of some concentrates on cytokine secretion and activity.
I have measured the levels of biologically active TGF-P and latent TGF-P 1 in the
same sample of coagulation factor concentrates that had previously been assessed
for their ability to inhibit the function of PHA-stimulated lymphocytes. Active TGF-
P levels were measured by a bioassay which was based on the ability of TGF-P to
inhibit the proliferation of the cell line Mv-l-Lu (Tucker et al, 1978; Like &
Massague, 1986). TGF-P is also found circulating in plasma as a latent complex
which is biologically inactive and undetectable by bioassay. Therefore, in order to
determine if any latent TGF-p was present in coagulation factor concentrates TGF-
pi was measured by ELISA.
Having confirmed that whether active and/or latent TGF-P is present in the sample
of coagulation factor concentrates, it remained to be determined whether its
presence was responsible for the inhibition of lymphocyte function in vitro. In order
to ascertain whether TGF-P contamination alone was responsible for inhibiting
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PHA-stimulated lymphocyte proliferation, TGF-(3 neutralisation was performed
during lymphocyte proliferation with various concentrates. Here data are presented
which clearly demonstrates that TGF-(3 has tittle part in the inhibition of PHA-
stimulated lymphocyte proliferation caused by factor VIII concentrates.
In this chapter the potential impact that levels of TGF-|3 found in concentrates





1.1 Preparation of T Lymphocytes
T lymphocytes were separated from PBMC (prepared as described on page 85) by
sheep red blood corpuscle (SRBC)-rosetting (Londei et al, 1991). Sheep blood
from healthy non-immunised animals collected in modified Alsevers solution to
provide a 50% vol/vol mixture (Scottish Antibody Production Unit {S.A.P.U.},
Carluke, UK) was layered over Lymphoprep and centrifuged at 800g for 15
minutes. One ml of the packed red cell pellet was removed and washed three times
in sterile saline. The final red cell pellet was resuspended in 15 ml of a 2% solution
of S-2-aminoethylisothiouronium bromide (AET) then incubated at 37°C for 15
minutes, shaking every fifth minute. The AET solution was freshly prepared,
adjusted to pH 8.0 and sterile filtered (|i.Star. Pore diameter 0.2 p.m. Costar Ltd,
UK) before use. The resulting AET treated SRBC were washed four times in saline
before being resuspended in 10 ml of RPMI 1640 medium containing 40% FCS to
give a final 10% suspension.
PBMC were prepared as described previously and adherent cells removed by
adjusting the concentration of the suspension to 1x10s cells/ml in RPMI 1640
medium containing 10% FCS and incubating at 37°C for 1 hour in an 80 cm2 culture
flask (Costar Ltd, UK). The remaining non-adherent cells were then adjusted to a
concentration of 4xl07 cells/ml in RPMI 1640 medium containing 40% FCS and
mixed with an equal volume of the freshly prepared AET-SRBC. Aliquots of 1 ml
of suspension were placed in round bottomed tubes (Costar Ltd.), centrifuged at
150g for 5 minutes then stored at 4°C for 60 minutes. The pellets were gently
resuspended, layered over Lymphoprep and centrifuged at 800g for 15 minutes.
The interface, containing non-rosetted mononuclear cells (B lymphocyte enriched
population) was discarded. T lymphocytes were freed from resetting SRBC by lysis
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of the SRBC by adding 10 ml of a 0.17 M ammonium chloride solution, and placing
on ice for 10 minutes. The T lymphocytes were washed once in RPMI 1640
medium containing 10% FCS, twice in sterile phosphate buffered saline (PBS), and
used immediately.
1.2 Origin and Maintenance of Mv-l-Lu Cells
The mink lung epithelial cell line Mv-l-Lu was obtained from ECACC (ECACC
No: 8805) for use in TGF-p bioassay. This cell line was maintained on RPMI 1640
medium with 5% FCS in 80 cm2 culture flasks. Confluent cell sheets were washed
twice in sterile PBS and sufficient 0.25% trypsin-EDTA solution (Sigma-Aldrich
Ltd.) added to cover the cells. Flasks were incubated at 37°C until the cell sheet
detached. The resulting cell suspension was washed three times in RPMI 1640
containing 5% FCS. Cells were split in a ratio of 1:6 and resuspended in culture
medium.
2. Antibodies
Antibodies to TGF-f3 were obtained from two sources for use in neutralisation
experiments. Dr. Meenu Wadhwa (National Institute of Biological Standards and
Control) kindly donated the antibody used in her study which identified TGF-fl as a
contaminant in factor VIII concentrates. According to her data, a 1:200 dilution of
the purified chicken, polyclonal anti-TGF-pl antibody was capable of neutralising 5
ng/ml TGF-[5l. A commercial polyclonal neutralising antibody to TGF-f) produced
by R & D Systems Europe, was also used in neutralising experiments. According to




3.1 PHA-Stimulated Lymphocyte and T Lymphocyte Proliferation Assays
Proliferative responses to 1 (ig/ml PHA were measured by culturing PBMC or
purified T lymphocytes in 96-well flat-bottomed microtitre plates. For this purpose,
a cell suspension of lxl06 cells/ml in RPMI 1640 medium supplemented with 10%
FCS was prepared. Triplicate wells containing 100 |il of cell suspension and 100 (ll
of serial doubling dilutions of coagulation factor concentrates (0.004-2 IU/ml) or
other test samples were prepared in culture medium. Again the range of
coagulation factor concentrate activity covered in vitro was chosen to reflect plasma
levels in patients following replacement therapy. Control cultures of cells in culture
medium alone, cells and PHA alone, and cells plus coagulation factor concentrate in
the absence of PHA, were included in each assay. Cultures were incubated for 96
hours before harvesting. Proliferation of cells in response to PHA was measured by
pulsing cultures with ljiCi/well of [methyl-3H] thymidine 18 hours before cell
harvesting.
3.2 Neutralising Lymphocyte Proliferation Assays
Contaminating TGF-(3 in coagulation factor concentrates was neutralised using
three different approaches.
Method 1:- Triplicate wells containing a total volume of 100 |il which contained a
1:200 dilution of purified chicken anti-TGF-(3l or dilutions of the commercial
neutralising antibody to TGF-p and 1 or 2 IU/ml of coagulation factor concentrate
were incubated at 37°C for 1 hour before the addition of PBMC. A suspension of
PBMC containing lxlO6 cells/ml in RPMI 1640 medium supplemented with 10%
FCS was prepared and 100 |il added to each well.
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Method 2:- Serial doubling dilutions of pan-specific TGF-(3 neutralising antibody (R
& D Systems Europe Ltd) or control IgG (S.A.P.U.) in 100 pi volumes were
prepared in triplicate, in 96-well flat-bottomed plates. To each antibody dilution 1
ng/ml of either TGF-(5l in purified form (R&D Systems Europe Ltd.) or TGF-(3
contained in coagulation factor concentrate was added. Plates were incubated at
37°C for 1 hour before addition of PBMC. A PBMC suspension containing lxlO6
cells/ml in RPMI1640 medium supplemented with 10% FCS was prepared and 100
pi added to each well.
Method 3:- Serial doubling dilutions of a the commercial polyclonal TGF-f3
neutralising antibody or control IgG (S.A.P.U.) in 100 pi volumes were prepared in
triplicate, in 96-well flat-bottomed plates. An equivalent inhibitory amount of
purified TGF-(3l or concentrate containing TGF-f) was added to dilutions of the
commercial neutralising antibody to TGF-p. The amount of coagulation factor and
TGF-()1 to be added was assessed by T lymphocyte proliferation assay. Plates were
incubated at 37°C for 1 hour before addition of the T lymphocytes. A T lymphocyte
suspension containing lxlO6 cells/ml in RPMI 1640 medium supplemented with
10% FCS was prepared and 100 pi added to each well.
Control cultures of cells in culture medium alone, cells and PHA alone, and PHA
stimulated cells plus coagulation factor concentrate in the absence of antibody, were
included in every experiment. Proliferation was stimulated with PHA which was
included at a final concentration of 1 pg/ml. All cultures were incubated for 96
hours before harvesting. Proliferation was measured by pulsing each well with 1
pCi of [methyl-3H]thymidine 18 hours before cell harvesting.
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4. Cytokine Bioassays
4.1 Bioassay for Transforming Growth Factor Beta
TGF-(3 was measured using a bioassay based on the ability of TGF-fJ to inhibit the
proliferation of the epithelial cell line Mv-l-Lu. For this purpose, Mv-l-Lu cells
were trypsinised as described previously, washed three times in RPMI 1640 and
resuspended at 2xl04 cells/ml in RPMI 1640 medium containing 5% FCS.
Triplicate wells in 96-well flat-bottomed plates were prepared containing 100 pi of
cell suspension and 100 pi serial doubling dilutions of coagulation factor
concentrate (0.004-2 IU/ml), or test sample in culture medium. A titration of a
standard purified human TGF-pl was included in every assay. Cultures were
incubated for 4 days before pulsing with 1 pCi/well [methyl-3H] thymidine 5 hours
prior to cell harvesting. In order to remove the cells before harvesting, wells were
washed twice with 200 pi PBS and 200 pi of 0.25% trypsin-EDTA solution added
15 minutes before harvesting. A dose response curve of percentage inhibition
versus the log of dilution of purified human TGF-J31 standard or coagulation factor
concentrate was plotted and the amount of active TGF-(3l estimated by comparison
of the coagulation factor dilution series to the standard curve, using parallel line
analysis (European Pharmacopoeia, 1971).
4.2 Neutralising Bioassay for TGF-J3
For this purpose, serial doubling dilutions of the commercial polyclonal neutralising
to TGF-J3 or control IgG in 100 pi volumes were prepared in triplicate, in 96-well
flat-bottomed plates. To each dilution equivalent inhibitory amounts of coagulation
factor concentrate or purified human TGF-J31 were added, as previously assessed by
TGF-p bioassay. Dilutions were incubated at 37°C for 1 hour before the addition of
the Mv-l-Lu cells. A suspension of Mv-l-Lu cells containing 2xl04 cells/ml in
RPMI 1640 medium supplemented with 5% FCS was prepared and 100 pi added to
each well. Cultures were incubated for 4 days, then pulsed with 1 pCi/well [methyl-
3H]thymidine, for 5 hours prior to harvesting.
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5. TGF-pi Enzyme Linked Immunosorbent Assay
Total TGF-J31 present in serum, plasma and coagulation factor preparations, was
measured using the Predicta TGF-J31 kit (Genzyme Diagnostics, UK). This kit is an
enzyme linked immunosorbent assay (ELISA) for the quantitative determination of
total TGF-pi in ng/ml. Testing was carried out according to manufacturers'
instructions.
A volume of 5 ml of blood from six normal healthy volunteers was collected by
venepuncture using a wide bore needle, to minimalise platelet disruption. Plasma
was prepared by decanting a 3 ml aliquot into an EDTA tube and centrifuging at
lOOOg for 10 minutes. Serum was prepared by allowing the remaining 2 ml of blood
to clot for 1 hour at 37°C, and centrifuging at 800g for 10 minutes.
A measured volume of acid activated sample, standard, or control was added to
each test well and incubated to allow any TGF-(3l present to be bound by the mouse
monoclonal antibody to TGF-fJl, immobilised on the microtiter plate. The wells
were washed and a direct-labelled horse radish peroxidase (HRP)-conjugated
polyclonal antibody to TGF-{Jl added which bound to the captured TGF-(3l during
further incubation. After washing, a substrate solution was added to the wells,
which produced a blue colour in the presence of peroxidase. The colour reaction
was stopped by the addition of acid which changed the blue colour to yellow. The
intensity of the yellow colour is directly proportional to the amount of TGF-pi
present in the sample. The absorbance of each well was read at 450 nm in a Titertek
Multiscan ELISA plate reader (Life Sciences Inrenational Ltd, UK), and a standard
curve constructed to quantitate TGF-J31 concentration in the controls and samples.
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RESULTS
1. Estimation of Active TGF-p Levels in Coagulation Factor
Concentrates
The coagulation factor concentrates which had previously been tested for their
ability to inhibit lymphocyte function were also tested in a TGF-P bioassay in order
to determine whether biologically active TGF-P was a contaminant. A bioassay
based on the ability of TGF-p to inhibit the growth of Mv-l-Lu, mink lung epithelial
cells, was used. As mentioned previously, the TGF-p family in man consists of
TGF-P 1, TGF-P2 and TGF-P3. These different TGF-p subtypes all inhibit the
proliferation of Mv-l-Lu cells, albeit variably (Anick et al, 1990). Therefore, it
must be assumed that this bioassay is measuring active TGF-P 1, TGF-P2 and TGF-
P3-
Coagulation factor concentrates of varying purity were tested in triplicate over a
range of dilutions (0.004-2 IU/ml). Where possible, more than one batch of each
concentrate was tested. Results obtained were expressed as cpm and percentage
inhibition calculated using the equation shown on page 78. Following conversion,
the data were then plotted graphically as for lymphocyte proliferation assays (page
95). A representative graph, demonstrating the inhibitory effects that two batches
of an intermediate purity factor VIII concentrate have on Mv-l-Lu cell proliferation,
is shown in Figure 26. The inhibition of Mv-l-Lu proliferation by coagulation
factor concentrates was found to be dose dependent.
For each experiment a standard curve was constructed of log purified human TGF-P
(0.001-5 ng/ml) versus percentage inhibition of proliferation. This curve was used
to estimate levels of active TGF-p in concentrates by parallel tine analysis. A typical





FIGURE 26: Representative graph showing the inhibition of
Mv-l-Lu cell proliferation by two batches of an intermediate purity
factor Vin concentrate, 8Y.
TGF-(3 Bioassay
hTGF-[31 (ng/ml)
FIGURE 27: Inhibition of Mv-l-Lu cell proliferation by a
standarised preparation of purified human TGF-pl.
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The levels of active TGF-P measured in each concentrate are shown in Tables 7(a),
7(b) and 7(c). All intermediate purity coagulation factor concentrates inhibited Mv-
1-Lu proliferation and hence contained biologically active TGF-(3, Table 7(a). Both
factor VIII and factor IX concentrates manufactured by conventional methods
contained active TGF-p.
The effects of ion-exchange purified products on Mv-l-Lu cell proliferation, and the
amounts of active TGF-P contained in these products varied greatly, Table 7(b).
The factor VIII concentrate, HPVIII and the vWF concentrate Concentre De
Facteur Willebrand both contained active TGF-p. However, the factor VIII
concentrate Immunate also prepared by ion-exchange, did not inhibit Mv-l-Lu
proliferation and hence did not contain any active TGF-(3. Unlike other
concentrates, the factor IX concentrate AlphaNine SD enhanced Mv-l-Lu cell
proliferation. When present at a final concentration of 2 IU/ml, both batches of this
concentrate caused a 100% increase in Mv-l-Lu cell proliferation in comparison
with control cultures, Figures 28.
This enhancement ofMv-l-Lu proliferation was also observed with three batches of
the affinity purified factor VIII concentrate Alpha VIII, Figure 29. This effect
appears to be a specific to some concentrates manufactured by Alpha Therapeutic,
since, it was not seen with any other product. The amounts of active TGF-p that
the other affinity purified products contained was variable. No active TGF-P was
detected in the affinity purified product 9MC. However, a high level of active TGF-
P (4.61 ng/ml) was detected the factor VIII product Alphanate, Table 7(c).
Products produced by immunoaffinity and those manufactured by recombinant
methods, contained no detectable biologically active TGF-f3.
The amount of active TGF-P present in coagulation factor concentrates was found
to correlate with both percentage inhibition of proliferation and percentage
inhibition of IL-2 secretion by PHA-stimulated lymphocytes. Using the Spearman
rank test the correlation of active TGF-P and percentage inhibition of lymphocyte
proliferation was 0.546 (p=0.01), while that for active TGF-P and percentage










Intermediate Z8 1-378 0.58 3.47
Profilate SD AR2003A 1.98 10.0
Profilate SD AR2004A 3.61 9.77
Profilate SD AR2008A ND 10.7
Profilate OSD AR4205A 4.61 5.00
8Y FHC 0494 4.05 0.43
8Y FHC4133 3.84 0.43
Haemate P 978641 3.40 0.65
Defix* 20720 1.87 7.60
9A* FJA0114 3.85 5.00
Ranee 1.58 - 4.61 0.43 -10.7
TABLE 7(a): TGF-P bioassay and TGF-pi ELISA results for intermediate
purity products.
Active TGF-P levels were assessed by TGF-P bioassay. Total TGF-pl values were
assessed by TGF-P 1 ELISA. Products marked with * are factor IX concentrates, all










HPvm 10040 1.22 0.54
HPVin 20390 3.29 3.36
HPVffl 30540 2.53 2.17
HPVin 30560 1.42 4.32
HPvm 30650 1.44 3.24
HPVin 40820 1.97 3.10
Immunate 09H309210S 0 1.36
Immunate 09H319212S 0 1.57
Immunate 09H319301S 0 1.09
Immunate 09H349211S 0 0.22
Immunate 09H359212S 0 1.63
AlphaNine SD* CA21401A NA 0.16






Range 0 - 3.29 0.11 - 4.32
TABLE 7(b): TGF-P bioassay and TGF-pi ELISA results for ion-exchange
products.
Active TGF-P levels were assessed by TGF-P bioassay. Total TGF-P 1 values were
assessed by TGF-P 1 ELISA. Products marked with * are factor IX concentrates,
those marked with # are von Willebrand concentrates. All others are factor VIII










Affinity Alpha VIH AP2005A NA 8.25
Alpha Vffl AP2006A NA ND
Alpha Vffl AP2008A NA 9.77
Alphanate AS4701A 4.61 5.94
9MC* PMC 2203 0 0.11
Immunoaffinity 8 SM FHD 4143 0 0.22
Monoclate P J53706 0 0.49
Recombinant Kogenate ADAH1 0 ND
Recombinate 95F22A250 0 ND
TABLE 7(c): Summary of TGF-{5 bioassay and TGF-pi ELISA results for
affinity purified, immunoaffinity purified and recombinant products.
Active TGF-P values were assessed by TGF-P bioassay. Total TGF-P 1 values were




FIGURE 28: Enhancement of Mv-l-Lu cell proliferation
(expressed as negative inhibition) by two batches of the ion-exchange
purified factor IX product AlphaNine SD. (Error bars too close to
points to be illustrated.)
TGF-(3 Bioassay
factor VIII (IU/ml)
FIGURE 29: Enhancement of Mv-l-Lu cell proliferation
(expressed as negative inhibition) by three batches of the affinity
purified factor VIII Alpha VIII. (Error bars too close to points to be
illustrated.)
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A common drawback of bioassays is that the cell lines used are not absolutely
specific for the cytokine of interest. For example, the growth of Mv-l-Lu cells is
also variably inhibited by TNF a and IFN a, as shown in Figure 30. Besides other
cytokines, serum proteins such as (X2M are known to affect TGF-p mediated growth
inhibition. In the mink lung bioassay 0C2M has been shown to inhibit the activity of
TGF-(32, however it has no effect on TGF-P 1 (Dannielpour & Sporn, 1990). In
addition, TGF-P is abundant in FCS. Thus, it follows that FCS will have a profound
effect on Mv-l-Lu cell proliferation. For this reason, different batches of FCS were
tested to identify one which allowed optimal inhibition with purified TGF-P 1 (data
not shown).
In order to ascertain the specificity of this assay, dilutions of some of the
concentrates tested were incubated with a neutralising polyclonal antibody specific
to TGF-p. The contaminating TGF-p present in two factor VIII concentrates,
HPVm (ion-exchange purified) and Profilate OSD (conventional fractionation) was
neutralised, using a commercial neutralising polyclonal antibody to TGF-p.
Preliminary bioassays were carried out to identify concentrations of HPVIII (IU/ml)
and purified human TGF-pi (ng/ml) which were equivalent inhibitors of Mv-l-Lu
proliferation. For example, Figures 31 and 32 demonstrate that 2 IU/ml of HPVIII
and 0.16 ng/ml TGF-pl cause equivalent inhibition of Mv-l-Lu cell proliferation.
These equivalent inhibitory concentrations of concentrate and purified TGF-P 1 were
incubated with increasing amounts of antibody to TGF-(3, prior to the addition of
Mv-l-Lu cells. The highest concentration of antibody (100 |ig/ml) reduced the
inhibition of HPVIII by 80% and TGF-p by 79%, effectively neutralising the
inhibitory activity of both samples, Figure 33. These results suggest that all the Mv-
l-Lu proliferation inhibitory activity of HPVIII is due to the presence of TGF-{3,
and not to some other cytokine.
The neutralisation of control purified TGF-P 1 by the antibody to TGF-P verifies
that the antibody is indeed neutralising the activity of TGF-p. When cultured with
Mv-l-Lu cells in the absence of concentrate, both the antibody to TGF-P and the




FIGURE 30: Inhibition of Mv-l-Lu cell proliferation by










FIGURE 32: Inhibition ofMv-l-Lu cell proliferation by purified
human TGF-fll. From these experiments it can be seen that HPVIII
(batch 30540, 2 IU/ml) and human TGF-pl (0.16 ng/ml) are




FIGURE 33: Neutralisation of equvalent inhibitory effects
of purified human TGF-(3l (0.16 ng/ml) and HPVIII (batch
30540, 2 IU/ml) on Mv-l-Lu cell proliferation by an
antibody to TGF-J31.
-■ HPVIII
-o purified human TGF-p 1
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shown). Concentrations greater than 100 |ig/ml of antibody to TGF-P were found
to be toxic to cells.
The same strategy was used to neutralise the TGF-P present in Profilate OSD.
Equivalent inhibitory amounts of concentrate and TGF-P were assessed by
preliminary bioassay (data not shown) and then neutralised by increasing
concentrations of antibody. The highest concentration of antibody (100 |ig/ml)
reduced the inhibitory effect of Profilate OSD by 69% and that of TGF-P 1 by 60%
(data not shown), suggesting that the majority of the inhibition of Mv-l-Lu cell
proliferation by this concentrate is due to the presence of contaminating TGF-p.
The addition of higher concentrations of neutralising antibody to TGF-P may have
abrogated a greater portion of the inhibitory activity however, since higher
concentrations of the antibody were toxic to Mv-l-Lu cells, this could not be
confirmed.
138
2. Estimation of Total TGF-pi Levels in Coagulation Factor
Concentrates
A commercial TGF-pi ELISA kit was used to estimate the total TGF-pi (active
and latent) present in the same range of coagulation factor concentrates in which
active TGF-P levels had been measured by bioassay.
The results are summarised in Tables 7(a), (b) and (c). TGF-pi was detected in all
intermediate purity coagulation factor concentrates, Table 7(a). In most cases the
total TGF-P 1 measured was greater than the active TGF-P levels, suggesting the
presence of latent, biologically inactive TGF-pl. However, in three cases the total
TGF-pi measured was found to be less than the active TGF-p.
All ion-exchange purified products tested contained some measurable TGF-P 1,
Table 7(b). The factor VIII product Immunate, which contained no active TGF-P
as assessed by bioassay, did however contain latent TGF-P 1. With few exceptions,
the total TGF-pl levels found in ion-exchange purified concentrates were greater
than active TGF-P levels.
The affinity purified products Alpha VIII and Alphanate contained relatively high
amounts of TGF-pl as assessed by ELISA. Some latent TGF-P was detected in
9MC, even though no active TGF-P was detected.
Immunoaffinity purified products contained small amounts of biologically inactive
TGF-P 1, Table 7(c). Recombinant products were not tested in this system.
A correlation was found between the levels of active TGF-P and total TGF-P 1.
Taking each observation as an independent result, the correlation coefficient using
the Spearman rank test was 0.485 (p=0.05). The levels of total TGF-pl in
coagulation factor concentrates were also found to correlate with both percentage
inhibition of proliferation and IL-2 secretion of PHA-stimulated lymphocytes. The
correlation coefficient of total TGF-pl and percentage inhibition of lymphocyte
proliferation was 0.665 (p < 0.001), and the correlation between total TGF-pi and
percentage inhibition of IL-2 secretion was 0.567 (p=0.02).
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3. Total TGF-pl Levels in Human Serum and Plasma
In order to predict the impact that the levels of contaminating TGF-pl in
coagulation factor concentrates would have on an individual receiving replacement
therapy, total TGF-pl levels were measured in human plasma and serum.
In the eight normal controls, the mean total TGF-(3l in plasma was 41 ng/ml (range
32-48 ng/ml), and in serum 50 ng/ml (range 21-75 ng/ml).
Assuming the average plasma volume is 40 ml/kg body weight and the average body
weight 70 kg, an average individual would have a plasma volume of 2800 ml.
If a haemophiliac of average body weight were to receive 3000 IU/ml of an
intermediate purity factor VIII concentrate (20 IU/ml, 150 ml transfused) to treat a
bleed, and the concentrate contained 10 ng/ml total TGF-(3l, that patient would
receive approximately 1500 ng of TGF-(3l. If the average plasma level of TGF-(3l
is 41 ng/ml as the results suggest, transfusion of this amount would lead to an
overall increase of 0.5 ng/ml in the total TGF-(3l levels in plasma, i.e. a change of
only 1.3%.
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4. Neutralisation of TGF-p in Coagulation Factor Concentrates
To establish whether TGF-P contamination of coagulation factor concentrates was
responsible for inhibition of lymphocyte proliferation, TGF-p activity was
neutralised by a specific antibody to TGF-p. TGF-p activity in coagulation factor
concentrates was neutralised by three different approaches.
The authors of the paper which identified TGF-P as a contaminant in coagulation
factor concentrates, Wadhwa et al, kindly donated the neutralising antibody used in
their study for this purpose. Following the method of Wadhwa et al, a
concentration of 1 IU/ml of each coagulation factor concentrate was incubated with
PHA stimulated lymphocytes in the presence or absence of a 1:200 dilution of the
antibody. When present at this concentration, the antibody was capable of
neutralising 5 ng/ml of TGF-Pl (Wadhwa et al, 1994). Addition of the anti-TGF-P
antibody failed to reverse the inhibitory effects that some concentrates have on
lymphocyte proliferation, Figure 34. The antibody itself had no effect on PHA-
stimulated lymphocyte proliferation (data not shown).
As confirmation that the donated antibody was indeed neutralising TGF-P, a similar
experiment was carried out using a commercial polyclonal neutralising antibody to
TGF-p. Increasing concentrations of the antibody (0.8 - 100 |ig/ml) were incubated
with 1 or 2 IU/ml of coagulation factor concentrate prior to the addition of
lymphocytes. This batch of antibody according to manufacturers' data, was capable
of neutralising 7.5 ng/ml of TGF-p 1 when present at 50 |ig/ml. As with the donated
antibody, the commercial antibody failed to abrogate the effects of three inhibitory
concentrates of varying purity, Figure 35. At the concentrations used, the antibody
itself had no effect on lymphocyte proliferation (data not shown).
Following these results, a different neutralisation strategy was used, whereby
equivalent amounts of purified TGF-p 1 and TGF-P-containing factor VIII
concentrates (1 ng/ml final concentration of TGF-p) were incubated with increasing
concentrations of the commercial neutralising antibody to TGF-P (0.8 - 100 |ig/ml),
prior to the addition of PHA-stimulated lymphocytes. The antibody, when present
even at the high concentration of 100 pg/ml, failed to neutralise any of the inhibitory
activity caused by the factor VIE concentrates (data not shown).
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It was noted that purified TGF-pl, when present at concentrations of up to
lOOng/ml, failed to cause inhibition of PHA-stimulated proliferation (data not
shown). Since FCS contains high levels of TGF-(3, it may be that a small increase in
TGF-p concentration would have no effect on lymphocyte proliferation. For this
reason, six different batches of FCS were used to support the growth of PHA-
stimulated lymphocytes and the effects of purified TGF-(3 on proliferation assessed.
Purified TGF-|3l was found to have slight inhibitory effects on proliferation in the
presence of two of the batches tested (data not shown). Therefore, one of these
batches was selected for further experiments. The final percentage of FCS used for
proliferation assays was also examined. It was found that a reduction in the
percentage of FCS from 10% to 2% brought about a further small increase in the
response of PHA-stimulated lymphocyte to purified TGF-pi. However, the counts
per minute upon reduction of FCS to 2% were very low (<2000 cpm) and hence
unreliable (data not shown). Following these results, the serum free growth
supplement insulin-transferrin-sodium selenite (ITSS) was substituted for FCS to
eliminate any of the problems possibly associated with levels of cytokines in FCS.
However, ITSS failed to provide adequate support for the growth of PHA-
stimulated lymphocytes (data not shown).
Several studies on the effects of TGF-P report inhibition of proliferation of T
lymphocytes by purified TGF-{31 (Fox et al, 1992; Ahuja et al, 1993). Therefore,
lymphocytes were substituted for purified T lymphocytes in PHA-stimulated
proliferation assays. Purified TGF-(3l and an inhibitory intermediate purity factor
VIII concentrate, Profilate OSD, were tested in a T lymphocyte proliferation assay.
T lymphocyte proliferation was inhibited by both Profilate OSD and TGF-J31, Figure
36. Profilate OSD was known to contain approximately 5 ng/ml TGF-(3l, as
assessed by both bioassay and ELISA, and, by calculation, the addition of 1 IU/ml
of concentrate was equal to the addition of 0.1 ng/ml of TGF-pl. However,
addition of equal amounts of purified TGF-fJl and concentrate containing TGF-pl
did not produce the same inhibitory effects, since purified TGF-pl, when present at
0.1 ng/ml, caused 5% inhibition of proliferation, whereas Profilate OSD, when
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present at 1 IU/ml (0.1 ng/ml TGF-P 1), only caused 96% inhibition of proliferation,
Figure 36.
Equivalent inhibitory amounts of this concentrate and purified TGF-P 1 were added
to increasing concentrations of the commercial TGF-P neutralising antibody and
tested in a T lymphocyte proliferation assay. From Figure 36 it can be seen that
0.125 IU/ml of Profilate OSD and 12.5 ng/ml purified TGF-P 1 are equivalent
inhibitors of PHA stimulated T lymphocyte proliferation. These concentrations of
concentrate and TGF-P 1 were incubated with the antibody dilutions prior to the
addition of T lymphocytes. A semilogarithmic graph of antibody concentration (0.8
- 100 jig/ml) versus percentage inhibition of T lymphocyte proliferation was
constructed, Figure 37. The antibody, when present at 50 or 100 qg/ml,
neutralised all the T lymphocyte inhibitory activity of TGF-P 1. However, it failed
to abrogate all the inhibitory activity caused by the equivalent inhibitory amount of
Profilate OSD, reducing it by only 44%.
Purified human TGF-P 1 and the inhibitory intermediate purity factor VIII
concentrate Profilate SD (batch AR2004A) were also tested in a PHA-stimulated T
lymphocyte proliferation assay. T lymphocyte proliferation was inhibited by both
the concentrate and the purified TGF-p 1, Figure 38. This batch of Profilate SD was
known to contain 3.61 ng/ml TGF-P as assessed by bioassay and by calculation, 1
IU/ml of concentrate was equal to the addition of 0.1 ng/ml of TGF-p. Addition of
equal amounts of TGF-pl in purified form or contained in the factor VIII
concentrate, to T lymphocytes had markedly different effects. The purified TGF-pl
did not inhibit T lymphocyte proliferation in response to PHA. However, the TGF-
P containing factor VIII concentrate caused 73% inhibition of proliferation.
As before, equivalent inhibitory amounts of TGF-P 1 in purified form and TGF-P
containing concentrate were incubated with increasing concentrations of commercial
TGF-P neutralising antibody and tested in a T lymphocyte proliferation assay.
Profilate SD, when present at 0.25 IU/ml was found to inhibit T lymphocyte
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proliferation to the same extent as 50 ng/ml TGF-pl, Figure 38. Higher
concentrations of antibody completely neutralised all the inhibitory activity caused
by purified TGF-pl, Figure 39. However, the antibody failed to neutralise









































































































































































FIGURE 34: Effects of a range of coagulation factor
concentrates on PHA-stimulated lymphocyte proliferation in the
presence or absence of anti-TGF-p neutralising antibody.
Concentrates were present at a final concentration of 1 IU/ml.
The antibody failed to abrogate the inhibitory effects of some
concentrates on PHA-stimulated lymphocyte proliferation.
□ coagulation factor concentrate alone
□ coagulation factor concentrate + TGF-(B neutralising antibody
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T Lymphocyte Proliferation Assay
TGF-pl (ng/ml)
FIGURE 36: Inhibition of proliferation of PHA-stimulated
T lymphoctes by the intermediate purity factor VIII
concentrate Profilate OSD (batch AR4205A) and purified
human TGF-pi. From this experiment it can be seen that
0.125 IU/ml of Profilate OSD and 12.5 ng/ml of purified
TGF-|3l are eqivalent inhibitiors of T lymphocyte
proliferation. Note that 1 IU/ml of Profilate which contains
approximately 0.1 ng/ml of TGF-pl as assessed by both
bioassay and ELISA causes 91% more inhibition than
purified human TGF-pl.
o Profilate OSD
♦ purified human TGF-pl.
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T Lymphocyte Proliferation Assay
anti-TGF-pl (|ig/ml)
FIGURE 37: Neutralisation of equivalent inhibitory effects
of purified human TGF-Pl (12.5 ng/ml) and Profilate OSD





T Lymphocyte Proliferation Assay
TGF-pl (ng/ml)
FIGURE 38: Inhibition of proliferation of PHA-stimulated
T lymphocytes by the intermediate purity factor VIII
concentrate Profilate SD (batch AR2004A) and purified
human TGF-pi. From this experiment it can be seen that
0.25 IU/ml of Profilate SD and 50 ng/ml of purified TGF-pi




T Lymphocyte Proliferation Assay
anti-TGF-|3l Qig/ml)
FIGURE 39: Neutralisiation of equivalent inhibitory effects
of purified human TGF-(3l (50 ng/ml) and Profilate SD
(batch AR2004A, 0.25 IU/ml) on the proliferation of
PHA-stimulated T lymphocytes.
hi Profilate SD (batch AR2004A)
<3 purified human TGF-pi
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DISCUSSION
1. Contamination of Coagulation Factor Concentrates with TGF-p.
A report published by Wadhwa et al (1994) identified TGF-p as a major
contaminant in factor VIII concentrates. Furthermore, the levels of TGF-p detected
in factor VIII concentrates were found to correlate strongly with their ability to
inhibit IL-2 secretion by a PHA-stimulated T cell line. The authors stated the
addition of specific TGF-p antibody reversed the inhibitory effect of some
concentrates on IL-2 secretion.
I have measured the levels of biologically active TGF-P and total TGF-P 1 in the
same sample of coagulation factor concentrates that had previously been assessed
for their ability to inhibit the proliferation, IL-2 and EL-6 secretion of PHA-
stimulated lymphocytes. Active TGF-p levels were measured by a bioassay which
was based on the ability of TGF-P to inhibit the proliferation of the cell line Mv-1-
Lu. In agreement with the published results, intermediate purity concentrates and
some ion-exchange and affinity purified concentrates inhibited Mv-l-Lu cell
proliferation, demonstrating that they contain biologically active TGF-P.
Immunoaffinity and recombinant products contained no detectable active TGF-(L
Furthermore, in addition to confirming the reported data I have shown that other
coagulation factor concentrates, factor IX and von Willebrand factor concentrates
of intermediate and ion-exchange purity also contain active TGF-p.
Two factor VIII concentrates Alpha VIII and AlphaNine SD, did not inhibit the
proliferation of this cell line, but enhanced its proliferation, suggesting that these
concentrates do not contain any active TGF-p. This would agree with the data
presented by Wadhwa et al who did not detect any biologically active TGF-P in the
four batches of Alpha VIII tested. The growth promoting activity present in these
two concentrates is probably due to some contaminant(s) which promotes the
growth of epithelial cells. It has been documented that the proliferation of Mv-l-Lu
cells is also affected by other cytokines, indeed I have shown Mv-l-Lu proliferation
is inhibited by both TNF a and IFN a. For this reason, specific neutralising TGF-P
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bioassays were carried out on two concentrates which inhibited Mv-l-Lu cell
proliferation. The results confirmed that the inhibitory effects that these two
concentrates exerted on Mv-l-Lu cell proliferation were indeed due only to the
presence of TGF-fi However, due to time constraints, neutralising bioassays were
performed on only two concentrates; therefore one can only assume that the
inhibition of Mv-l-Lu cells by other concentrates is due to TGF-P contamination.
TGF-(3 is found circulating in the plasma as a latent complex which is biologically
inactive and hence undetectable by bioassay. Therefore, to determine if any latent
TGF-(3l was present in coagulation factor concentrates, TGF-(3l was measured by
ELISA. Using this method, TGF-(3l was detected in all coagulation factor
concentrates tested. Unfortunately, recombinant products were not available for
testing in this system. Wadhwa et al failed to detect any latent TGF-(3 in
immunoaffinity purified concentrates. However, this could be due to the ELISA
technique which I employed being more sensitive than the method used by Wadhwa
et al, which involved acid activating TGF-|3 in concentrates, then testing in a
bioassay.
As with active TGF-{3 levels, the levels of total TGF-J31 generally decreased as the
product purity increased. The levels of active and total TGF-{3 measured in each
concentrate were found to correlate with its ability to inhibit both the proliferation
and IL-2 secretion of PHA-stimulated lymphocytes. However, some exceptions
were noted. The factor VIII concentrates Immunate and Alpha VIII which both
cause profound inhibition of lymphocyte proliferation contain no active TGF-(3, but
do contain latent TGF-(H. It may be argued that perhaps the latent TGF-(3l
contained in these concentrates is being activated during tissue culture, however,
immunoaffinity purified concentrates, which possess no immune modulating activity,
contain latent TGF-pl, which is remaining inactive throughout culture. Another
exception is the ion-exchange purified factor VIII concentrate HPVIII, which
contains active TGF-p but caused only moderate inhibition of proliferation and
failed to inhibit IL-2 secretion. These exceptions would suggest that, even though a
correlation exists between TGF-P levels and inhibition of lymphocyte function,
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TGF-P levels may serve as a marker of concentrate purity rather than being the sole
and direct cause of inhibition of lymphocyte function in vitro.
In some instances, the active TGF-P measured in concentrates was greater than total
TGF-P 1 measured. This may be due to the Mv-l-Lu cells used in the TGF-P
bioassay being inhibited by other cytokines, or by other members of the TGF-P
family, TGF-P2 and TGF-P3, which are not detected by the TGF-P 1 ELISA. Since,
the polyclonal antibody to TGF-P neutralised all the Mv-l-Lu antiproliferative
activity in one such concentrate, HPVIII, it would appear that the increased level of
active TGF-P detected is due to other isoforms of TGF-P and not some other
contaminant(s). Nonetheless, other contaminants are obviously present in some
coagulation factor concentrates since two concentrates did not inhibit the
proliferation ofMv-l-Lu cells but enhanced their proliferation.
2. Neutralisation ofTGF-P Activity in Coagulation Factor Concentrates
Wadhwa et al stated that the addition of a specific TGF-P antibody reversed the
inhibitory effects of some concentrates on IL-2 secretion by a PHA-stimulated T cell
line. However, upon closer examination of their results, it may be seen that the
inhibition of IL-2 secretion caused by seven factor VIII concentrates was reversed
by neutralising antibody in only one case, partially reversed (5-50%) in five cases
and unaffected in one case. From their results, it can only be concluded that in the
majority of factor VIII concentrates tested, contaminating TGF-P is responsible for
a portion of the inhibition of IL-2 secretion, and hence is only a component of the
immune modulating contaminant, rather than, as suggested, the major contaminant.
Having confirmed that TGF-P was a contaminant of some factor VIII concentrates
and having determined that it was also present in other coagulation factor
concentrates it remained to be established whether its presence was responsible for
the inhibition of lymphocyte function in vitro. TGF-P neutralisation was undertaken
during lymphocyte proliferation with various concentrates to determine whether
TGF-P contamination alone was responsible for inhibiting PHA-stimulated
proliferation. TGF-P activity in 1 IU/ml of coagulation factor concentrate was
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neutralised by the addition of an antibody to TGF-pi. The antibody used in this
initial experiment was the same polyclonal chicken anti-TGF-P antibody used by
Wadhwa et al in their neutralising assays. When included in PHA-stimulated
lymphocyte proliferation assays along with various inhibitory coagulation factor
concentrates, the antibody failed to abrogate any significant portion of the observed
inhibition of proliferation. A final concentration of 1 IU/ml of coagulation factor
concentrates was equivalent to the addition of active TGF-P at a final concentration
of 0-0.18 ng/ml. According to data published by Wadhwa et al, this antibody when
present at the concentration used, was capable of neutralising 5 ng/ml of TGF-p,
and hence was used in great excess. The results from this experiment suggests that
no portion of the activity inhibiting the proliferation of PHA-stimulated lymphocytes
is due to TGF-p.
In order to confirm that the failure of this antibody to reverse inhibition of
proliferation was not due to loss of activity of the donated antibody, a commercial
neutralising polyclonal antibody was included in a similar PHA-stimulated
lymphocyte proliferation assay. Even though this commercial antibody was present
at a concentration capable of neutralising 7.5 ng/ml of TGF-P 1, it failed to neutralise
the lymphocyte proliferation inhibitory activity of three factor VIII concentrates.
This design of neutralising experiment also carried out by Wadhwa et al did not
include controls such as purified TGF-p 1 alone and purified TGF-p 1 plus antibody,
to ensure that the antibody was neutralising TGF-J3. Therefore, a second
neutralising strategy was devised whereby equivalent amounts of control purified
TGF-P 1 and of TGF-P contained in a factor VIII concentrate were incubated with
increasing concentrations of the commercial neutralising antibody, prior to the
addition of PHA-stimulated lymphocytes. When factor VIII concentrates were
present at what was equivalent (in terms of functional effect) to 1 ng/ml active TGF-
p, the antibody, even at very high concentrations, did not neutralise the inhibitory
activity in the two concentrates. From this set of experiments, it can again be
concluded, that even though active TGF-P is present in coagulation factor
concentrates, its presence does not account for any of the observed inhibition of
PHA-stimulated lymphocyte proliferation.
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Contaminating TGF-p in coagulation factor concentrates was also targeted for
removal by immunoprecipitation. This strategy proved to be unsuccessful, since
when concentrates known to contain active TGF-p were immunoprecipitated for
TGF-P, no change in the concentrates' activity in TGF-p bioassay was observed.
As mentioned above, as a control for these neutralising experiments, purified human
TGF-pl was incubated with PHA-stimulated lymphocytes. Addition of up to 100
ng/ml of purified TGF-P failed to inhibit the proliferation of PHA-stimulated
lymphocytes, suggesting that lymphocytes are not responding to the addition of
exogenous TGF-p in purified form or contained in coagulation factor concentrates.
It is possible that the response of PHA-stimulated lymphocytes to purified TGF-p 1
may be blunted due to saturation with TGF-P already contained in FCS. Purified
TGF-pi was found to have slight inhibitory effects on lymphocyte proliferation in
the presence of two of the batches tested but this inhibition did not reach statistically
significant levels. Following this result, the final percentage of FCS used was varied
to determine if a reduction would permit the detection of inhibition by exogenous
purified TGF-pi. A reduction in the percentage of FCS from 10% to 2% brought
about a further small relative increase in the measurable effect of purified TGF-p 1
on PHA-stimulated lymphocytes. However, the inhibition of proliferation was still
not statistically significant. This lack of inhibition of lymphocyte proliferation by
purified TGF-p 1 may also be due to (X2M also contained in FCS. As discussed
previously, the serum protein 0C2M binds bioavailable TGF-P, forming a biologically
latent complex. It is perhaps this complex formation which accounts for lack of
inhibition of proliferation of lymphocytes on the addition of purified TGF-p 1.
Purified TGF-P 1 has been demonstrated to inhibit the proliferation of PHA-
stimulated purified T lymphocytes (Ahuja et al, 1993; Fox et al, 1992). Therefore,
purified T lymphocyte preparations were substituted for unseparated lymphocytes in
PHA-stimulated proliferation assays. As reported, purified TGF-P 1 did indeed
inhibit T lymphocyte proliferation in PHA-stimulated tests. Following this result
two TGF-P containing intermediate purity factor VIII concentrates were tested in a
PHA-stimulated T lymphocyte proliferation assay in parallel with an equivalent
amount of purified human TGF-P 1. However, addition of equivalent amounts of
154
purified TGF-P 1 and that contained in the factor VIII concentrates did not inhibit T
lymphocyte proliferation to the same extent. When present at 0.1 ng/ml in purified
form, TGF-P caused only slight or no inhibition, whereas, when present at the same
concentration in the two factor VIII concentrates, almost complete inhibition was
observed. This result would seem to suggest that contaminant(s) present in these
concentrates other than TGF-pl are responsible for the majority of the T
lymphocyte inhibitory activity.
To determine what portion of the T lymphocyte inhibitory activity was due to TGF-
(3 contamination with biologically active TGF-P neutralising T lymphocyte
proliferation assays were carried out on these concentrates. The results obtained
suggest that approximately half of the T lymphocyte inhibitory activity of these two
intermediate purity concentrates is due to TGF-p contamination.
In conclusion, while TGF-P contamination is not responsible for any of the observed
inhibition of PHA-stimulated peripheral blood lymphocyte proliferation caused by
concentrates, it is responsible for 43-44% of their inhibitory effects on purified T
lymphocyte proliferation.
3. Impact of Levels of Contaminating TGF-P in Coagulation Factor
Concentrates on Plasma TGF-P Levels
Total TGF-P 1 levels were measured in the plasma and serum of normal individuals,
and the increase in the level of TGF-P 1 calculated if that individual were to be
transfused with a concentrate containing relatively high levels of contaminating
TGF-Pl. If an individual (with a basal level of 41 ng/ml total TGF-pi) were to
receive 1500 ng of TGF-P 1 (equivalent to 3000 IU of coagulation factor) this
would lead to an increase of only 0.5 ng/ml in total plasma TGF-pi. It seems
inconceivable that the very small increase would have any impact on the immune
system of an individual whose normal plasma TGF-P 1 level is in the order of 41
ng/ml. Therefore, it may be concluded that TGF-P is probably not responsible for
immune modulation observed in HIV-negative haemophiliacs.
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CHAPTER 5
Studies on the Molecular Nature of the Immunosuppressive
Agent(s) in Factor VIII Concentrates
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INTRODUCTION
The nature of the conatminant(s) responsible for inhibiting PHA-stimulated
lymphocyte proliferation was invsetigated further, since no specific contaminant had
been implicated as being responsible for the inhibition of PHA-stimulated
lymphocyte proliferation. Several approaches as outlined in this chapter, were taken
in order to attempt to identify contaminants of immunomodulatory behaviour.
The presence of proteins in factor VIII concentrates other than factor VIII itself was
investigated by two methods. Firstly the components of a selection of concentrates
were separated electrophoretically by denaturing SDS-polyacrylamide gel
electrophoresis, and the proteins visualised by silver stainning. The results
demonstrated the presence of many proteins in the concentrates that were not to
factor VIII.
Confirmation of the presence of contaminating proteins lead to the design of an
experiment to investigate whether the inhibitory activity of a concentrate was
entirely due to protein contamination or a contaminant of some other nature. This
investigation involved a concentrate being exposed to the protease trypsin, and
being tested in a lymphocyte proliferation assay. The results from this crude
experiment suggested that only a portion of the activity of this concentrate was due
to protein contamination.
Many entries in the literature have suggested that the presence of a low molecular
weight dialysable component may influence lymphocyte proliferation (McDonald et
al, 1985; Vermot Desroches et al, 1992; Wadhwa et al, 1992). Accordingly,
dialysis of several inhibitory products was carried out. The results showing that
some products purified by ion-exchange and affinity chromatography contained a
dialysable inhibitory substance.
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As these preliminary experiments only provided sketchy details as to the nature of
the contaminants, gel filtration of a factor VIII concentrate was performed, in an
attempt to isolate particular components and estimate their molecular weight.
Fractionation revealed the presence of six lymphocyte inhibitory activities, two of
which were identified, one containing TGF-(3 the other containing formulation
buffer. Unfortunately, the four other activities remain unidentified.
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MATERIALS AND METHODS
1. Polyacrylamide Gel Electrophoresis
1.1 Sample Preparation
Factor VIII concentrates were reconstituted according to manufacturers'
instructions and 4 pi (final concentration of approximately 2 pg protein) added to
11 jLi.1 of 1 x SDS gel-loading buffer (0.05 M Tris-Cl (pH 6.8), 0.1 M dithiothreitol,
2% SDS, 0.1% bromophenol blue and 10% glycerol). Dithiothreitol (DTT) (Sigma-
Aldrich Ltd.) was added to the loading buffer from a 1 M stock just before use.
Preparations of human albumin (20% solution. Immuno Ltd, UK) and purified
human TGF-pl were also prepared to be electrophoresed. 4 pi aliquots of human
albumin solution and of 2 pg/ml of purified human TGF-J31 (R&D Systems Ltd.)
were added to 11 pi of 1 x SDS gel-loading buffer.
Rainbow molecular weight markers (Amersham Life Science) high molecular weight
range (14.3-200 kDa) or low molecular weight range (2.4-46 kDa) were also
prepared by adding 10 pi of marker to 5 pi of 1 x SDS gel-loading buffer. All
samples were denatured by heating to 100°C for 3 minutes prior to loading.
1.2 SDS-PAGE
Electrophoresis of samples was performed under denaturing conditions using slab
gels in the discontinuous buffer system of Laemmli (1970). Samples were resolved
by electrophoresis through 6, 8, 10 and 15% polyacrylamide gels, containing 0.375
M Tris (pH 8.8) and 0.1 % SDS.
A volume of 30 ml of resolving gel mix was polymerised following the addition of
25 pi N,N,N',N'-tetramethylethylenediamine (TEMED) and 300 pi ammonium
persulphate (both supplied by Sigma-Aldrich Ltd.).
A 5% polyacrylamide stacking gel containing 0.25 M Tris (pH 6.8) and 0.1% SDS
was used to concentrate the sample before resolution. A volume of 10 ml of
stacking gel mix was prepared and poured on top of each resolving gel.
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Samples were electrophoresed for approximatley 4 hours at voltage of 15 V/cm in
Tris-glycine electrophoresis buffer containing 0.025M Tris, 0.25 M glycine and
0.1% SDS.
1.3 Silver Staining
SDS-polyacrylamide gels were silver stained using the Silver Stain Plus Kit (Biorad
Laboratories Ltd. UK). This kit allowed the detection of nanogram quantities of
protein. Staining was carried out according to manufacturers' instructions.
Gels were fixed in fixative enhancer solution with gentle agitation for 30 minutes at
room temperature. The fixative enhancer solution was decanted from the staining
vessel and the gels washed twice by gentle agitation in deionised distilled water for
20 minutes. Gels were stained and developed in a freshly prepared staining and
developing solution for 20 minutes or until desired staining intensity was reached.
Following staining, the stain was discarded and the gels placed in a 5% acetic acid
(BDH Laboratory Supplies Ltd, UK) solution to stop the staining reaction. After
stopping the reaction, the gels were rinsed in distilled water for 5 minutes, then
photographed.
2. Physical Manipulation of Coagulation Factor Concentrates
2.1. Immunoprecipitation of TGF-|3
TGF-p present in coagulation factor concentrates was targeted for removal by
immunoprecipitation. This procedure involved the binding of antibody to TGF-p to
an insoluble matrix. The product for this purpose used was GammaBind G Plus
Sepharose (Pharmacia LKB Biotechnology, Uppsala, Sweden). GammaBind G is a
recombinant form of Protein G, immobilised to Sepharose CL-6B, which binds to
the Fc region of IgG from a variety of species, leaving the F^ region available for
binding antigen. One ml aliquots of concentrate were incubated on ice for 1 hour
with 100 |!g of commercial anti-TGF-p antibody, prior to the addition of 20 (il of a
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50% slurry of GammaBind G Plus Sepharose in PBS. The beads were rotated for
even mixing for 4 hours at 4°C. The Sepharose was removed by brief microfugation
at high speed and the supernatant retained. A further 100 pg of antibody was added
to the supernatant and the procedure repeated. The depleted coagulation factor
concentrates were sterile filtered (pStar. Pore diameter 0.2 |im) and tested
immediately in PHA-stimulated lymphocyte proliferation assays and TGF-p
bioassays, as described previously on pages 88 and 125 respectively.
2.2 Trypsinisation of a Coagulation Factor Concentrate
For this purpose, serial doubling dilutions of trypsin (0.08-1 mg/ml) (Bovine
Pancreas. Sima-Aldrich Company) in 25 pi volumes were prepared in triplicate in
96-well flat-bottomed-plates. To each trypsin dilution 2 IU/ml of Profilate OSD
was added. Plates were incubated at 37°C for 1 hour before the addition of trypsin
inhibitor (0.02- 3 mg/ml) (Soya bean. Sigma-Aldrich Company Ltd). In order to
neutralise completely the trypsin activity, three times the amount of trypsin inhibitor
to trypsin was added. The resulting mix of 100 pi volume was incubated for a
further hour at 37°C before the addition of PBMC. A PBMC suspension containing
lxlO6 cells/ml in RPMI 1640 medium supplemented with 10% FCS was prepared
and 100 pi added to each well. PHA was included at a final concentration of 1
pg/ml. Control cultures of PBMC in culture medium alone, PBMC and PHA alone,
and PBMC plus Profilate OSD in the absence of PHA were included in the assay.
Cultures were incubated for 96 hours before harvesting. Proliferation was measured
by pulsing each well with lpCi of [methyl-3H]thymidine 18 hours before cell
harvesting.
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2.3 Dialysis ofClotting Factor Concentrates
Benzoylated cellulose dialysis tubing (Sigma-Aldrich Ltd.) was used to remove
microsolutes of less than 2 kDa from clotting factor concentrates. Concentrates
were reconstituted according to manufacturers' instructions and 5 ml placed in
dialysis tubing that was tightly tied to expel air. Concentrates were dialysed against
RPMI 1640 medium (no antibiotics or FCS included) overnight at 4°C with three
changes of solution. Following dialysis, the resulting solution was sterile filtered
(p.Star. Pore diameter 0.2 |im). A 1 ml aliquot of each concentrate was retained,
and stored at 4°C as a control. A further 1 ml aliquot of concentrate was also
retained and sterile filtered as a control. Dialysed concentrates were tested in a
PHA-stimulated lymphocyte proliferation assays as described previously on page 88.
3. Gel Filtration
3.1 Column Dimensions
Two columns were used to fractionate the ion-exchange factor VIII concentrate
HPVni.
Column 1:- volume 300 ml, height 40 cm, radius 1.5 cm, packed with Sepharose
CL-4B (molecular weight fractionation range 60 - 2000 kDa. Pharmacia LKB
Biotechnology).
Column 2:- 180 ml volume, height 90 cm, radius 0.8 cm, packed with Sephadex G-
150 (molecular weight fractionation range 5 - 300 kDa. Pharmacia LKB
Biotechnology).
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3.2 Preparation of Column Media
Sepharose CL-4B was supplied as a ready-to-use suspension containing 20%
ethanol as a preservative. Following packing of the column, three column volumes
of PBS were passed through in order to stabilise the bed and remove the ethanol.
Sephadex G-150 was prepared by mixing 10 grams of powdered G-150 with 300 ml
of PBS. The resulting thick slurry was swollen in a boiling water bath for 5 hours,
then allowed to reach the temperature of column operation before packing. Once
the column was packed, three column volumes of PBS were passed through the
column.
3.3 Column Running Conditions
Column 1 was eluted with PBS at a rate of 20 ml/hour. A total of 80 fractions of a
4 ml volume were collected. Fractionation was carried out at room temperature
(18-22°C).
Column 2 was eluted with PBS at a rate of 10 ml/hour. A total of 200 fractions of a
1 ml volume were collected. Fractionation was carried out at 4°C.
3.4 Void Volume Determination
The void volume (Vo) of the columns was determined by running a solution of Blue
Dextran 2000 (molecular weight 2000 kDa. Pharmacia LKB Biotechnology) down
the columns. A 1 mg/ml solution of Blue Dextran in PBS was freshly prepared,
filtered and applied to the column. The volume of the blue dextran loaded was 1-
2% of the total gel bed volume. The presence of Blue Dextran in the fractions was
monitored at a wavelength of 620 nm. The Vo was calculated by measuring the
volume of eluent from the start of sample application to the centre of the Blue
Dextran elution peak.
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3.5 Calibration of Gel Filtration Columns
Calibration of column 1 was performed by running 0.5 ml of normal human serum
(prepared as described previously) diluted with 2.5 ml of PBS down the column and
collecting 80 fractions of a 4 ml volume. Fractions were assayed for lgM (970
kDa) and IgG (146 kDa) by radial immunodiffusion (RID) and for albumin (68 kDa)
by absorption at 280 nm.
Calibration of column 2 was performed in two stages, in order that the proteins be
sufficiently resolved. One ml of human serum (prepared as described previously)
diluted in 1 ml of PBS, was fractionated and the 200 fractions collected, assayed for
IgM and IgG by RID, and for albumin by absorption at 280 nm. Following this, 2
ml of a solution containing a final concentration of 1 mg/ml lysozyme (14.3 kDa)
(Sigma-Aldrich Ltd.) and 1 mg/ml aprotinin (6.5 kDa) (Sigma-Aldrich Ltd.) was
passed through the column and the fractions monitored for the presence of protein
by absorption at 280 nm.
3.6 Radial Immunodiffusion Plates
RID plates were prepared by dissolving 0.075 grams of purified agar (Difco
Laboratories, USA) in 5 ml of PBS. The agar solution was warmed until boiling,
then allowed to cool to 37°C before either 200 pi of anti-human IgM serum (mu-
chain specific. S.A.P.U.) or 125 |il of anti-human IgG serum (gamma-chain
specific. S.A.P.U) was added. The resulting mix was poured into 5 cm diameter
Petri dish (Sterilin. Mackay and Lynn, UK) and allowed to cool to room
temperature. Once set, seven equidistant wells of 2 mm diameter were bored in the
agar. Plates were stored at 4°C until required.
In order to assay for the presence of immunoglobulins, 2 (J.1 of each fraction were
pipetted into the RID plate wells, and plates left to stand at room temperature.
Appropriate controls of purified IgG or IgM (S.A.P.U.) were included in every
plate. Plates were read on an RID plate reader (Binding Site Ltd, UK) after 18
hours for IgG plates and 48 hours for IgM plates.
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3.7 Sample Preparation and Application
The factor VIII concentrate HPVIII, batch number 30540, was fractionated on
column 1. This batch of HPVIII contained 230 IU/vial of factor VIII and
approximately 5 mg/vial plasma proteins. A total of 460 IU of HPVIH 30540 in 4
ml of distilled water was applied to column 1.
The factor VIII concentrate HPVIH, batch number 30650, was fractionated on
column 2. This batch of HPVHI contained 315 IU/vial of factor VIII and
approximately 5 mg/vial plasma proteins. A total of 315 IU of HPVHI 30650 in 2
ml of distilled water was applied to column 2.
A 2 ml volume of formulation buffer used in the manufacture of HPVHI was also
fractionated on column 2. The formulation buffer contains sodium citrate (3
mg/ml), calcium chloride (0.15 mg/ml), sodium chloride (15 mg/ml), glycine (9
mg/ml), lysine (3 mg/ml) and sucrose (1 mg/ml).
3.8 Testing of Column Fractions
Column fractions were monitored for protein by measuring their absorbance at
280 nm.
Gel filtration fractions were tested in lymphocyte proliferation assays (final PHA
concentration 1 fig/ml) and TGF-f3 bioassays for inhibitory activity. For assay,
triplicate wells containing 50 jil of fraction, 50 |il of culture medium and 100 pi of
lymphocyte or Mv-l-Lu cell suspension (cell concentration as stated previously)
were prepared. Culture conditions, harvest and pulse time were as described
previously. For details of both assays see pages 88 and 125 respectively. All
fractions were sterile filtered (pStar. Pore diameter 0.2 |im) before being included
in assays.
In order to detrmine the molecular weight of the proteins of interest, the elution
volume was measured and the calibration curve for each column used to determine
the molecular weight of the unknown.
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RESULTS
1. Characterisation of Inhibitory Component(s) Present in
Coagulation Factor Concentrates
1.1 SDS PAGE of Factor VIII Concentrates
SDS polyacrylamide gel electrophoresis was used to visualise the protein
composition of factor VIII concentrates. Four factor VIII concentrates of varying
purity, purified human TGF-J31 and purified human albumin were separated by
electrophoresis, through 6, 8, 10 and 15% SDS polyacrylamide gels, Figures 40-43,
respectively. The gels were silver stained using a commercial kit which allowed the
detection of nanogram quantities of protein.
The 6, 8 and 10% gels resolved the high molecular weight components of these
preparations, and the 15% gel the low molecular weight components. Purified
human albumin was included as a control, since it was added as a carrier protein
during the reconstitution of purified human TGF-pl. In addition, both the affinity
purified product and the monoclonally purified product have human albumin added
as a stabiliser. Inclusion of these controls allowed the identification of protein bands
belonging to albumin or contaminating TGF-p in these preparations.
Many bands with both high and low molecular weights were observed in all factor
VIII concentrates, Figures 40-43. Some bands were of very low intensity,
suggesting that these proteins are present in only trace amounts.
The 6% polyacrylamide gel allowed separation of components between 46 and 200
kDa, Figure 40. The multiple polypeptides of factor VIII which have a molecular
weight range of 80-210 kDa, were not visible on this gel, perhaps due to the minute
amounts present. A band with a molecular weight >200kDa was identified which
appeared only in the lymphocyte inhibitory concentrates. No other bands appearing
exclusively in the inhibitory concentrates were identified.
The 8% polyacrylamide gel allowed separation of components between 30 and 200
kDa, Figure 41. Multiple protein bands were observed in all the preparations tested.
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Many of these bands in the hnmunoaffinity and affinity purified products could be
attributed to albumin and degradation products of albumin. Other protein bands
with a molecular weight of 80-210 kDa could be attributed to factor VIII
polypeptides. A band with molecular weight >200 kDa was again observed only in
those concentrates which were inhibitory to lymphocyte function.
The 10% polyacrylamide gel allowed separation of components between 21.5 and
200 kDa, Figure 42. The band at >200 kDa was again observed only in inhibitory
concentrates. This band appeared less intense in HPVIII than in the other two
concentrates, Profilate OSD and Alphanate which inhibit lymphocyte proliferation to
a greater extent than HPVIII.
The 15% polyacrylamide gel allowed separation of components between 2 and 46
kDa, Figure 43. Bands of the correct molecular weight for TGF-{31 (25 kDa
homodimer, and 12.5 kDa monomer) were not observed when purified human TGF-
pl was resolved on polyacrylaimde gels.
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FIGURE 43: 15% SDS POLYACRYLAMIDE GEL
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1.2 Trypsinisation of a Factor VIII Concentrate
To assess whether all the inhibitory activity of coagulation factor concentrates was
due to the presence of protein, the intermediate purity factor VIII concentrate
Profilate OSD was treated with trypsin and included in a lymphocyte proliferation
assay. Profilate OSD was incubated at 37°C for 1 hour with increasing
concentrations of trypsin (0.08 -1 mg/ml). The trypsin activity was then neutralised
by the addition of trypsin inhibitor (0.02 -3 mg/ml) and further incubation for 1
hour. A semilogarithmic graph was constructed of log concentration of trypsin :
trypsin inhibitor (0.03 - 4 mg/ml) versus percentage inhibition of lymphocyte
proliferation, Figure 45.
As shown previously, Profilate OSD, when present at 2 IU/ml, caused 80%
inhibition of lymphocyte proliferation, Figure 9. The lowest concentration of trypsin
had no effect on the inhibitory activity of Profilate OSD. However, as the trypsin
concentration increased, the percentage inhibition of lymphocyte proliferation
decreased until 0.5 mg/ml trypsin : trypsin inhibitor complex was reached. At this
concentration and higher, the percentage inhibition caused by Profilte OSD reached
a plateau at approximately 60%. Higher concentrations of trypsin : trypsin inhibitor
complex than 0.5 mg/ml were found to inhibit lymphocyte proliferation.
If the inhibition caused by these higher levels of trypsin : trypsin inhibitor complex
was subtracted from the percentage inhibition of proliferation due to trypsinised
Profilate OSD, it can be seen that the highest concentration of trypsin is capable of
removing approximately 59% of the observed inhibitory activity of 2 IU/ml Profilate
OSD, leaving a total of 41% inhibition which is trypsin resistant.
172
Lymphocyte Proliferation Assay
TrypsinrTrypsin Inhibitor Complex (mg/ml)
FIGURE 44: Removal of lymphocyte inhibitory activity
of Profilate OSD (batch AR4205A) by trypsinisation.
—• Trypsin treated Profilate OSD (2IU/ml)
—■ TrypsimTrypsin Inhibitor Complex
o Trypsin treated Profilate OSD (2IU/ml) minus
inhibitory effect of TrypsimTrypsin Inhibitor Complex
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1.3 Dialysis of Factor VIII Concentrates
To determine if any portion of lymphocyte proliferation inhibitory activity was due
to some dialysable, low molecular component of coagulation factor concentrates,
inhibitory concentrates were dialysed against RPMI 1640 culture medium, at 4°C
overnight.
Following dialysis, concentrates were sterile filtered, before testing. In some cases,
to ensure no activity was lost in the filtration process, undialysed concentrate was
filtered as a control. Doubling dilutions of all manipulations were tested in PHA-
stimulated lymphocyte proliferation assays.
Dialysis of the intermediate purity factor VIII concentrate Prolfilate OSD, had no
effect on its ability to inhibit lymphocyte proliferation, Figure 46. Filtration of the
concentrate through a 0.2 (am filter also had no effect on the inhibitory activity.
In contrast, dialysis of ion-exchange purified factor VIII concentrate, HPVIII and
the affinity purified factor VIII concentrate Alpha VIII removed approximately 46%
and 41% respectively of the inhibitory activity, Figures 47 and 48.
Dialysis of the inhibitory affinity purified factor VIII concentrate Alphanate was




FIGURE 45: Inhibition of proliferation of PHA-stimulated
lymphocytes by the intermediate purity factor VIII concentrate
Profilate OSD (batch AR4205A), and various physical manipulations
of this concentrate.
0 Profilate OSD ♦ filtered Profilate OSD
° dialysed Profilate OSD
Lymphocyte Proliferation Assay
factor VIII (IU/ml)
FIGURE 46: Inhibition of PHA-stimulated proliferation of
lymphocytes by the ion-exchange purified factor VIII concentrate
HPVm, and dialysed HPVIII.




FIGURE 47: Inhibition of proliferation of PHA-stimulated
lymphocytes by the affinity purified factor VIII concentrate Alpha
VIII (batch AP2005A), and various physical manipulations of the
concentrate.
° Alpha VIII control D dialysed Alpha VIII
Lymphocyte Proliferation Assay
factor VIII (IU/ml)
FIGURE 48: Inhibition of proliferation of PHA-stimulated
lymphocytes by the affinity purified factor VIII concentrate Alphanate
(batch AS4701A), and various physical manipulations of this
concentrate.
0 Alphanate control ♦ filtered Alphanate
® dialysed Alphanate
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1.4. Fractionation of a Factor VIII Concentrate by Gel Filtration
Gel filtration of a factor VIII concentrate enabled the separation of components of
that concentrate according to differences in size. The concentrate chosen for this
purpose was the ion-exchange purified product HPVIII. Fractions collected from
gel filtration columns were monitored for the presence of protein by absorption at
280 nm. Fractions were also tested in triplicate for inhibitory activity in lymphocyte
proliferation assays or in a TGF-fi bioassay.
Two batches of the concentrate HPVIII were fractionated, batches 30540 and
30650. Both these batches of HPVIII had previously been shown to inhibit
lymphocyte proliferation, causing 70% and 67% inhibition of lymphocyte
proliferation respectively, when present at 1 IU/ml. Both batches also contained
active TGF-(3 as assessed by bioassay; 30540 contained 2.53 ng/ml and 30650
contained 1.44 ng/ml.
Results from gel filtration experiments are expressed in the form of an elution
diagram, where elution volume is plotted against absorbance (280 nm), and
percentage inhibition of lymphocyte proliferation or percentage inhibition of Mv-1-
Lu cell proliferation.
(i) Fractionation through Column 1
Column 1 was packed with the gel filtration media Sepharose CL 4B, which has a
fractionation range of 60-2000 kDa for globular proteins. Prior to fractionation of
the concentrate, the Vo (void volume) of the column was determined and the
column calibrated by fractionating standards of known molecular weight. The Vo
of the column was found to be 84 ml. A calibration curve of elution volume versus
log molecular weight of standards for column 1 was constructed and is shown in
Figure 49. A total of 460 IU/ml (10 mg of protein) of HPVIII batch 30540, was
applied to the column and 80 fractions of a 4 ml volume collected.
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Two protein peaks were detected by absorbance at 280 nm, the first with an elution
volume of 144 ml, the second at 284 ml, Figure 50. Those fractions monitored for
protein were then sterile filtered, and assayed both for their ability to inhibit PHA-
stimulated lymphocyte proliferation and for inhibition ofMv-l-Lu cell proliferation.
Testing of fractionated HPVIII batch 30540 in lymphocyte proliferation assays
revealed four peaks of lymphocyte inhibitory activity, peaks A, B, C and D, Figure
50. The first with an elution volume of 95 ml (Peak A. Molecular weight >970
kDa), a second minor peak at elution volume 144 ml (Peak B. Molecular weight
approximately 550 kDa), a third at elution volume 210 ml (Peak C. Molecular
weight <68 kDa) and a fourth at 272 ml (Peak D. Molecular weight <68 kDa).
PBS, used as elution buffer had no effect on lymphocyte proliferation.
Testing for active TGF-J3 in a TGF-p bioassay revealed the presence of three
inhibitory peaks, Figure 52; the first at elution volume 192 ml (Peak E), the second
at elution volume 215 ml (Peak F), the third with an elution volume of 300 ml
(Peak G), all with a molecular weight <68 kDa.
From this experiment it can be concluded that when HPVIII batch 30540 is
fractionated, four peaks of lymphocyte inhibitory activity are revealed, with
molecular weights >970 kDa, -550 kDa, and two peaks with a molecular weight
<68 kDa. The two peaks with a molecular weight <68 kDa also inhibiting Mv-l-Lu
proliferation as well as lymphocyte proliferation, suggesting that these fractions
contain active TGF-(3 or some activity which inhibitsMv-l-Lu proliferation.
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Gel Filtration Calibration Curve
elution volume (ml)
FIGURE 49: Calibration curve for column 1, Sepharose CL 4B,
useful fractionation range for globular proteins 60-20,000 kDa.
The column was calibrated by monitoring the elution volumes of
proteins from human serum.
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(ii) Fractionation ofHPVIII through Column 2.
Column 2 was packed with the gel filtration media Sephadex G-150, which has a
fractionation range of 5-300 kDa for globular proteins. As with column 1, the Vo
was determined, and the column calibrated before fractionation of the test sample.
The Vo was found to be 45 ml. A calibration curve of log molecular weight of
standards versus elution volume for column, is shown in Figure 52. A total of 315
IU/ml (5 mg of protein) of HPVIII 30650 was applied to the column and 200
fractions of a 1 ml volume collected.
Two protein peaks were detected by absorbance at 280 nm, Figure 53. The first
was observed at elution volume 52 ml, and a second minor peak at 60 ml.
Testing fractionated HPVIII batch 30650 in lymphocyte proliferation assays
revealed four peaks of inhibitory activity, Figure 53. The first with an elution
volume of 52 ml (Peak 1. Molecular weight >970 kDa), which corresponds to the
major protein peak. A second minor peak was observed at elution volume 62 ml
(Peak 2. Molecular weight -220 kDa), corresponding to the minor protein peak. A
third peak occurred at elution volume 69 ml (Peak 3. Molecular weight -120 kDa)
and the fourth at 160 ml (Peak 4. Molecular weight -6.5 kDa).
To determine if this fourth low molecular weight peak was due to low molecular
weight stabiliser, such as citrate, which is used in the formulation of this product, a
sample of formulation buffer containing these stabilisers was applied to column 2,
Figure 54. The buffer was found to elute at 150 ml, which is approximately the
same point as the low molecular weight components of HPVIII.
From fractionation of HPVIII batch 30560, it can be concluded that this batch of
concentrate also contains four peaks of inhibitory activity, with molecular weights
>970 kDa, -220 kDa, -120 kDa and -6.5 kDa.
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elution volume (ml)
FIGURE 52: Calibration curve for column 2, Sephadex G-150,
useful fractionation range for globular proteins 5-300 kDa. The
column was calibrated by monitoring the elution volumes of proteins
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FIGURE 54: Elution profile of HPVIII formulation
buffer on Sephadex G-150 (useful fractionation range
5-300 kDa). Fractions were assayed for their ability to
inhibit PHA-stimulated lymphocyte proliferation. Eluent
= PBS. Void volume 45 ml.
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2. Testing of Other Cytokines in Lymphocyte Proliferation Assays
The cytokines IFN a, IFN y and TNF a, were tested for their effects on PHA-
stimulated lymphocyte prohferation. Both IFN a and TNF a inhibited lymphocyte
proliferation to some extent, Figure 56. The inhibition of proliferation caused by












1. Identification and Characterisation of Other Protein Components in
Coagulation Factor Concentrates
The presence of other proteins in coagulation factor concentrates, besides the
coagulation factor itself, was determined by electrophoretic separation and
visualisation of proteins by silver staining. Protein components of factor VIII
concentrates of varying purity were separated and visualised by this method. To
achieve effective separation over a wide range of molecular weights, concentrates
were separated through four formulations of polyacrylamide gel. Many protein
bands other than those attributable to factor VIII or human albumin were detected.
The only band identified whose appearance correlated precisely with lymphocyte
inhibitory activity in the concentrates, was one with a molecular weight >200 kDa.
Biologically active TGF-fl homodimer or monomers of TGF-J3 could not be
identified conclusively by this method, perhaps due to the minute amounts (0.02 ng
TGF-J3) on the gels being below the limit of detection of this system.
Having demonstrated that proteins other than the coagulation factor itself are
present in coagulation factor concentrates, an inhibitory concentrate was treated
with trypsin. This crude method was hoped to be able to determine whether all the
inhibitory activity was due to protein contamination. Approximately 34% inhibition
of lymphocyte proliferation was removed by treatment with 0.25 mg/ml
trypsin:trypsin inhibitor complex, higher concentrations of the trypsin:trypsin
inhibitor complex inhibiting lymphocyte proliferation. However, if the inhibition
caused by high levels of the complex were to be subtracted from the inhibition due
to trypsin-treated Profilate OSD, approximately 59% of the inhibitory activity of 2
IU/ml Profilate OSD could be removed by the highest concentration of trypsin,
suggesting that 59% of the activity of this concentrate is due to protein the other
41% being trypsin -resistant protein or non-protein.
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1.2. Dialysis of Coagulation Factor Concentrates
Several studies have shown that the inhibitory activity of factor VIII concentrates on
lymphocyte function is removed, completely or partially, following dialysis. Since, a
portion of the inhibitory activity of Profilate OSD was trypsin resistant, this
concentrate was dialysed to establish whether any portion of the remaining activity
was due to some low molecular weight component. No portion of this concentrates
inhibitory activity on PHA-stimulated lymphocyte proliferation was removed by
dialysis. This is in agreement with data obtained by Wadhwa et al (1992) using the
same concentrate.
Other concentrates of varying purity were also dialysed. Approximately 40% of the
inhibition of PHA-stimulated lymphocyte proliferation by two ion-exchange purified
factor VDI concentrates was abrogated by dialysis, whereas only 25% of the affinity
purified factor VIII concentrates' activity was removed. These results suggest that
a dialysable component with a molecular weight < 2 kDa, present in ion-exchange
and affinity purified concentrates, is responsible for a portion of the inhibitory
activity of these concentrates. These results are similar to those obtained by
Wadhwa et al, who on dialysing factor VIII concentrates, reported that a greater
portion of ion-exchange concentrates' inhibition of IL-2 secretion was dialysable
than that of intermediate purity concentrates. The dialysable components of ion-
exchange concentrates are most probably the stabilisers used in the manufacturing
processes, such as sodium citrate and amino acids, used to increase the ionic
strength of the preparations and as bulking agent.
This technique is quite unrefined, and difficult to adequately control, since many
factors may change in the overnight dialysis such as solution pH. In addition,
components other than those < 2 kDa may be lost through unwanted adherence to
the daialysis tubing. Accordingly no firm conclusions can be made from the data
obtained. Nontheless, even thought the dialysis protocols used by myself and
Wadhwa et al vary, the dialysable percentage of inhibitory activity obtained for
identical concentrates is very similar, perhaps adding credence to these data.
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1.3. Fractionation of Coagulation Factor Concentrates
Fractionation of two batches of the ion-exchange purified factor VIII concentrate
through two different gel filtration media revealed the presence of many peaks of
inhibitory activity. Gel filtration of HPVIII batch 30540 produced four peaks of
inhibitory activity, one of high molecular weight, which came off the column straight
after the void volume, the second a minor peak which corresponded to the protein
peak, and two peaks with a molecular weight <68 kDa which inhibited both
lymphocyte proliferation and Mv-l-Lu cell proliferation, suggesting that they
contain active TGF-[3. In conclusion, the lymphocyte inhibitory activity of this
batch of concentrate seems mainly to be composed of an unidentified high molecular
weight component >970 kDa and active TGF-fi. The small inhibitory peak, with a
molecular weight of approximately 550 kDa, is probably due to the effect of protein
concentration in these fractions.
Gel filtration of HPVIII batch 30650 through Sephadex G-150, which has a lower
molecular weight fractionation range than the Sepharose CL 4B used to fractionate
batch 30540, also revealed the presence of four peaks of inhibitory activity. The
first peak with a molecular weight corresponding to the major protein peak, the
second corresponding to the minor protein peak and a third with a molecular weight
of approximately 120 kDa. A fourth peak was observed which was subsequently
shown to be formulation buffer. No peak was observed at the fractions
corresponding to the correct molecular weight for active TGF-(3, perhaps due to this
batch of concentrate containing a smaller amount than the batch fractionated on
Sepharose CL 4B. In conclusion, the main activity in this batch of HPVIII appears
to be due to three components, two unidentified with molecular weights >970 kDa
and 120 kDa and a third component which is most probably formulation buffer.
Thus, by fractionating two batches of this concentrate using two types of gel
filtration media, I have demonstrated the presence of the following lymphocyte
inhibitory activities.
- >970 kDa unidentified —550 kDa protein, unidentified
- -220 kDa protein, unidentified —120 kDa unidentified
- <68 kDa contains active TGF-(3 - <6.5 kDa formulation buffer
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Wadhwa et al (1994) also performed gel filtration experiments in order to determine
the molecular weight of contaminants. The concentrate chosen for their
experiments was an intermediate purity factor VIII concentrate. Fractionation
revealed the presence of two peaks if inhibitory activity at 60 kDa and 200 kDa.
Allowing for differences in column media, dimensions and slight calibration
discrepancies, it would appear that the peak I have observed at < 68 kDa
correspond to that observed by Wadhwa et al. It is suggested by the authors that
the two peaks of inhibition are due to contamination with TGF-(3, confirming this by
neutralisation experiments. By testing the fractions in a TGF-fJ bioassay my results
agree that the < 68 kDa fraction (their data 60 kDa) is indeed due to TGF-fi.
However, close examination of the neutralisation data for these fractions shows only
a portion of the activity being neutralised by antibody to TGF-fk
In the concentrate I have chosen for fractionation, an ion-exchange purified factor
VIII concentrate, I have detected five other peaks of inhibitory activity, > 970 kDa,
~550 kDa, -220 kDa, -120 kDa and <6.5 kDa. Only the < 6.5 kDa peak being
identified as formulation buffer. The reason for these other peaks not being
detected by Wadhwa et al may be due to the use of different concentrates.
However, one would expect the ion-exchange to contain less contaminants. More
likely the difference is due to the assay system used to detect immunomodulatory
activity. As previously discussed the PHA-stimulated lymphocyte proliferation






1. Effects of Coagulation Factor Concentrates on Normal Lymphocytes.
I have performed a comprehensive study on the effects that a range of coagulation
factor concentrates of varying purity have on lymphocyte function in vitro. A
general trend emerged throughout the data whereby, as product purity increased the
inhibition of lymphocyte function in vitro decreased. Many other studies have
focused on factor VIII concentrates alone. In this study factor IX and von
Willebrand factor concentrates were also included. The results demonstrated that
coagulation factor concentrates other than factor VIII concentrates are just as
inhibitory to lymphocyte function. Where appropriate, the data obtained from this
study was compared to that published by others, and found to be in close
agreement.
The relevance of these in vitro studies to the immune modulation demonstrated by
haemophiliacs receiving coagulation factor therapy remains unclear. I have shown
that factor VIII and factor IX concentrates of the same purity group are as
inhibitory as each other in vitro. However, this does not seem to be reflected in the
in vivo data, as researchers have found that while haemophilia A patients
demonstrate immune abnormalities, haemophilia B patients displayed immune
characteristics similar to that of negative controls (Carr et al, 1984; Cuthbert et al,
1992). This may be explained by the presence of different inhibitory contaminants in
factor VEI, factor IX and von Willebrand factor concentrates. It is not unlikely that
the different techniques used to manufacture these products gives rise to different
contaminants or abundance of those contaminants. Those present in factor VIII
concentrates inhibiting lymphocyte function both in vitro and in vivo, whereas,
those present in other coagulation factor concentrates only inhibiting lymphocyte
function in vitro. Thereby, resulting in divergent results between haemophilia A and
B patients. Nonetheless, this suggests that what is observed in vitro cannot
necessarily be translated to the in vivo situation. Therefore, one must be cautious
that conclusions derived from in vitro data as to the immunomodulatory effects of
products is not applied to the in vivo situation.
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2. Effects of Coagulation Factor Concentrates on the Immune System in vivo
In vitro studies for assaying the immune modulating capacity of coagulation factor
concentrates are useful, however, they do not give us any information on the impact
that concentrates may have on the immune system in vivo. The only way to assess
this is to compare one concentrate to another in terms of variation in some immune
parameter, such as CD4+ count.
To date there are few studies on HIV negative haemophiliacs comparing the effects
of different purity products on CD4+ counts. The data available suggest that CD4+
counts do decline in haemophiliac patients albeit at a slower rate than in HIV
infected patients, and this decline is observed regardless of whether they are
receiving intermediate or high purity products (Teitel et al, 1989; Cuthbert et al,
1990; Fukatake et al, 1991). Nevertheless, there is debate as to whether this
apparent decline in CD4+ counts is significant. Furthermore, there has been a study
on previously untreated patients which found that CD4+ counts remain within the
normal range, regardless of product purity (Evans et al, 1991).
The data from comparison studies on HIV positive haemophiliacs are also
contradictory. Several studies suggest that treatment with higher purity products
stabilises CD4+ counts (Brettler et al, 1989; de Biasi et al, 1991; Seremitis et al,
1990; Goldsmith et al, 1991; Seremitis et al, 1993; Goedert et al, 1994). These
results are highly controversial since, if higher purity concentrates are capable of
stabilising CD4+ counts in HIV positive haemophiliacs, it could be reasoned that
replacement therapy may be of benefit to individuals who are not haemophiliacs but
HIV positive! Concern has also been expressed about the design of some areas of
these studies. Much of the impact that they have is weakened by the fact that
retrospective controls were used, that the CD4+ counts in the test and control
groups was often not equivalent and that the assignment of patients to purity groups
was not random. In summary, studies of this nature to date are inconclusive. It
therefore remains the subject of intensive debate as to whether there is any benefit
from treatment with higher purity products. Until such comparison studies have
been completed successfully no firm conclusions can be drawn regarding the
immune modulating effects of products from one particular purity group.
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Nonetheless, there is no reason to believe that higher purity concentrates would be
more harmful than less purified concentrates. If higher purity concentrates were to
extend the life span of HIV positive patients, can clinicians afford to wait until data
from randomised trails are available? In my view a move towards increasing use of
immunoaffinity purified or recombinant coagulation factor concentrates will finally
eliminate anxieties about clinically relevant immune modulation.
3. Contribution of Blood-Borne Virus Infection to the Immune Abnormalities
Observed in Haemophiliacs
The extent to which coagulation factor concentrates contribute to the immune
modulation observed in haemophiliacs is also under debate. Two recent studies
suggest that chronic blood-borne virus infection is a major contributory factor to
abnormalities observed in vitro in cells of the immune system derived from
haemophiliac boys and that factor VIII concentrates play a minor role (Evans et al,
1995; Pasi et al, 1995).
The proliferative response of T lymphocytes, derived from groups of haemophiliac
boys to the lectins PHA and Con A were assessed. The proliferative response of T
lymphocytes to lectins was found to be normal in HCV and HIV uninfected boys,
whereas the those infected with either HCV or both HCV and HIV have impaired
responses (Evans et al, 1995). The impact of blood-borne virus infection on
monocyte antigen presentation and cytokine secretion was also investigated in the
same groups of boys. A reduction in cytokine production was observed only in
boys infected with both HIV and HCV, suggesting that HIV as an aetiological
agent. Whereas, antigen presentation was reduced in boys infected with only HCV
or both HCV and HIV (Pasi et al, 1995). The authors conclude that this evidence
suggests that the impairment in the immune response observed in haemophiliac cells
in culture is due to infection with blood borne viruses such as hepatitis C and HTV.
These findings do not entirely agree with in vivo data published by other researchers
(Carr et al, 1984; Cuthbert et al, 1992). If viral infection was the cause of immune
modulation in haemophiliacs, why are immune changes so mild in haemophilia B
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patients? Infection with blood-borne viruses also does not explain the inhibitory
effect that coagulation factor concentrates have on the PHA-stimulated proliferation
of normal donor lymphocytes, observed by myself and many other researchers.
Evans et al (1995) suggest that the concentrations of coagulation factor used in
these studies have been variable and often substantially greater than would be
achieved in vivo following treatment. I have found that with many coagulation
factor concentrates significant inhibition of PHA-stimulated lymphocyte
transformation occurs at concentrations as low as 0.1 IU/ml, which are indeed
readily achievable in vivo following treatment.
This issue may be resolved through longer term studies such as the continued
monitoring of the virally uninfected boys for clinically relevant immune
abnormalities. However, as suggested before the move towards treatment with
recombinant purified products would hopefully finally eliminate anxieties about
immune modulation, and whether the cause is viral or due to contaminants in
concentrates.
4. Is TGF-p Involved in Factor VH[ Induced Suppression of Immune
Function?
TGF-p comprises a family of multifunctional polypeptides that regulate the cellular
growth and differentiation of a wide variety of cells (Sporn et al, 1987; Massague,
1990). The TGF-P family in man consists of TGF-pl, TGF-P2 and TGF-P3. TGF-
P is released from cells, and circulates in plasma as a latent complex which does not
bind to receptors (Pricher et al, 1986; Wakefield et al, 1988; Massague, 1990).
Several configurations of latent TGF-p have been identified, including the large
latent complex and the TGF-P-a2M) form (O'Connor-McCourt & Wakefield, 1987;
Wakefield et al, 1988; Huang et al, 1988).
The large latent complex, secreted by many cell types including platelets,
lymphocytes and macrophages, is comprised of two distinct gene products with a
total molecular weight of 235 kDa. It consists of the mature TGF-P (a 25 kDa
disulphide linked homodimer), a second 75 kDa dimer, the latency associated
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protein (LAP) and a 135 kDa latent TGF-P binding protein (LTBP) (Wakefield et
al, 1988). LAP is linked by a disulphide bond to the LTBP, which is the product of
a separate gene while the TGF-P dimer is associated with the LAP by electrostatic
interactions (Sha et al, 1991). Following secretion of the latent form of TGF-(3,
activation must occur to release the biologically active dimer form. Latent TGF-p
can be activated by a variety of chemical and physical treatments, including extremes
of pH or temperature, detergents, proteases or urea (Lawrence et al, 1985;
Miyazono et al, 1990; Brown et al, 1990), suggesting that latency is maintained by
non-covalent forces.
It has been demonstrated by immunoassay that all detectable TGF-p in plasma and
serum is bound to the 720 kDa glycoprotein (X2M, implying that OC2M is the major
carrier of active TGF-P (Huang et al, 1987; O'Connor-McCourt & Wakefield,
1987). Dissociation of TGF-p-oc2M complex can be achieved under mildly acidic
conditions (Huang et al, 1988; O'Connor-McCourt & Wakefield, 1987). Heparin
and dextran sulphate are also capable of dissociating TGF-p form OfeM (LaMarre et
al, 1990; McCafferty et al, 1989) suggesting that proteoglycans on the cell surface
may dissociate TGF-p-cx2M complexes similarly.
The starting material for all coagulation factor concentrates used in my study,
except those manufactured by recombinant techniques, is human plasma. Since
TGF-P is derived from platelets, lymphocytes and macrophages, it is probably not
surprising that plasma derived concentrates contain TGF-p. Prior to the
coagulation factor fractionation process donated plasma is frozen until processing
and melted slowly to produce cryoprecipitate. As postulated by Wadhwa et al
(1994), this treatment of the plasma may cause the lysis of residual platelets
contained in the plasma and hence the release of latent TGF-P into the feedstock.
Latent TGF-p, as previously discussed, can be activated in vitro by various physio-
chemical treatments which include temperature and detergents. Since two of the
most commonly used viral inactivation methods incorporated into the fractionation
processes are solvent/detergent and heat treatment, it may be that latent
contaminating TGF-P is being activated by these processes. TGF-P in plasma and
serum is bound in a latent complex with a2M, so in addition to latent TGF-P
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released by platelet lysis, activation of biologically latent a2M-TGF-(3 complex
could contribute to the levels of active TGF-P detected in coagulation factor
concentrates.
I have confirmed the findings of Wadhwa et al (1994) that most intermediate purity,
ion-exchange and affinity purified factor VIII concentrates contained active TGF-p,
whereas immunoaffinity and recombinant did not. In addition, I have also
demonstrated that concentrates of other coagulation factors such as factor IX and
vonWillebrand factor also contain active TGF-p. Latent TGF-pl was also found to
present in all plasma derived concentrates. However, this appears to be remaining
inactive throughout the culture period as even though immunoaffinity purified
concentrates contain the latent cytokine they have no effect on lymphocyte
proliferation.
Even though TGF-P is definitely a contaminant of coagulation factor concentrates
the role that it plays in the in vitro inhibition of lymphocyte function appears to be
minimal. The authors of the original report stated that the addition of specific TGF-
P antibody reversed the inhibitory effect of some concentrates on IL-2 secretion.
However, their neutralisation data is unconvincing, and clearly demonstrates that in
most cases only a portion of the activity is due to TGF-p. Using many different
approaches to neutralisation, including the method used by Wadhwa et al (1994), I
found that the addition of excess antibody to TGF-p could not abrogate any of the
inhibition of PHA-stimulated lymphocyte proliferation caused by concentrates. Only
when a purified T lymphocyte system was used could a significant amount of the
activity be removed by addition of antibody to TGF-p. The only conclusion that can
be drawn from this is that the TGF-P present in concentrates is inhibiting a portion
of T lymphocyte proliferation, most probably by inhibiting EL-2 secretion.
However, the overall effect that TGF-P inhibition by this mechanism has on PHA-
■ stimulated lymphocyte proliferation is minimal, since no reversal of the effects by a
specific antibody was observed. This would agree with my previous conclusion that
TGF-p levels serve purely as a marker of concentrate purity rather than being the
sole and direct cause of inhibition of lymphocyte function in vitro.
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Another factor to be considered is the impact that the levels of contaminating TGF-
P contained in coagulation factor concentrates would have on the immune system of
patients receiving therapy. As described in chapter 4, total TGF-P 1 levels were
measured in the plasma and serum of normal individuals, and the increase in the
level of TGF-pl calculated if that individual were to be transfused with a
concentrate containing relatively high levels of contaminating TGF-pl. The results
demonstrating that treatment would lead to an increase of only 0.5 ng/ml in total
plasma TGF-pi, i.e. a change of only 1.3%.
It has been demonstrated that mice injected with TGF-pi for the treatment of auto
immune diseases have a marked depression in immunologic responses (Kuruvilla et
al, 1991). However, these animals were given 2 |ig/ml TGF-P, a far greater amount
than that likely to be received by a haemophiliac receiving replacement therapy. In
addition, pharmacokinetic studies in rats have shown that both active and latent
TGF-P are cleared rapidly from the circulation, active TGF-P within a few minutes
and latent TGF-P within 90 minutes (Wakefield et al, 1990). It seems inconceivable
that the very small increase would have any impact on the immune system of an
individual whose normal plasma TGF-P 1 level is in the order of 41 ng/ml.
Therefore, it may be reasonably concluded that TGF-p is not responsible for
immune modulation observed in HIV-negative haemophiliacs. Furthermore, if TGF-
P were to be responsible for the immune abnormalities observed in haemophiliacs in
vivo, why then do haemophilia B patients and those with von Willebrands disease
not demonstrate any clinically relevant immune abnormalities? Since, factor IX and
von Willebrand factor concentrates both contain comparable amounts of TGF-P to
factor VIII concentrates. This would again seem to suggest that TGF-P plays no
role in observed immune disturbances.
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5. Mechanism of Inhibition of PHA-Stimulated Lymphocyte Proliferation by
Coagulation Factor Concentrates
Where the merit of using in vitro assays of immune modulation to determine
whether a concentrate will be of harm to a patient is doubtful, they have been shown
to be invaluable as a tool for screening for active contaminants in concentrates.
Many groups have attempted to elucidate the mechanism of inhibition of lymphocyte
function by coagulation factor concentrates. The toxicity of intermediate purity
factor VIII concentrates to PBMC has examined by McDonald et al (1985),
Lederman et al (1986) and Wang et al (1986), by incubating PBMC with
concentrate and counting viable cells, identified by trypan blue exclusion or
cytofluorometery. Both groups reported that inhibition of lymphocyte proliferation
by intermediate purity concentrates was not due to a mere cytotoxic effect.
Vermot-Desroches et al (1992) confirmed the above observations using an ion-
exchange product and assessing cell viability by Eosin Red dye exclusion. These
observations have been confirmed by a two other groups (Hay et al, 1990; Wadhwa
et al, 1992). No group had studied the effects of other inhibitory coagulation factor
concentrates, or those purified by affinity techniques. Accordingly, I tested these
preparations and found perhaps unsurprisingly that they did not mediate their
inhibitory effects through cytotoxicity.
McDonald et al (1985) investigated whether the inhibition of PHA or Con A-
stimulated proliferation was due to a direct interaction between the mitogens and
some component(s) in intermediate purity factor VIII and factor IX concentrates.
The mitogens were allowed to react in double diffusion plates against factor VIII of
factor IX concentrates. No precipitation was detected between either clotting factor
preparation and PHA. However, some precipitation was detected between ConA
and both factor VIII and factor IX preparations. Perhaps more convincingly, simple
binding of lectin by some component(s) in an intermediate factor VIII concentrate
was also investigated by Lederman and colleagues (1986). Gel filtration of a
mixture of iodine125-labelled PHA and the factor VIII concentrate revealed no
binding of isotope to fractions with inhibitory activity.
200
Direct binding of inhibitory component(s) in factor VIII concentrates to cell surface
components involved in mitogen mediated triggering of IL-2 secretion was
investigated by Wadhwa et al (1992). Attempts were made to adsorb substance(s)
of this nature by incubation of factor VIII concentrates with resting or PHA-
activated T cells. No reduction in inhibitory activity in those concentrates absorbed
with activated or non-activated cells was observed. These results imply that
inhibitory component(s) mediate their effect by mechanism(s) which do not involve
simple blocking of cell surface components involved in mitogen stimulation.
The time course of the effect of an ion-exchange purified factor VIII concentrate on
PHA-stimulated lymphocyte proliferation has also been investigated by adding
preparations at different times after the activation of proliferation by the mitogen
(Vermot-Desroches et al, 1992). The results showed that maximum inhibition was
obtained when the concentrate was added 6 hours after PHA addition. When the
concentrate was added after this time, the degree of inhibition was gradually
reduced, suggesting that the inhibitory influence of this product was limited to an
early event in the process of lymphocyte activation. Similar results were obtained
by Wang et al (1986) who observed that when intermediate purity factor VIII
concentrate was added later than 8 hours after the stimulant, the degree of inhibition
was reduced. However, the maximum inhibition was observed when concentrate
was added simultaneously with mitogen.
The kinetics of inhibition of IL-2 secretion by an intermediate purity factor VIII
concentrate was also investigated by Wadhwa et al (1992). Their results
demonstrated that delayed exposure of a T cell line to the factor VIII concentrate
for more than 2 hours resulted in the progressive attenuation of the inhibitory effect
on PHA induced IL-2 secretion.
The inhibition of lymphocyte function by some factor VIII concentrates is thought
to be independent of monocyte interaction (Hay et al, 1990; Vermot-Desroches et
al, 1992). Hay and colleagues found that lymphocyte proliferation in response to
phorbol-myristate-acetate (PMA), a reaction which is not reliant on monocyte
interactions, was inhibited by some factor VIII concentrates. Furthermore, the
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depletion of monocytes from PBMC preparations to < 1% did not affect some
factor Vm concentrates' ability to inhibit lymphocyte proliferation.
The role of monocytes in the inhibition of lymphocyte mitogenic functions caused by
an ion-exchange purified factor VIII concentrate was also investigated by Vermot-
Desroches et al (1992). As pure T lymphocytes do not proliferate in response to
mitogen, monocyte interaction was tested by measuring T lymphocyte proliferation
in the presence of varying numbers of monocytes. A similar degree of inhibition of
PHA-stimulated lymphocyte proliferation was observed, irrespective of the
percentage ofmonocyte cells.
In summary, these data from several research groups indicate that the inhibitory
effect of factor VIII concentrates is not exerted through a simple blocking of cell
surface components, binding of mitogen or direct cytotoxicity. Several independent
reports also conclude that the inhibitory component exerts its effect almost
immediately on addition of the concentrate. Having reviewed this data, I concluded
that it was probably unnecessary to study this further, but it would be more
constructive to focus on the identification and characterisation of inhibitory
components in concentrates.
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6. Identification and Characterisation of Other Components in Coagulation
Factor Concentrates
One must postulate that if TGF-P is capable of evading the fractionation process to
be found in active form in coagulation factor concentrates, that many other
cytokines or biologically active substances may also contaminate these concentrates.
Some of them perhaps having an impact on in vitro immune function. Accordingly
further investigation into the possible nature and number of these contaminants was
necessary.
Many factors have been considered to be causing immune abnormalities in
haemophiliacs. It has been proposed that the in vitro effects of coagulation factor
concentrates are due to some specific component(s), rather than being a "non¬
specific" function of protein concentration. Wadhwa et al (1992) reported that the
inhibition of IL-2 secretion from T cells by factor VIII concentrates differed
considerably among the various intermediate purity concentrates, suggesting that
the inhibitory action was due to some specific component(s). My data also supports
this view, since within purification categories there was some variation in the effects
concentrates have on both assays.
The coagulation factors themselves have also been implicated as being
immunomodulatory. However, it is unlikely that factor VIII or factor IX are
responsible for the previously mentioned in vitro effects, since I have found that
highly purified (immunoaffinity) factor VIII and factor IX products have no effect
on PA-stimulated lymphocyte proliferation or IL-2 secretion. This is supported by
the lack of effects that recombinant factor VIII products have on lymphocyte
proliferation assays. This opinion is also upheld by other published data (Schreiber
etal, 1987; Wadhwa et al, 1992; Wadhwa etal, 1994).
Albumin which is added as a stabiliser to some concentrates has also been
implicated. However, the above results, which show a lack of inhibitory activity
with immunoaffinity purified and recombinant products, also exclude albumin as
being a component of coagulation factor concentrates causing these in vitro effects,
since both immunoaffinity purified and recombinant factor VIII have human serum
albumin added as a stabiliser. Furthermore, a purified preparation of human albumin
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was tested by Thorpe et al (1989) for it's effects on IL-2 secretion by PHA-
stimulated T cells and found to have no effect.
Other proteins present at considerable concentrations in intermediate purity factor
VIII concentrates are fibronectin and fibrinogen. Schultz and Shahidi (1990 &
1990a) reported that fibronectin is a potent inhibitor of PHA-stimulated lymphocyte
proliferation. The authors demonstrated that lymphocyte proliferation was inhibited
in a dose-dependent manner over a range of concentrations of fibronectin (100-400
jig/ml). Similar levels of fibronectin are present when factor VIII concentrate are
included in lymphocyte proliferation assays. In contrast, Wang et al (1986)
reported that both purified fibronectin and fibrinogen had no effect on PHA-
stimulated lymphocyte proliferation. It seems unlikely that fibrinogen or fibronectin
are responsible, since, ion-exchange and affinity products some of which are very
inhibitory to lymphocyte function contain only trace levels of these proteins.
It has been proposed that immune complexes or IgG aggregates are a possible cause
of adverse immunological reactions. As previously mentioned, it has been
demonstrated that both heat-aggregated IgG and certain factor VIII concentrates
affect monocyte/macrophage function (Eibl et al, 1987; Mannhalter et al, 1988).
The same group of investigators subsequently demonstrated that small amounts
(ng/ml) of factor VIH-anti-factor VIII immune complexes could modulate Fc-
receptor bearing cells (Mannhalter et al, 1990). However, as I have found that
immunoaffinity purified factor VIII concentrates which contain trace amounts of
these complexes (murine IgG complexed to factor VIII) do not affect PHA-
stimulated lymphocyte proliferation or IL-2 secretion this does not seem likely.
Again this view is supported by other researchers (Schreiber et al, 1987; Wadhwa
et al, 1992). Furthermore, Thorpe et al (1989) has demonstrated that neither IgG
preparations nor heat-aggregated IgG have any inhibitory effect on IL-2 secretion
by PHA-stimulated T lymphocytes.
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Recently the serum protein 012-macroglobulin (a2M) has been implicated as a
contaminant in factor VIII concentrates. a2M is one of the major plasma
glycoproteins in man, its concentration in plasma varying between 2-4 mg/ml. In its
native state, a2M has a molecular weight of 720 kDa and consists of four identical
polypeptide chain subunits ofmolecular weight 185 kDa which are held together by
both disulphide and non-covalent bonds (James, 1980). The main biological
function of a2M has been attributed to its "pan-proteinase" binding activity,
allowing it to interact with and capture virtually any proteinase (Barret & Starkey,
1973; Gonias et al, 1982). The proteinase inhibitory function of a2M remains of
uncertain physiological importance. a2M also interacts with a wide variety of other
molecules and ions, such as cytokines, immune complexes, lectins and other
mitogenic substances, and a number of these reactions have been shown to impair
immune responses (James, 1980). Cytokine binding by a2M has been observed with
platelet derived growth factor (PDGF), TGF-p, IL-2, IL-6, IFN-y and tumour
necrosis factor (TNF) (James et al, 1994). a2M is thought to perform a carrier
function in which cytokines circulate bound to a2M, or a targeting role by which
cytokines are delivered to cells with a2M receptors.
Abstracts by Hay et al (1995 & 1995a) suggest that some factor VIII concentrates
exert varying degrees of amidolytic activity which is related to a2M enzyme
complexes. Hay and colleagues tested a range of factor VIII concentrates for their
amidolytic activity and their effect on lymphocyte function. A strong correlation
between amidolytic activity and lymphocyte function was reported. Activity was
found to be greatest in intermediate purity concentrates and barely detectable in
monoclonally purified and recombinant products. Gel fractionation of concentrates
revealed that molecular weight column fractions of 80,000 kDa of inhibitory
concentrates exerted the most activity. The authors concluded that the reported
inhibition of lymphocyte function in vitro may be due to the presence of a2M and to
a low molecular weight component.
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In conclusion, for PHA-stimulated lymphocyte proliferation assays, the inhibitory
activity caused by some coagulation factor concentrates is not due to the presence
of the coagulation factor itself, albumin, fibronectin, fibrinogen or TGF-fl. The
contribution of a2M to the inhibition of lymphocyte function observed in vitro at
present remains unconfirmed.
I have fractionated two batches of an ion-exchange purified factor VIII concentrate
using gel filtration, and have demonstrated the presence of six components which
inhibit lymphocyte proliferation. Of the six peaks of inhibitory activity identified
using this technique, only two of them were identified as containing a particular
contaminant. One peak of inhibitory activity was found to be due to low molecular
weight stabilisers which are used in the formulation of this product. However,
whilst this activity causes measurable inhibition of lymphocyte proliferation in vitro
it is highly unlikely that it will have any effect on lymphocyte function in vivo.
Another peak with a molecular weight of < 68 kDa was found to contain active
TGF-p. Whether it is responsible for the observed inhibition of lymphocyte
proliferation remains undetermined, as unfortunately neutralising experiments using
a specific antibody were not performed on these fractions. However, as discussed
previously the amount of TGF-P present in this concentrate is unlikely to cause the
immune abnormalities observed in vivo. Four other lymphocyte inhibitory activities
with molecular weights > 970 kDa, -550 kDa, -220 kDa and -120 kDa remain
unidentified. The serum protein a2M has been implicated as contributing to the
inhibition of lymphocyte function observed in vitro. However, it seems unlikely that
it contributes to the inhibition of lymphocyte proliferation by this concentrate, since
no component of the corresponding molecular weight was revealed during gel
filtration or SDS-PAGE. However, further experimentation would be required to
confirm this interpretation.
These unidentified components which have been shown to inhibit lymphocyte
function in vitro, may be the key to the immune abnormalities observed in vivo in
haemophiliacs receiving these concentrates. If time were permitting, perhaps
protein sequencing of these fractions might reveal the identity of some of these
fractions allowing the relevance of contamination of concentrates with them to be
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assessed. Furthermore, fractionation of inhibitory factor IX and von Willebrand
concentrates may have revealed the presence of different contaminants to those
present in factor VIII concentrates, perhaps explaining why haemophilia A patients
display more immune abnormalities than haemophilia B or von Willebrand factor
patients.
In summary, I have performed an extensive study on the effects of coagulation
factor concentrates of varying purity on in vitro assays of immune function. I have
made new observations regarding the effects of high purity concentrates on
lymphocyte proliferation in vitro and have for the first time directly compared the
effects of coagulation factor concentrates on both PHA-stimulated lymphocyte
proliferation assays and lymphocyte IL-2 secretion. In addition, I have eliminated
many of the possible candidates present in coagulation factor concentrates, reported
to cause immune modulation in vitro. I have also demonstrated the presence of four
previously unreported lymphocyte inhibitory activities present in an ion-exchange
chromatography purified factor concentrate, however, further, investigation is
required in order to identify these components.
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Intermediate Z8 1-369 10
Z8 1-378 10
Profilate SD AR2003A 23
Profilate SD AR2004A 35
Profilate SD AR2008A 35
Profilate OSD AR4205A 49
8Y FHC0484 25
8Y FHC 0494 25
8Y FHC4133 26.5





Appendix l(i):- Intermediate purity product coagulation factor activities.



















Alpha Vin AP2005A 108
AlphaVin AP2006A 408
Alpha VIA AP2008A 108
AlphaNine SD* CA21401A 40









Appendix l(ii):- Ion-exchange product coagulation factor activities.
Products marked with * are factor IX concentrates, those marked with # are von







Affinity Alphanate AS4701A 98
9MC* PMC 2203 57
Mean 77.5




Recombinant Kogenate ADAH1 25
Recombinate 95F22A250 100
Mean 62.5
Appendix l(iii):- Affinity, immuoafflnity and recombinant product coagulation
factor activities.
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